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ABSTRACT
Anaemia commonly complicates surgery and critical illness. This thesis comprised four
studies of this important clinical problem. Thefirst study was a retrospective study based in a
major teaching hospital Intensive Care Unit (ICU). Three existing datasets were merged to
provide a study dataset that described the demographics and severity of illness for a cohort of
critically ill patients (n = 489). The epidemiology of anaemia during ICU admission to death
or discharge home from hospital was described. 81.5% of patients were discharged anaemic
to the community after surviving critical illness. 35.5% had a haemoglobin concentration
<100g/L. 82% of patients had normocytic normochromic blood indices at hospital discharge.
The second study was a prospective observational study that further investigated blood
transfusion practice in a cohort of patients (n = 185) after ICU discharge. 72.2 % of these
patients were discharged home anaemic; 83% had normocytic normochromic blood indices at
hospital discharge. These data confirmed the retrospective analysis. Hospital physicians used
restrictive transfusion practice after ICU discharge; the median pre-transfusion Hb was 74 g/L
(interquartile range: 68-76 g/L). The third study measured red blood cell 2,3-
diphosphoglycerate (2,3-DPG) levels and P50, which both reflect the ability of red cells to
deliver oxygen to tissues, in a prospective cohort of 111 patients admitted to the ICU. Factors
that were associated with 2,3-DPG and P50 were investigated. The data showed that critically
ill patients have lower levels of 2,3-DPG compared with normal healthy controls. Red cell
2,3-DPG during critical illness had a strong association with patients' acid base status.
Acidemia was strongly associated with low DPG concentrations, which was counterintuitive.
2,3-DPG concentration had the strongest association with P50 raising the possibility that
oxygen unloading could be impaired in critically ill patients. The fourth study merged several
large existing databases to document the incidence, patterns, and likely aetiology of anaemia
and the incidence of red cell transfusion in patients presenting for elective major orthopaedic
surgery. The dataset comprised approximately 3500 patients presenting over one year to a
single orthopaedic hospital. The relation between pre-operative haemoglobin status, other
factors, and peri-operative transfusion was investigated. 17 % of patients with known pre¬
admission Hb levels were anaemic. Most of these patients (64%) had normocytic
normochromic anaemia. 303 patients received a total of 838 red cell units. Low per-admission
Hb levels were common among those who were transfused during hospital admission.
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CHAPTER ONE
NORMAL RED BLOOD CELL PHYSIOLOGY
INTRODUCTION
Red blood cells are essential for life as they carry oxygen to the entire body's tissues
(Hoffbrand 1999). Anaemia due to blood loss, red cell destruction, or ineffective
erythropoiesis is a potentially serious health problem. Blood transfusion is
considered one of the standard treatments of anaemia. However, despite major
advances in blood safety concerns remain about the risks of blood transfusion
(Mollison 1993). Two clinical areas in which anaemia and blood transfusion are
common are the intensive care unit, and elective orthopaedic surgery. These two
groups of patients use a considerable amount ofblood. The decrease in blood
availability world wide due to decrease in the number ofblood donors and
continuing increases in demands is an alarming problem (2004a, 2004b). Treating
anaemia without allogeneic blood and using transfusion-sparing interventions such as
low haemoglobin transfusion triggers could reduce the need of red blood cells.
Investigating causes and types of anaemia in these settings could help in identifying
alternative methods of treatment.
It has been shown that low pre-operative haemoglobin level is associated with peri¬
operative red cell transfusion (2004b, SIGN guideline, page 363). In this thesis, we
investigated the incidence and type of pre-operative anaemia in patients undergoing
elective orthopaedic patients and the associated red cell transfusion. Our intention
was to obtain data that could help design strategies that decrease blood use.
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A low haemoglobin transfusion trigger is used widely in the intensive care unit.
However, it is unclear how patients' own red cells function during the course of the
illness particularly when many patients become anaemic. In addition, it is not known
how long anaemia lasts after an episode of critical illness.
In the present work red cell function in critically ill patients was investigated by
measuring red cell 2,3-Diphosphoglycerate. The relationship between haemoglobin
level and red cell 2,3-Diphosphoglycerate during critical illness was investigated.
The relationships between red cell 2,3-Diphosphoglycerate and many other
physiological variables were also examined. We also studied the prevalence of
anaemia and its characteristics at the time of hospital discharge for this group of
patients who were managed with low transfusion trigger strategy in the ICU.
A literature review was done for each study separately. The literature search was
done through: a) The National Centre for Biotechnology Information (PubMed, a
service of the National Library of Medicine), b) E-library (NHS, Education for
Scotland), c) Cochrane library, and c) Edinburgh University electronic library. A
priority was given to meta-analysis, Cochrane reviews, and clinical studies that carry
in their title the key words that related to our studies. Other clinical studies and
reviews that investigated the key words were also included. This general introduction
reviews red blood cell physiology and the pathophysiology of anaemia. Chapters 2,3,
and 4 review the literature relevant to each study.
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ERYTHROCYTE STRUCTURE
The red cell is essentially a semi-permeable cellular membrane enclosing a viscous
30% protein solution. The protein is almost entirely haemoglobin, which comprises
95% of the dry weight of the cell. Erythrocytes are characterized by a large surface
area-to-volume ratio due to their unique biconcave discoidal shape. This
configuration minimizes diffusion distances between cell surface and haemoglobin
molecules.
The mean red cell diameter is about 8 pm with marginal and central thickness of
about 2 and 1 pm.
The erythrocyte's biconcave form is apparently related to certain membrane proteins,
such as spectrin, which may have contractile properties.
The outer surface of the erythrocyte membrane is composed principally of
glycoprotein, which carries several major blood group antigens (A, B, M, N) (2004a,
Brobeck 1979).
HAEMOGLOBIN (Hb)
Haemoglobin (mol.wt 64 500) contains four haem groups linked to four globin
chains, and can bind four molecules of oxygen (Hoffbrand, Lewis, Tuddenham,
editors 1999).
Haemoglobin serves as the oxygen carrier in blood, but it also plays a vital role in the
transport of carbon dioxide and hydrogen ions. The capacity of haemoglobin to bind
oxygen depends on the presence of the haeme group (monopolypeptide unit), which
gives haemoglobin its distinctive colour. The haem consists of elemental iron and an
organic component. The organic part, protoporphyrin, is made of four-pyrrole group
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(tetrapyrrol). Four methyl, two vinyl, and two propionate side chains are attached to
a tetrapyrrole ring to form protoporphyrine IX.
The iron atom in haem binds to the four nitrogens in the centre of the protoporphyrin
ring. The iron can form two additional bonds, one on either side of the haeme plane.
Haemoglobin contains 0.34% iron by weight. Thus 1ml of packed erythrocytes
contains approximately 1 mg of iron (Beutler, Lichtman, Coller, Kipps, editors
1995).
ERYTHROPOIESIS
BLOOD CELL PRODUCTION (MARROW)
The marrow is one of the largest organs in the human body and is the principle site
for blood cell formation. In normal adults its daily production amounts of about 2.5
billion red cells, 2.5 billion platelets, and 1.0 billion granulocytes per kilogram of
body weight. The rate of production is adjusted to actual needs and can be varied
from nearly zero to many times normal (Beutler, Lichtman, Coller, Kipps, editors
1995).
Mature blood cell production takes place from progenitor cells, which can undergo
rapid proliferation and development in response to several cytokines
A schematic representation of the structure of the haemopoietic system is shown in
figure (1.1) (Hoffbrand, Lewis, Tuddenham, editors 1999).
Erythrocytes are the most common circulating haemopoetic cells. The precursor
forms within the marrow are nucleated but, when released into the peripheral blood,
they no longer contain a nucleus. Red cells have a finite lifespan of around 120 days,
at which time they are destroyed primarily in the reticuloendothelial system. Red
4
cells recently released from the bone marrow contain trace amounts ofRNA that can
be stained with supravital stains and recognized as reticulocytes. The reticulocyte
count can give a vital insight into the synthetic function of the marrow (Webb,
Shapiro, Singer, Suter, editor 1999).
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Erythropoietin, a hormone produced mainly by the kidney, stimulates bone marrow
differentiation and production of red blood cells. Decreased renal oxygen delivery
secondary to hypoxia, anaemia, or ischaemia augments erythropoietin synthesis.
Additional stimulants of erythropoietin production include vasoconstrictors such as
norepinephrine, anti-diuretic honnone (ADH), and angiotensin. Suppressants of
erythropoietin synthesis include hyperoxia, increased red cell blood volume, and
reduced renal mass. Furthermore, the adenosine antagonist theophylline inhibits
erythropoietin production (Webb, Shapiro, Singer, Suter, editor 1999).
Iron metabolisim and transport
Iron absorption
Iron absorption depends not only on the amount of iron in the diet, but also, and
more importantly, on the bioavailability of that iron, as well as the body's needs for
iron. A normal western diet provides approximately 15 mg iron daily. Of that iron,
digestion within the gut lumen solubilizes about one-half, from which about 3 mg
may be taken up by mucosal cells and about 1 mg transferred to the portal blood in a
healthy adult male. Iron absorption can be influenced at several different stages
(Hoffbrand, Lewis, Tuddenham, editors 1999). The minimal daily iron requirements
are shown in table (1.1). Factors affecting iron absorption are shown in table (1.2).
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Table (1.1): The minimal daily iron requirements (Beutler, Lichtman, Coller, Kipps,
editors 1995)
Amount that must be Minimal amount that





Young non pregnant women 2 20
Pregnant women 3 30
Men & postmenopausal women 1 10
Table (1.2): Factors affecting iron absorption (Hoffbrand, Lewis, Tuddenham, editors
1999)






Acid pH (e.g.gastric HC1)
Low molecular weight soluble
chelates (e.g.vitamin C, amino
acids)












Alkalis (e.g. pancreatic secretions)






In plasma iron is bound to transferrin, which is a glycoprotein. Normally,
approximately one-third of the transferrin iron-binding sites are occupied by iron.
About 200 mg of transferring carry about 1 OOpg/dL of iron. Once an atom of iron
enters the body, it is virtually in a closed system [internal iron cycle] (figure 1.2)
(Beutler, Lichtman, Coller, Kipps, editors 1995). Iron compartments in normal
subject are shown in table (1.3).
Table (1.3):Iron compartments in normal subjects (Beutler, Lichtman, Coller, Kipps,
editors 1995)
Compartment Iron content, mg Total body iron, %
Haemoglobin iron 2,000 67
Storage iron (ferrintin, haemosiderin) 1,000 27
Myoglobin iron 130 3.5
Labile pool 80 2.2
Other tissue iron 8 0.2
Transport iron 3 0.08
The values represent estimates for an "average" person, that is, 70 kg, 177 cm (70 in)
in height.
Iron storage compartment
Iron storage exists in two distinct forms: ferritin and haemosiderin. In adult men the
storage iron amounts to 800 to 1,000 mg; in adult women it is a few hundred
milligrams less (Beutler, Lichtman, Coller, Kipps, editors 1995; Hoffbrand, Lewis,
Tuddenham, editors 1999).
Ferritin is found in virtually all cells of the body and also in tissue fluids.
Hepatocytes, and other cells, have ferritin receptors on their cell membranes that are
involved in the binding and internalisation of ferritin from plasma or interstitial fluid.
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Serum ferritin concentration correlates with total-body iron stores, which makes this
measurement important in diagnosis ofmany iron disorders.
Haemosiderin is found predominantly in cells of the monocyte-macrophage system
in the marrow, Kupffer cells of the liver, and in the spleen. Haemosiderin contains 25
















Figure (1.2): Internal iron cycle
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Factors that modify erythropoiesis
Inflammation
Inter-leukins, colony stimulatingfactors and cytokines
Interleukins, colony-stimulating factors, and other cytokines are responsible for the
regulation of blood cells production; they are molecules with bioactivity in the
lympohaemopoietic pathways. Some of these molecules have stimulatory effect on
red cell production such as erythropoietin, interleukin-1 (IL-1), IL-3, IL-9, KIT
ligand, platelet-derived growth factor, hepatocye growth factor, insulin-like growth
factor II, and membrane bound burst-promoting activity.
Others have inhibitory effect on red cell production, such as H-subunit ferritin,
transforming growth facor-P, prostaglandin El and E2, inhibin, lactoferrin, and
seraspenide (Beutler, Lichtman, Coller, Kipps, editors 1995; Hoffbrand, Lewis,
Tuddenham, editors 1999).
Iron and haematenics
Deficiencies of iron, vitamin Bl2, or folic acid on the one hand and/or the presence of
primary bone marrow disease on the other may result in a decreased production of
red blood cells. Underlying chronic diseases (i.e. malignancies, systemic diseases,
metabolic disturbances) or (chronic) infections may also result in a decreased red cell
production. Anaemia in the latter group of disorders is characterized by an
underproduction of red blood cells owing to a decreased availability of iron.
Depletion of the body iron stores during chronic infection probably has an
immunological aetiology and is modulated by the production of cytokines (Webb,
Shapiro, Singer, Suter, editor 1999).
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Vitamin B,2 andfolate
Deficiency is caused by: poor intake, drugs, alcoholism (folate), and malabsorption.
Vitamin BI2 deficiency occurs with ileal and gastric pathology. Effects include
megaloblastic anaemia, glossitis, and stomatitis. Neuropathy or neuromyelopathy
(subacute combined degeneration) occur with B12 deficiency. The normal
requirements are 3 mg/kg/day folate and 2 pg/day vitamin B,2 (Webb, Shapiro,
Singer, Suter, editor 1999).
STRUCTURAL HAEMOGLOBIN VARIANTS
Many structural haemoglobin variants have been described, most ofwhich result
from single amino acid substitutions. Single amino acid substitutions may cause
clinical disorders as they may alter the stability and the functional properties of the
haemoglobin molecule and causes abnormal oxygen binding (Hoffbrand, Lewis,
Tuddenham, editors 1999).
HAEMOGLOBIN VARIANTS THAT CAUSE ABNORMAL OXYGENBINDING
The high oxygen affinity haemoglobin variants
These result from single amino acid substitutions at critical parts of the haemoglobin
molecule that are involved in the configurational changes which underlie haem-heam
interaction and the production of a sigmoid oxygen dissociation curve. Many occur at
the junctions between the a and (3 subunits. Others involve the amino acids that are
involved with the binding of 2,3-DPG to haemoglobin.
Fetal haemoglobin has a high oxygen affinity (left-shifted the haemoglobin oxygen
dissociation curve) because it cannot interact with 2,3-DPG; mutations of the DPG
binding sites have similar effect (Hoffbrand, Lewis, Tuddenham, editors 1999).
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All the high oxygen affinity variants have a left-shifted oxygen dissociation curve
with a reduced P50. Thus, the variant haemoglobin holds on to oxygen more avidly
than normal haemoglobin; this potentially lead to tissue hypoxia. This in turn causes
an increased output of erythropoietin and an elevated red cell mass. Most patients
with this type ofHb are healthy and are only identified when a routine
haematological examination shows an unusual high Hb level or packed cell volume.
Low oxygen affinity variants
At least six haemoglobin variants with reduced oxygen affinity have been reported
such as Kansas haemoglobin. The amino acid substitution is at the interface between
the a and P globin chains. This condition should be thought of in any patient with an
unexplained congenital cyanosis (Hoffbrand, Lewis, Tuddenham, editors 1999).
Sickling disorder
Sickling disorder occurs due to the presence of an abnormal Hb variant, namely
haemoglobin S (HbS). HbS has increased oxygen affinity. Due to the number of
relevant genes, the propotion of a-chain variant is half that of a P-chain variant. HbS
undergoes liquid crystal formation as it becomes deoxygenated due to unusual
solubility characteristics. Fully oxygenated sickle cells are more rigid than normal
and tend to adhere to vascular endothelium. Factors such as hypoxia and infection
can trigger sickle cell crises that characterised by cyanosis, haemolysis, and thrombo¬
embolic manifestations.
Acidosis profoundly affects the sickling of red cells, even when oxygen saturation is
normal. Alkalosis, on the other hand, by shifting the equilibrium toward the oxy
confrontation, tends to retard sickilng but impairs oxygen release to tissue. In
standard conditions, HbS shows low P50 levels [12-15 mmHg] with markedly shift
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of the oxygen haemoglobin dissociation curve to the left (Beutler, Lichtman, Coller,
Kipps, editors 1995; Hoffbrand, Lewis, Tuddenham, editors 1999).
OXYGEN TRANSPORT
OXYGEN CONTENT
Each 100 ml of blood contains about 20 ml of oxygen, almost all of which is carried
on the haemoglobin. Oxygen is poorly soluble in blood.
The oxygen content ofblood (Co2) is: (Aitkenhead, Smith, editors 1996)
C02 (ml. 100 ml"1 blood) = 0.023 x P02 (kPa) + (1.34 x Hb (g.dl"1) x S02 (%)/100.
From the above-mentioned equation, blood oxygen content can be affected by:
Anaemia, carbon mono-oxide (CO) poisoning, pulmonary diseases, and abnormal
haemoglobin structure (Brobeck 1979).
OXYGENDELIVERY
Oxygen delivery is a function of cardiac output and arterial 02 content. Arterial 02
content is dependent on haemoglobin concentration and percentage of 02 carried by
the haemoglobin molecule, or saturation. Oxygen dissolved in plasma contributes a
negligible amount to overall delivery (Thamer, Richard, Klinkmann, Ivanovich,
Lang, Cotter 2000).
Oxygen transport variables
a. D02 = CO X Ca02
D02= 02 delivery
CO= cardiac out-put
Ca02= arterial oxygen content
b. Ca02= % saturation of haemoglobin X 1.34 (mL/g) X [Hg] (g/L)
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c. C0= HRX SV
HR= heart rate
SV= stroke volume (Webb, Shapiro, Singer, Suter, editor 1999; Thamer, Richard,
Klinkmann, Ivanovich, Lang, Cotter 2000).
An absolute reduction in D02 could occur as a result of a reduction in haemoglobin,
Pa02, and hence Sa02(% of Hb oxygen saturation), or from a reduction in CO which
could be the result of low stroke volume or heart rate (Webb, Shapiro, Singer, Suter,
editor 1999).
CARBON DIOXIDE TRANSPORT
Carbon dioxide is carried in the blood in three forms; dissolved, as bicarbonate, and
in combination with proteins as carbamino compounds.
Haemoglobin is an important element in the carriage of carbon dioxide. Oxygenation
of the haemoglobin molecule causes the release of a proton, which in turn, reacts
with bicarbonate to liberate C02 according to the following reaction
HHB (deoxy Hb) + 02 ^ Hb02 " + H+
H+ + HC03 " 5=t H2C03 ^ H20 + C02
The reactions take place in the lungs in the direction indicated; in peripheral tissues
the reactions are reversed and allow more C02 to be carried in venous blood.
Within the red cell, a zinc-containing enzyme, carbonic anhydrase (c.a.), greatly
facilitates the transport ofC02 from the tissue to the lungs
H20 + C02 5=s H2C03 (in the presence of c.a.)
16
Haemoglobin also forms carbamino complexes to aid in the transport of carbon
dioxide.
RNH2 + C02^ RNHCOOH
Deoxyhaemoglobin binds more C02 as a carbamino compound than does the
oxyhaemoglobin, and the haemoglobin shuttle between oxyhaemoglobin and reduced




Anaemia in an individual is defined as a haemoglobin concentration in blood that is
below the expected value, when age, gender, pregnancy and certain environmental
factors, such as altitude, are taken into account (Emmanuel, McClelland, Page,
editors 1997).
It is also defined as a reduction in red cell mass, resulting in a lowered haemoglobin
and haematocrit level, and leading to a decrease in the oxygen-carrying capacity of
the blood (Webb, Shapiro, Singer, Suter, editor 1999).
World Health Organization Criteria to define anaemia based on normal haemoglobin
range at the see level are shown in table (1.4) (Emmanuel, McClelland, Page, editors
1997).






First trimester: 0-12 weeks
Second trimester 13-18
weeks
















These values simply define anaemia. They are often used as thresholds for
investigation and treatment, but not indications for transfusion.
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The National Cancer Institute (NCI) considers normal haemoglobin levels as 120 to
160 g/L for women and 140 to 180 g/L for men. The World Health Organization
(WHO) and the National Cancer Institute have provided scales for characterizing
haemoglobin levels, shown in table (1.5) (Yount, Lai, Cella 2002).
Table (1.5): NCI and WHO scales of anaemia (Yount, Lai, Cella 2002)
Grade (severity) NCI scale WHO scale
0 (none) Normal limits** >110
1 (mild) 100 to normal 95 to 109
2 (moderate) 80 to 100 80 to 94
3 (severe) 65 to 79 65 to 79
4 (life-threatening) <65 <65
Hb values (g/L).
** 140 to 180 g/L for mean and 120 to 160 g/L for females.
CLASSIFICA TION OFANAEMIA
Anaemia can be classified according to its pathological causes in several ways. Two
common approaches are:
1. According to red blood indices namely mean red cell volume, mean red cell
corpuscular haemoglobin and mean corpuscular haemoglobin concentration
[MCV, MCH and MCHC respectively] (table 1.6)
2. According to pathophysiology (table 1.7)
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Table(1.6):Classificationofanaemiac ordingtredbl oc llindi s(Emm nuel,McCl lland,P g ,editor1997). Bloodfi mRedcellindices
Cause
Microcytic,hypochromicwithabnonnalred cells Macrocytic,norm chromic Macrocyticpolychromasia
Lowmeanc llvolume(MCV) Lowmeanc llhaemoglobin(MCH) Lowmeanc llhaemoglobi concentration(MCHC)
IncreasedMCV IncreasedMCV
Acquired
•Irondeficiency •Sidroblasticanaemia •Anaemiaofchronicdis rder
Congemital
•Thalassaemia •Sideroblasticanaemia.












•Leukaemia Metastaticc ncer Myelofibrosis Severeinf ctions
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Table(1.7):Classificationofnaemiac ordingti pathophysiologyBeutl r,Lichtmall r,Kiedit r1995) Anaemiapr dominantlycausedbydecreadllo uctioAna usedincre sede ythrocytedestructi nolos
a.Disturbanceofproliferationnddifferenti tiohaemopoietic stemcells (1)Aplasticanaemia (2)Anaemiaofleukandmyelodysplastics n rome b.Disturbanceofproliferationanddifferenti tionryth oid progeniororrecurs rc lls (1)Purecellaplasia (2)Anaemiaofchronicr nalfailure (3)Anaemiaofendocrinedis r ers (4)Congenitaldyserythropo eticanaemia c.DisturbanceofNAsynthesis(megalo lasticana mia) (1)VitaminB 2deficie cy (2)Folicaciddeficiency (3)Acquiredandcongenitaldefectsip ri erim din metabolism d.Disturbanceofhaemoglobinsynthesis(hyp chr m canae ia) (1)Irondeficiencyanaemia (2)Congenitaltra sferri aemiandidi pathicpulmon ry haemosidrosis (3)Thalassemia e.Disturbanceoferythropoieticr gul tion (1)Lowxygenaffinityhaemoglobinopathies
a.Intrinsicb ormality (1)Membraned fect (a)Hereditaryspherocytosis,ellipocytosis,and pyropoikilocytosis (b)Hereditaryacanthocytosisdstomatocytosis (2)Enzymedeficiency (a)Glucose-6-phosphatedehydrogenaseeficiency (b)Pyruvatekinasdeficiency (c)Prophyria (3)Globinabnormality (a)Sickleellanaemia (b)Unstablehaemoglobin (4)Paroxysmalnocturnhaemoglobinuria b.Extrinsicab ormality (1)Mechanical (a)Marchhaemoglobinuriandsportanaemia (b)Traumaticcardiahaemolytianaem a (c)Microangiopathichaemolyticanaem a (2)Chemicalorphysica (a)Haemolyticanaemiadutchemicalorp ysical agents
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Anaemiapr dominantlycausedbydecreadllproductioac usedincre sede ythro ytedestructi nolos
f.Unknownmultipleechanisms (1)Anaemiaofchronicdis rders (2)Anaemiassociatedwithmarrowinfiltr ti n (3)Anaemiaassociatedwithnutrition ldeficien ies Sideroblasticanaemia
(3)Infection (a)Haemolyticnaemiadutinfectionwith microorganisms (4)Anti-bodymediator (a)Acquiredhaemolyticanaem adutw rm- reactingautoantibodies (b)Cryopathichaemolytisyndrome (c)Drugreactioninvolvi gantibodiesr ctiwith reythrocytes (d)Alloimmunehaemolyticdiseasefthenewborn (5)Hyperactivityofthemonocyte-m crophagesyst m (a)hypersplenism (6)Bloodloss (a)Acutebloodlossanaemia
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CLINICAL IMPORTANCE OFANAEMIA
Anaemia is a condition of low haemoglobin level, which is the main oxygen carrier
to the tissues. A lower Hb level can potentially affect oxygen delivery to all of the
body's organs. This can lead to serious health problems. Areas that are often
highlighted in literature are as follow:
Impaired quality of life and fatigue
Symptoms of anaemia generally affect quality of life. It has been shown that 31% of
patients with severe anaemia due to renal causes have severe impairment of quality
of life (Valderrabano 2000). Anaemia due to malignancy contributes to fatigue and
low quality of life scores (Sabbatini 2000). Some studies have shown that increasing
Hb level in anaemic patients with different diseases such as chronic renal failure,
malignancy, inflammatory bowel diseases, and rheumatoid is associated with better
quality of life (Gasche, Dejaco, Waldhoer et al. 1997; McMahon, Mason, Skinner,
Burge, Grigg, Becker 2000; Quirt, Robeson, Lau et al. 2001).
Increased cardiovascular morbidity
Compensatory haemodynamic changes during anaemia, which lead to increased
cardiac output and systemic blood flow are associated with cardiac morbidity due to
increased cardiac work at a time of decreased oxygen supply to the heart muscles
(Eckardt 1999). For example, it has been shown that renal patients with Hct < 33%
have higher cardiac death rates than patients with Hct >33% (Collins, Li, St Peter et
al. 2001). The presence of coronary disease is widely acknowledged as a factor that
may decrease tolerance to anaemia.
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Hinder cognitive function
Low oxygen delivery to the brain due to low Hb level is associated with impairment
in cognitive function (Kusunoki, Kimura, Nakamura, Isaka, Yoneda, Abe 1981). It
has been shown that elevating Hct level in patients with cerebrovascular disorders
was associated with significant improvement in cognitive function. In anaemic
patients with renal disease, correction of Hb levels to its normal level was shown to
improve neurophysiological parameters indicative of cognitive function and memory




PREVALENCE OF ANAEMIA AMONG SURVIVORS OF CRITICAL
ILLNESS MANAGED WITH CONSERVATIVE TRANSFUION
TRIGGERS
Anaemia is common in the critically ill. The pathogenesis of anaemia in this
group of patients is very complex. Regardless of the heterogeneity of underlying
diseases and complications necessitating ICU treatment, anaemia is extremely
common in this patient population. Many patients are already anaemic when
admitted to the ICU. This holds true not only for post-operative admissions, but
also for patients with medical diseases (Rogiers, Zhang, Leeman et al. 1997;
Hebert 2000; Vincent, Baron, Reinhart et al. 2002; Eckardt 2002).
REVALENCE OF ANAEMIA IN CRITICALLY ILL PATIENTS
A TADMISSION TO ICU
A recent history of anaemia before ICU admission is associated with the incidence
and the degree of anaemia at the time of admission. Vincent et al found that at the
time of ICU admission, 13% of patients had a recent history of anaemia; of those
patients, 36.6% had an admission haemoglobin less than 10 g/dL. Of all patients with
an admission haemoglobin level less than 10 g/dL, 48.9% had neither a history of
anaemia nor of acute bleeding before admission (Vincent et al. 2002).
Some studies have investigated the prevalence of anaemia at the time of ICU
admission. Eckardt et al showed that nearly halfof ICU admissions had reduced
haemoglobin concentration. In this study patients with an Hb < 120 g/L had a
significantly worse prognosis than those admitted with higher Hb values (Eckardt
2002).
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Table (2.1) shows the reported published ICU admission haemoglobin in some
studies. None of these studies have mentioned the normal reference ranges for Hb
or Hct.
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Progression of anaemia during the period of ICU treatment is reflected by further
reduction in mean Hb levels and frequent blood transfusion. Some studies have
specifically investigated Hb levels and their change during ICU stays.
In a prospective observational cohort study, which took place in a large Scottish
ICU unit, Chohan et al found that 55% of ICU patients who spent > 24 hours in
ICU had Hb < 90g/L at least once during their ICU stay. 52% of these patients
had Hb < 90g/L on the first day of ICU admission, and 77% had Hb < 90g/L
within 2 days of admission (Chohan, McArdle, McClelland, Mackenzie, Walsh
2003). In another study, von Ahsen et al. also showed that 77% of all ICU
admissions had Hb level of< 90g/L by day two of ICU stay (von Ahsen, Muller,
Serke, Frei, Eckardt 2001).
Some authors found that by intensive care unit day 3, almost all patients (95%)
admitted became anaemic (Eckardt 2002) (Goldhill, Boralessa, Boralessa 2002)
(Hobisch-Hagen et al. 2001).
In a multi-centre Canadian randomised control trial, Hebert et al studied patients
where Hb was < 90 g/L within 72 hours of ICU admission. The average ICU Hb
concentration in patients randomised to a Hb transfusion trigger < 70 g/L and
transfused with one red cell unit on each occasion was 85 g/L (Hebert, Wells,
Marshall et al. 1995).
Nguyen and colleagues studied the time course of haemoglobin concentrations in
non-bleeding intensive care unit patients. They found that for the entire ICU stay,
the fall in haemoglobin concentrations averaged 0.52 g/dL/day. In those patients
who stayed in the ICU for >3 days, haemoglobin concentrations decreased by
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0.66 g/dL/day for the first 3 days and by 0.12 g/dL/day thereafter. For patients
who stayed at least 1 week, haemoglobin concentration decreased by 0.58
g/dL/day during the first 3 days and by 0.21 g/dL/day thereafter (Nguyen, Bota,
Melot, Vincent 2003).
CAUSES OF ANAEMIA DURING CRITICAL ILNESS
In general there are three potential causes of anaemia in critically ill patients: 1)
blood loss, 2) reduced red cell life span and 3) disturbed erythropoiesis.
BLOOD LOSS
Von Ahsen et al. estimated total blood loss of patients during their intensive care
unit stay and found that total blood loss, as estimated from the difference
between the initial and last measured Hb concentration and the amount of Hb
transfused during the ICU stay, was a median of 128 mL per patient per day (von
Ahsen, Muller, Serke, Frei, Eckardt 2001). The authors suggested that blood loss
in ICU patients is mainly due to frequent diagnostic blood sampling (diagnostic),
hidden and major bleeding (non-diagnostic).
Blood sampling
ICU patients may face the dilemma of an iatrogenic transfusion requirement
because ofmultiple blood sampling. Andrews et al quantified the mean number
ofblood gas samples taken per patient and estimated the mean blood loss
resulting from this, in the critically ill. They found that patients who were
ventilated for >24 hours had a statistically significant greater blood loss (mean
50.16 ml per day) when compared to those who were ventilated for less than a
day (mean 34.33 ml per day). A subgroup of patients who underwent renal
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replacement therapy had the greatest blood loss (mean 55.18 ml per day). This
increased loss was significantly greater when compared to patients not in acute
renal failure (mean 42.18 ml per day). When patients underwent multiple
therapies such as total parental nutrition, potassium replacement and insulin
therapy that are frequently thought to be associated with increased sampling,
there was no statistically significant difference in blood loss (mean 48.28 ml per
day) (Andrews, Waterman, Hillier 1999).
Vincent et al. determined the frequency ofblood drawing and the associated
volume ofblood lost. They found that the number and volume ofblood samples
drawn in the 24-hour period varied widely across patients. The mean number of
draws per patient was 4.6, the mean volume per drawn was 10.3 ml, and the
average total volume was 41.1 ml for the 24-hour period. They also studied the
relation between number of blood samples draw and organ dysfunction, and they
found that there was a significant positive correlation between organ dysfunction
and number ofblood draws and total volume drawn (Vincent et al. 2002).
Von Ahsen et al. found that the median volume of diagnostic blood loss declined
from 41 mL on day 1 to less than 20 mL after 3 weeks of ICU admission and
contributed 17% (median) to estimate total blood loss. Acute renal failure, fatal
outcome, and high-simplified acute physiology score on admission were
associated with increase in total blood loss (von Ahsen, Muller, Serke, Frei,
Eckardt 2001).
142 ICU patients were studied by Corwin et al. to detennine the amount of
diagnostic blood loss. These authors found that these patients were
phlebotomized a total of 176 L of blood for diagnostic tests during their ICU
32
stay. The mean daily blood sample volume withdrawn from non-transfused
patients was 45 ml/day, for patients who were transfused with 1 to 5 units was 61
ml/day and for patients who were transfused more than 10 units was 70 ml/day.
They commented in their study that phlebotomy for diagnostic tests can lead to
reduced haemoglobin levels and increase the likelihood of red cell transfusion,
and that patients who had a daily phlebotomy were more likely to be transfused
compared with those who did not (Corwin, Parsonnet, Gettinger 1995).
There are many causes for blood sampling in ICU patients. Vinh Nguyen Ba et al,
described briefly the number, volume and different causes for withdrawing blood
from patients in ICU and they reported that the mean volume of a standard blood
sample was 3 to 4 mL. The mean volume of a blood gas sample was 1.5 mL, with
an additional 2 mL of discarded blood. Blood culture sampling involved a
specimen of 10 mL, usually taken three times. The average number of blood
samples per day was 11.7, and the total volume ofblood taken per day was 40.3
mL. The number ofblood samples each day was 14.0 for septic patients and 10.9
for non-septic patients. The mean blood volume drawn daily was 49.0 mL in the
septic patients and 36.7 mL in the non-septic patients (Nguyen, Bota, Melot,
Vincent 2003).
Non-sampling blood loss
Non-acute blood loss in critically ill patients is considered by some to play a
major role in ICU anaemia. It is possible that much of it is caused by occult
bleeding from the gastrointestinal tract due to impairment in mucosal integrity,
which can be found in many critically ill patients. However, such losses are
difficult to quantify and can take different forms such as haematemesis, grossly
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bloody nasogastric aspirates, and nasogastric aspirates containing coffee grounds
material, and melaena (Cook, Fuller, Guyatt et al. 1994; Eckardt 2001).
Stress ulceration can cause overt and clinically important bleeding in critically ill
patients. Although the pathophysiology is not completely understood, factors that
may play an aetiological role include decreased gastric pH, increased gastric
mucosal permeability, and ischaemia. In a prospective study by Schuser et al. of
174 patients in a medical/respiratory ICU to evaluate the occurrence of upper
gastrointestinal bleeding, they found that 14% of ICU patients had overt or occult
gastrointestinal bleeding after ICU admission. These patients had higher
mortality and increased length of ICU stay than non-bleeding patients (Schuster,
Rowley, Feinstein, McGue, Zuckerman 1984; Cook, Heyland, Griffith, Cook,
Marshall, Pagliarello 1999).
Von Ahsen et al. recorded the amount of diagnostic blood loss and estimated the
total blood loss from the changes in Hb levels and the amount of red cells
transfused. They found in many patients treated for long periods in the ICU that
the contribution of diagnostic blood loss to the total blood loss amounted to 17%
(range, 10%-28%), they referred the other 83% of total blood loss to various
other reasons, e.g., occult gastrointestinal bleeding and renal replacement
therapy. However, occult blood losses, by definition, were not directly measured
in this study (von Ahsen, Muller, Serke, Frei, Eckardt 2001).
Cook et al. described briefly in a multi-centre randomised study the blood loss
during ICU stay for 1200 patients who required mechanical ventilation. They
found 23.3% of all cases had gastrointestinal bleeding episodes such as
haematemesis, bloody nasogastric aspirate, and melaena in the first 5 days of
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ICU stay, on days 6-10 (43.3% of cumulative cases), days 11-15 (73.3% of
cumulative cases), day 16-20 (80.0% of cumulative cases), and after day 21
(100.0% of cumulative cases). The overall incidence of clinically important
bleeding was 1.93 per 1000 ICU days. The authors defined clinically important
bleeding as a) overt gastrointestinal bleeding with a spontaneous decrease in
blood pressure >20 mmHg within 24 hours of bleeding, b) an increase in pulse
rate of 20 beats/min with decrease in systolic blood pressure of 10 mmHg, c)
decrease in Hb of> 20 g/L within 24 hours and transfusion of 2 units of red
blood cell, and d) failure of the Hb to increase by at least 20 g/L after transfusion
with 4 units of red cells (Cook, Heyland, Griffith, Cook, Marshall, Pagliarello
1999).
In another multi-centre study, Cook et al. investigated the risk factors for
clinically important gastrointestinal bleeding in critically ill patients. Clinically
important bleeding occurred in 1.5% of all patients after a mean of 14 days from
admission. The risk factors were respiratory failure, coagulopathy, hypotension,
sepsis, hepatic failure, renal failure, enteral feeding, glucocorticoids
administration, organ transplantation, and anti-coagulant therapy. They found
that respiratory failure and coagulopathy were the only independent risk factors.
31% ofpatients with high risk factors and 0.1 % of patients at low risk had
clinically significant bleeding (Cook et al. 1994).
In another multi-centre study by Cook et al. to estimate the effect of clinically
important gastrointestinal bleeding on mortality and ICU length of stay, the
authors studied 1666 critically ill patients, of whom 59 patients developed
clinically important bleeding. The authors found when they used different
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analytic approaches to explore the risk of death in relation to clinically important
gastrointestinal bleeding that this risk was increased in bleeders (relative risk =
2.9, 95% confidence interval (CI)= 1.6-5.5). They found also that bleeding was
associated with a significant increase in the length of ICU stay (median length of
stay attributable to clinically important bleeding = 3.8, 95% CI = -0.01 to 7.6
days) (Cook, Griffith, Walter et al. 2001).
Cook et al. did a multi-centre randomised trial to compare the use of sucralfate
with H2- receptor antagonist for the prevention of upper gastrointestinal
bleeding. They found that critically ill patients who received H2 receptor
antagonist had a significantly lower rate of clinically important bleeding (Cook,
Guyatt, Marshall et al. 1998).
Some studies related clinically important gastrointestinal bleeding to different
risk factors. Schuster et al evaluated prospectively the risk of upper
gastrointestinal bleeding after admission to a medical intensive care unit. They
found that there were no statistically significant relationships with patient's age,
chronic obstructive pulmonary disease, hypotension and/or shock. There were
statistically significant relationships with number of days in ICU, coagulopathy,
acute respiratory illness, malignancy, sepsis, requirement for mechanical
ventilation, and days ofmechanical ventilation (Schuster, Rowley, Feinstein,
McGue, Zuckerman 1984).
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REDUCED RED CELL SURVIVAL
Little is known about red cell life span during critical illness. However considering
the systemic inflammatory response and complement activation, a premature
destruction of red cells is possible. In particular the survival time of transfused red
cells may be reduced in this group of patients. Under conditions during which the
intra-vascular lifetime or red cells are reduced, either due to external blood loss or
due to premature destruction, the ability to increase red cell production in the marrow
becomes particularly relevant (Eckardt 2001).
Disturbed erythropoiesis
Disturbed eryrthropoiesis is increasingly recognised to be a potentially major
contributor to anaemia in association with critical illness. Measuring reticulocyte
count or percent can assess erythropoietic activity of the bone marrow (Beutler,
Lichtman, Coller, Kipps, editors 1995; Seidenfeld, Piper, Aronson 2002). Several
studies have shown that anaemic critically ill patients have low or nonnal
reticulocyte count and/or reticulocyte percent. Table (2.2) summarises mean Hb
or Hct values and the corresponding reticulocyte count or percent in studies
related to the critical care setting.
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Table (2.2): Summary ofmean values of Hb or Hct and reticulocyte % measured
in the critically ill patients.
Author Hct (%) or Hb (g/L) Reticulocyte percent (%)
or count (x 109/L)
Corwinetal. 30.4±3.7% 1.7 ± 1.1%
(Corwin 2001c)










Corwinetal. 99.7 g/L 1.82%
(Corwin 2001a)
All the above-mentioned studies agreed that in anaemic critically ill patients there
is disturbance in erythropoiesis that is reflected by low reticulocyte count or
percent. However, they did not mention the normal reference ranges for Hb, Hct,
reticulocyte count, or reticulocyte percent.
Corwin et al. showed that when the mean reticulocyte percent increased by 2.5%
(from the baseline to the final value), the mean Hct also increased by 4.8%. In
another group of patients when the mean reticulocyte percent increased by 0.8%,
the mean Hct increased by 1.4%. This results emphasis the fact that any change
in reticulocyte production is usually accompanied by change in the degree of
anaemia.
There are several possible mechanisms of abnonnal and/or inadequate red cell
production [table (2.3)].
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Effect of inflammation on bone marrow
Iron metabolism during critical illness
Anaemia in many critically ill patients as well as in patients with chronic
inflammatory diseases is characterized by an imbalance in iron homeostasis.
During the immune response, iron is shifted from the environment into immune
cells, where it is incorporated into the storage protein ferritin. Consequently, the
anaemia of chronic disease is characterized by low serum iron concentrations
despite increased storage iron. The iron transport protein transferrin may be at the
lower limit or below normal. Recent suggestions focus on an association between
activation of the immune system and the development of anaemia in critically ill
patients (Hobisch-Hagen et al. 2001).
More than 90% of ICU patients have low serum iron, low total iron binding
capacity, and low serum iron/total iron binding capacity ratio but do have a
normal or, more usually, an elevated serum ferritin concentration. There is
usually no evidence of adequate reticulocyte response (Corwin 2001a; Corwin
2001b; Weiss 2002). von Ahsen et al. measured the parameters of erythropoiesis
in critically ill patients during the course of their disease. The median reticulocyte
count was 57 xl015/L during the first 2 days of ICU admission, during the period
between 6th and 8th day of admission was 47 xlOl5/L; and nearly after 2 weeks of
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admission it was 45 xl015/L.The authors did not mention the normal reference
range (von Ahsen, Muller, Serke, Frei, Eckardt 2001). However, Bellamy et al.
suggested that at ICU admission, 35% of patients could have functional iron
deficiency, suggested by the presence of hypochromic red cells and reduced
reticulocyte Hb concentration (Bellamy, Gedney 1998). Functional iron
deficiency is thought to indicate adequate iron stores but a block to incorporating
iron into newly fonned red cells. Bellamy et al. also found that patients with
functional iron deficiency had longer stays in intensive care compared with
patients without functional iron deficiency. They explained the results by
suggesting that functional iron deficiency may be a marker of nutritional status or
general health (Bellamy, Gedney 1998).
Research in animals and humans has suggested that adequate iron scores are
important for immune function and a deficiency may, therefore, predict patients
with inappropriate immune responses. Patients may also develop functional iron
deficiency in response to immune activation (Bellamy, Gedney 1998).
Rodriguez RM et al. carried out a multi-centre cohort study to determine the
prevalence of iron, vitamin B12, and folate deficiency in long-term intensive care
unit patients as a part of a study to evaluate erythropoietin response in this cohort.
Out of 5288 patients admitted to their ICUs only 184 patients were screened for
iron, B12, and folate deficiency. The authors defined B12 and folate deficiency if
their levels were below the hospital laboratory reference range (the actual levels
were not mentioned in the paper). Iron deficiency was diagnosed when iron/total
iron binding capacity ratio of<15% combined with a ferritin <100 ng/L was
present. Percentage of patients with iron deficiency was 9%. The authors
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described the characteristics of the 160 anaemic critically ill patients not iron,
folate, or B12 deficient [table (2.4)]. The mean Hb for this group of patients was
103 g/L (Rodriguez, Corwin, Gettinger, Corwin, Gubler, Pearl 2001).
Table (2.4): Summary of the characteristics of critically ill patients not iron,
folate, or B12 deficient (Rodriguez, Corwin, Gettinger, Corwin, Gubler, Pearl
2001).
Percentage
Mean ± SD age
Mean ICU length of stay







Mean total iron binding capacity
Mean ferritin
83%
60.3 ± 19.2 years old
18 ± 16.5 days
24% pneumonia, 21% other




103 ± 12 g/L
1.66 ± 1.09%
27.5 ± 32 pg/dl
170.2 ±65.3 pg/dl
726.8 ± 1203.7ng/mL
The authors did not mention the nonnal reference ranges for the parameters.
These findings emphasise the fact that at an early point of critical illness, most
patients have iron studies similar to the anemia of chronic disease (Rodriguez,
Corwin, Gettinger, Corwin, Gubler, Pearl 2001).
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Two other studies recorded parameters of iron metabolism during the course of
the critical illness. Table (2.5) summarizes data from these studies.









*von Median Median Median Median
Ahsen
et 1-2 4.8 471 144 16
al.(von
Ahsen, 6-8 6 767 126 15
Muller,
Serke, 13-15 6.5 795 131 22
Frei,
Eckardt 20-25 8.1 774 142 24
2001)
31-40 7.8 723 152 20
**van Mean Mean Mean Mean
Iperen
et 0 20.5 891 1.4 0.12
al.(van
Iperen, 10 28.4 1273 1.5 0.14
Gaillard







* Nonnal reference ranges: iron = 7-30 pmol/L, ferritin = 10-300 ng/ml,
transferrin = 200-400 mg/dL, and transferrin saturation (%) = not mentioned.
** Nonnal reference ranges: iron = 55-170 pg/dL, ferritin = 10-200 pg/L,
transferrin = 2-3.6 g/L, and transferrin saturation = 0.20-0.45 (fraction).
Erythropoietin concentration during critical illness
Increasing knowledge in the critical care setting indicates that the anaemia
commonly seen in critically ill patients represents a combination of blood loss
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and an "acute" anaemia of chronic disease. EPO levels that are inappropriately
low for the degree of anaemia characterize this type of anaemia (Goodnough
2001).
In contrast to patients with iron-deficiency anaemia, most critically ill patients
display blunted erythropoietin response to physiologic stimuli despite
comparable haemoglobin concentrations. Inflammatory mediators appear to
cause the blunted EPO response by inhibiting the genomic regulation of
transcriptional and/or posttranscriptional events (Hobisch-Hagen et al. 2001;
Corwin 2001a).
Serum EPO concentrations are only mildly elevated, with little evidence of
reticulocyte response to endogenous EPO in critically ill patients (Corwin
2001b). Rodriguez et al. aimed to evaluate erythropoietin (EPO) response to
anaemia in a cohort of long-term intensive care unit patients. The mean and
median day 2 EPO levels in their study were not significantly higher than the
nonnal level and serial EPO levels in most persistently anaemic patients
remained within the nonnal range (Rodriguez, Corwin, Gettinger, Corwin,
Gubler, Pearl 2001).
Table (2.6) summarizes published studies that have measured EPO levels in
critically ill patients during ICU stay. Comparing the results of these studies was
difficult as the authors used different reference ranges for EPO level and some
authors did not mention the nonnal reference range.
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Rodriguezet al.(Rodriguez, Corwin, Gettinger, Corwin, Gubler,Pearl 2001)
4.2-27.8 mlU/ml
Mean±SDmlU/ml 35.2±35.6 28.3±31.5 33±54.4 21.5±16 7 29.8±23.6
Notincludedth paper
Day2 Week1 Week2 Week3 Week4
113 41 29 12 9
Hobisch-EIagen


























































































Nutritional deficiencies during critical illness
Malnutrition is a common problem in critically ill patients that can be present
upon admission to the ICU or can develop during the course of critical illness.
Deficiencies of folate and/or vitamin B,2 could occur as a part of the malnutrition
process that occurs during critical illness (Cerra, Benitez, Blackburn et al. 1997).
Few studies have investigated the prevalence of different types of anaemia during
ICU admission. Rodriguez et al. aimed to determine the prevalence of vitamin
B12, and folate deficiency. They found that 2% were B12 deficient, and 2% were
folate deficient on the second or third day of ICU admission, however, the
authors did not mentioned serum levels of these parameters (Rodriguez, Corwin,
Gettinger, Corwin, Gubler, Pearl 2001).
In another prospective clinical study in a medical intensive care unit, von Ahsen
and colleagues measured parameters of erythropoiesis and red blood cell
metabolism that included vitamin B12, and folic acid levels during ICU stay. The
nonnal reference range used for B12 was 240-1100 ng/L and for folate was >3.6
pg/L.Table (2.7) summarises the median values of Hb, B12, and folate for the
study during the follow up period (von Ahsen, Muller, Serke, Frei, Eckardt
2001).
Rogiers el al. measured vitamin B12 and folic acid levels in critically ill patients
in one of their studies. They did not show the data, however, they mentioned that
their levels were within nonnal limits (Rogiers et al. 1997).
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Table (2.7): Summary of the median levels of Hb, B12, and folate in critically ill
patients (von Ahsen, Muller, Serke, Frei, Eckardt 2001).
Day Fib g/L B12 ng/L Folate pg/L
1-2 113(n = 71) 565 (n = 30) 4.1 (n = 31)
6-8 109 (n = 51) 612 (n = 32) 4 (n = 31)
13-15 104 (n = 25) 784 (n= 15) 4.6 (n- 15)
20-25 104 (n = 17) 723 (n= 14) 3.9 (n = 14)
31-40 112 (n = 8) 983 (n = 8) 5 (n = 8)
n = number of patients
Effect of inflammation on the marrow during critical illness
Released pro-inflammatory cytokines, e.g., tumour necrosis factor-[alpha] (TNF-
[alpha]), interleukin-1 (IL-1), and interleukin-6 (IL-6) inhibit erythroid precursor
cells formation from the bone marrow and reduce the formation of erythropoietin
(EPO). The mechanism of this type of anaemia is still unclear. There are some
different explanations for mechanisms by which cytokines might affect
erythropoiesis such as; a) direct inhibitory effect on red cell production, b)
inflammation may impair iron availability for erythropoiesis, c) critically ill
patients have inappropriately low erythropoietin concentrations for the degree of
anaemia (Gabrilove 2000; McLellan, McClelland, Walsh 2003).
Another explanation for the effect of inflammatory cytokines on erythropoiesis
was given in a review by Ebert et al. where they clarified that the production of
erythropoietin is under the influence of a gene (EPO gene). Inflammatory
cytokines affect EPO gene expression and thus affect EPO production and
erythropoiesis (Ebert, Bunn 1999).
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Rogiers P. et al. did a study to investigate the relationship between endogenous
EPO and haematocrit levels in different groups of critically ill patients. They
included ambulatory patients with iron-deficiency anaemia, without acute illness,
or acute renal failure as a control group. The mean EPO and Hct levels of the
study are shown in table (2.8)
Table (2.8): Summary of the mean EPO level and Hct in critically ill patients
(Rogiers et al. 1997).
Group EPO level (IU/L) Haematocrit(%)
Control (iron deficiency anaemia) 845 30.3
Sepsis without acute renal failure 124 28.9
Sepsis with acute renal failure 136 28.2
Non-sepsis without acute renal 199 29.8
failure
Non-sepsis with acute renal failure 103 32.4
The authors concluded that EPO response to anaemia is blunted in critically ill
patients, in acute renal failure, and in the presence of sepsis. They suggested this
might result from the production of pro-inflammatory mediators (Rogiers et al.
1997).
Hobisch-Hagen et al assessed the relation between anaemia, serum erythropoietin,
iron status, and inflammatory mediators in multipally traumatized critically ill
patients. They measured serum EPO, some inflammatory markers, some serum
cytokines, and iron status. They found that haemoglobin concentration was low at
admission and did not increase during the observation time. Serum EPO
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concentration was low and did not show significant increases thereafter. No
correlation was found between EPO and haemoglobin concentrations. Serum iron
was significantly decreased on day 2 post-trauma and remained low during the
study. Serum ferritin increased steadily from day 2, reaching its maximum on day
9. In contrast, concentrations of transferrin were low from admission onward. TNF-
a remained within the normal range. sTNF-rl was high at admission and increased
further. ILl-ra was above the normal range. IL-6 was very high at admission and
did not decrease thereafter. The initial neopterin concentration was normal, but
increased until day 9. Significant correlations over time were found for EPO/IL1-
ra, EPO/ferritin, and reticulocytes/ferritin. Haemoglobin was not correlated with
any of the measured parameters (Hobisch-Hagen et al. 2001).
In summary, studies that investigated the relation between inflammatory mediators
and anaemia of critical illness have shown that there is an association between
some erythroid and inflammatory indices. However, these studies did not prove
that it was a causative relationship.
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CRITICAL HAEMOGLOBIN CONCENTRATION IN CRITICAL ILNESS
The minimal haemoglobin level tolerated in the absence of haemorrhage without
organ dysfunction is often referred to as "critical haemoglobin." Below this level,
compromised oxygen delivery can occur, resulting in a decrease in oxygen
consumption or an increase in lactate. Decrease in oxygen delivery, and in turn
oxygen consumption is called the "critical oxygen delivery". It is important to realize
that the critical delivery is not a fixed value, but varies between organs and is
dependent on the metabolic activity of the tissue (Spahn, Casutt 2000; McLellan,
McClelland, Walsh 2003).
The critical haemoglobin in the critical care setting is uncertain because of lack
of data from controlled trials, and practice guidelines are based primarily on
expert consensus and, therefore, vary in their recommendations. The decision to
accept a certain level ofHb does not depend only on Hb levels, but it is usually
based on factors such as volume status, acuteness of the anaemia, severity of the
symptoms, age and the presence of co-morbid conditions, particularly
cardiovascular and pulmonary diseases (Sherk, Granton, Kapral 2000).
Few studies have investigated the critical haemoglobin values in humans, as it is
difficult to do such studies. Valuable data are available from: a) healthy
volunteers, b) surgical setting, c) case reports and data collected from Jehovah's
Witness patients, and d) animal studies. Table (2.9) summarises some of these
studies.
50
Table(2.9):Summaryofpublishedstudi sthatinvestigat dcr ticalHblevel AuthorTypeofstudyAimofthestudy
Settings
Resultsandconclusions
Haisjacklet al.(Haisjackl, Luz,Sparret al.1997)
Animalstudyi Pigs-
Tostudytheeffectsf progressive isovolaemic haemodilutionnthe intestinalfunctions pigs.
12pigsusedforth study,5usedascontrol groupand7were haemodilutedgradually
tohaematocritsf20%, 15%,0and6%.
ArterialpHdecr ased significantlyathematocrit <10%.Intestinaloxygen supplywasellmaintained
tosystemichematocrit valuesofapproximately 10%.
Spahnet al.(Spahn, Seifert,Pasch Schmid1998)
Surgicalpatients underwentfirst timeitralvalve replacement surgery.
Toinvestigatethe effectoflowHbevels onhaemody amic parametersndoxygen consumptionafter isovolaemic haemodilution.
20patientsw th significantmitr lvalve disease,after phlebotomy,m an haemoglobinvaluewas decreasedfrom130g/L
to100g/Lwith maintainingcentr l venouspressuretohe baselinvalue.






































































Weiskopft al.(Weiskopf, Viele,Feiner etal.1998)
Humanhealthy volunteers.
Toinvestigatethe effectofacute isovolemicreductionf bloodHbconcentration to50g/Linhealthy restinghumanso cardiovascularsystem oxygentransport.
2groups,11conscious healthyp tientsriorto anaesthesiandsurgery and21volunteersnot undergoingsurgery. MeanHbw sreduced byvenipuncturefrom 131to50g/Land isovolaemiawas mentainedby intravenousfluids. Cardiovascular parameters,arterialnd mixedvenousoxygen content,oxyhemoglobi saturation,ndar erial bloodlactatewer measuredbeforand afterhaemodilution. Electrocardiogram usingHoltermonitor wererecord d continuously.











to50g/Lnhe cardiovascularsystem andwhetheritould resultinfatigue.
8subjects,Hlev lwas decreasedto50g/Lby venesectionand isovolaemiawas maintained.Energy levelsatvarioustimes duringbloodcollection weremeasuredu ing visualanalogscale. Heartrateandbloo pressurewererecord d.
Energylevelwaso ratHb
of70,6and5g/L comparedthebaselin . Heartr teincre s dwithout changeinsupinblood pressure.Theauthors concludedthatesfindings arenotecessarily indicationsforblood transfusionandcabe toleratedbyhealthyadults.
Vielet al.(Viele, Weiskopf 1994)
Jehovah's Witnesses patients
Toassessthlowe t tolerableH concentration.
61casereportsr view forJehovah'sWitnesse patientsw thHb<80 g/LorHct<24%
50patientsdied,23 associatedwithHb<50g/L, however3ofth mdi daft cardiacsu gery.25pati nts survivedwithHb<50g/L. Thedatasugg stedt atlow Hbcanbetoleratedand survivalipossible.
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Clinical experiences in the non-critical care setting suggest that a Hb < 50 g/L is
associated with a higher mortality. In young healthy volunteers undergoing
isovolaemic haemodilution, Hb concentrations can fall to < 50 g/L without any
serious side effects. The risks are greater in those with compromised coronary
blood flow; they appear to need a higher Hb value (Goldhill, Boralessa,
Boralessa 2002) (Weiskopf et al. 1998).
COMPLICATIONS OF ANAEMIA DURING CRITICAL ILNESS
CARDIACISCHAEMIA
Anaemic critically ill patients with ischaemic heart disease are of particular
concern. This population may be at particular risk from anaemia due to
underlying coronary artery disease. However, they may also be more predisposed
to complications of red blood cell transfusion such as volume overload (Hebert,
Szick 2000).
Some clinical trials have examined the effect of anaemia on myocardial
ischaemia. Nelson et al. studied the effect of postoperative anaemia on
myocardial ischaemia and morbid cardiac events in high-risk vascular patients in
the intensive care unit. 27 patients who underwent major vascular surgery were
attached to continuous ambulatory electrocardiographic monitoring from the
evening before surgery up to 80 hours during the postoperative period. All
patients had a mean baseline haematocrit value of>30%. The haematocrit value
of each patient during the study period was the average of all haematocrit value
obtained on post-operative day one. Patients were divided into 2 groups
according to their post-operative haematocrit levels; a) patients with post-
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operative haematocrit <28%, 77% developed cardiac ischaemia and 46% had a
morbid cardiac event, and b) patients with post-operative haematocrit level >28,
14% developed cardiac ischaemia and 0% morbid cardiac event (cardiac
ischaemia was defined as ischaemic ECG changes and morbid cardiac event as
cardiac death, myocardial infarction, and ischaemic pulmonary oedema) (Nelson,
Fleisher, Rosenbaum 1993).
Other studies support an association between anaemia and cardiac morbidity in
patients with coronary heart disease. Carson et al did a retrospective cohort study
in 1958 patients who underwent surgery and declined blood transfusion for
religious reasons. Overall 30-days mortality was 3.2%; the mortality was 1.3% in
patients with preoperative haemoglobin 12 g/dL or greater and 33.3% in patients
with preoperative haemoglobin less than 6 g/dL. The increase in risk of death
associated with low preoperative haemoglobin was more pronounced in patients
with cardiovascular disease than in patients without. The effect ofblood loss on
mortality was larger in patients with low preoperative haemoglobin than in those
with higher preoperative haemoglobin. The results were similar in analyses of
postoperative haemoglobin and 30-day mortality or in-hospital morbidity
(Carson, Duff, Poses et al. 1996). Another Canadian analysis by Hebert at al. of a
large cohort of critically ill patients found that in patients with cardiac disease,
there was a trend toward an increased mortality when haemoglobin values were <
95 g/L (55% versus 42%) as compared with anaemic patients with other
diagnoses (Hebert et al. 1997).
Wu et al. conducted a retrospective study in a large cohort of patients (78,974
elderly subjects> 65 years old) who were hospitalized with acute myocardial
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infarction to evaluate whether there was an association between improving
anaemia with blood transfusion and 30-day mortality. Patients were categorized
according to the haematocrit on admission. The authors found that anaemic
patients with low haematocrit values on admission had higher 30-day mortality
rates. In this study the outcome of anaemic elderly patients with acute myocardial
infarction was related to the degree of anaemia. Improving anaemia by blood
transfusion was associated with a lower short-term mortality rate among patients
if they were anaemic with a haematocrit on admission < 30% (Wu, Rathore,
Wang, Radford, Krumholz 2001).
Not all studies show associations between low haematocrit and adverse outcomes
in patients with ischaemic heart disease. Spies et al investigated the haematocrit
value and its effect on myocardial oxygen supply after coronary artery bypass
grafting. They found that high haematocrit > 34% was associated with increased
rate ofmyocardial infarction, severe left ventricular dysfunction and mortality
rate. By multivariate analysis they found that ICU admission haematocrit was the
most significant predictor of adverse outcomes (Spiess et al. 1998).
Walsh TS et al suggested that patients with stable or mild coronary artery disease
could probably be managed with transfusion triggers of 70 to 80 g/L unless they
have evidence ofworsening ischaemia or infarction. Patients with severe,
symptomatic disease should probably be close to 100 g/L if there is evidence of




Patients without pulmonary disease may tolerate anaemia for two reasons. First,
adaptive mechanisms occur (including an increase in cardiac output, and an
increase in the 2,3-diphosphoglycerate content of the red blood cells). A second
factor, however, is that these patients have a normal Pa02; minor reductions in
oxygen delivery to the tissues may thus not be critical. However, the case may be
different in patients with acute or chronic respiratory disease (Schonhofer,
Wenzel, Geibel, Kohler 1998).
Most ICU patients in the UK are ventilated at sometime during their ICU stay.
Weaning from the ventilator is therefore an important part of critical care during
which oxygen delivery and therefore Hb may be important. Marini and
colleagues documented that anaemic patients with chronic obstructive pulmonary
disease (COPD) might be weaned successfully from mechanical ventilation after
haemoglobin is boosted to levels above the currently accepted guidelines for
blood administration. The authors related their findings to; a) reduced
physiological dead space, b) alteration in mixed venous gas, c) improving oxygen
carrying capacity to vital organs such as heart, brain, and neuromuscular system
by red cell transfusion (Marini 1998; Toy, Feiner, Viele, Watson, Yeap,
Weiskopf 2000).
Schonhofer et al hypothesised that in patients with severe chronic obstructive
pulmonary disease (COPD) anaemia might induce an increase in ventilation
requirements. If so, transfusion of red blood cells would lead to a reduction in
minute ventilation (VE), which should result in reduced work ofbreathing
(WOB). They tested this hypothesis in patients with severe COPD. Anaemic
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patients without pulmonary disease served as controls. The authors explored
whether blood transfusion reduces minute ventilation and work ofbreathing
(WOB) in patients with COPD. They prospectively evaluated VE and WOB in 20
anaemic adults (haemoglobin of <11 g/dL). Ten patients had severe COPD and
ten patients were without lung disease (Schonhofer, Wenzel, Geibel, Kohler
1998).
In both groups, the haemoglobin and haematocrit increased significantly after
transfusion. When compared with the baseline values, there was a significant
post-transfusion reduction ofVE; WOB decreased in patients with COPD. In
patients without lung disease VE did not change after transfusion (Schonhofer,
Wenzel, Geibel, Kohler 1998).
Schonhofer, in another publication, reported a case series of five anaemic patients
(Hb 87 g/L) with chronic obstructive lung disease in whom trials ofweaning
from the ventilator were unsuccessful. After transfer to a weaning centre, blood
was transfused to increase the haemoglobin value to 120 g/L or higher.
Subsequently, all patients were weaned successfully. They concluded that in
anaemic patients with chronic obstructive lung disease there should not be a fixed
transfusion threshold. In anaemic patients in whom difficulty in weaning from
the ventilator is experienced, blood transfusion should be tailored to the
individual patient's needs. Transfusion in those with chronic obstructive airways
disease may lead to successful weaning (Schonhofer, Bohrer, Kohler 1998).
In contrast, Corwin H.L. et al included 1302 critically ill patients in an EPO trial
(detail of the study discussed later). Hb increased significantly in the treatment
group compared to the placebo group. In a sub-group ofpatients who were
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mechanically ventilated, the increase in Hb levels was not associated with shorter
ventilation times (Corwin, Gettinger, Pearl et al. 2002).
Hebert et al. studied a sub-group of 713 patients from the TRICC study (the study
discussed in detail later). This group of patients were mechanically ventilated,
357 patients in the restrictive group and 356 patients in the liberal group. Table
(2.10) summarises ventilatory characteristics for both groups.
Table (2.10): Summary ofmean values of the ventilatory characteristics of a sub¬
group of patients in the TRICC study (Hebert, Blajchman, Cook et al. 2001).
Restrictive group Liberal group
Durations ofmechanical ventilation 8.3 8.3
(days)
Ventilator-free days (days) 17.5 16.1
Patients successfully weaned (%) 82 78
Relative risk of extubation success 1.07 1.1
From these results, the authors concluded that there was no evidence that
maintaining a higher Hb level by red cell transfusion shortened mechanical
ventilation time in critically ill patients (Hebert et al. 2001).
NEUROLOGICAL STATUS
Acute reduction of haemoglobin concentration to 7g/dl does not affect healthy
human cognitive function. However, further reduction to 6 and 5g/dl produces
subtle, reversible increases in reaction time and impaired immediate and delayed
memory, and these effects can be reversed by blood transfusion (Toy, Feiner,
Viele, Watson, Yeap, Weiskopf 2000).
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Weiskopf et al. studied nine healthy volunteers with a mean age of 29 years. The
authors tested their memory abilities before the study using computerized
neuropsychologic tests. Acute isovolaemic reduction of their Hb was carried out
to 70, 60, and 50 g/L. Neuropsychologic tests were carried out at each Hb level.
The authors found no change from baseline at Hb level of 70g/L. Reaction time
to external stimuli increased at Hb 60g/L, and immediate and delayed memory
was affected at Hb 50g/L. When Hb increased to 70g/L with blood transfusion,
the neuropsychologic tests returned to the baseline again. The authors suggested
that the reversibility of the cognitive function was due to the improvement in the
brain oxygenation caused by the transfused red blood cells (Weiskopf, Kramer,
Viele et al. 2000).
Granberg et al. performed a prospective qualitative investigation of the ICU
syndrome/delirium. The aim of their study was to explore the relationship
between the ICU syndrome/delirium and age, gender, length of ventilator
treatment, length of stay and severity of disease, as well as factors related to
arterial oxygenation and the amount of drugs used for sedation/analgesia. They
observed nineteen mechanically ventilated patients who had stayed in the ICU for
more than 36 hours, and interviewed then in depth twice after discharge.
Demographic, administrative and medical data were collected as a part of the
observation study (Granberg Axell 2002).
The authors found that patients with severe delirium had significantly lower
haemoglobin concentrations than those with moderate or no delirium. Patients
suffering from severe delirium spent significantly longer time on the ventilator
and in the ICU, and were treated with significantly higher daily doses of both
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fentanyl and midazolam in comparison with those reporting only moderate or no
symptoms of delirium. There were no significant differences in the Therapeutic
Intervention Scoring System scores, reflecting the degree of illness, between
patients with and without delirium.
They concluded that ICU syndrome/delirium was associated with decreased
haemoglobin concentrations and extended times on the ventilator. The authors
suggested that prolonged ICU stays and treatment with higher doses of sedatives
and opioids in patients with delirium could be a secondary phenomena rather
than a cause (Granberg Axell 2002). However, the observational nature of the
study means a causative link between anaemia and delirium is not proven.
ERYTHROPOIETIN THERAPY DURING CRITICAL ILLNESS
In recent years a number of case reports, small trials and two larger trials have
been published on the use of erythropoietien therapy in patients treated in ICU.
Following the administration of high doses of erythropoietin, the majority of
these reports demonstrated an increase in reticulocyte counts within a few days
and subsequent rise in Hb levels (Eckardt 2002). The blunted production of
endogenous erythropoietin in response to anaemia suggests that pharmacological
doses of EPO may be useful in critically ill patients to reduce the number of red
cell transfusions and/or improve anaemia (Corwin 2001a).
There are many issues related to the use of EPO therapy during critical illness.
Inflammatory mediators that blunt the action of endogenous EPO and reduce
bone marrow activity may have similar effects on exogenous EPO. It is unclear
from the present clinical trials the optimum time to start EPO therapy in this
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group of patients. Furthermore, it is unclear if this treatment can be effective in
preventing and treating anaemia of critical illness, and decreasing the need of
allogeneic blood transfusion. The optimum EPO dose requires further evaluation
and more studies are needed to show which sub-group of critically ill patients
receive greatest benefit.
The studies investigating the role ofEPO therapy in the critical care setting are
summarised in table (2.11).
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Table(2.11):Summaryofclinic ltrialshatinvestigatedtusofEPOthcr ticalrese ting. AuthorAimofthestudyIntervention
Results
VanIperent al.(vanIperen, Gaillard, Kraaijenhagen, Braam,M rx vande2000)
Randomisedclin cal trialoinvestigate endogenousEPO productionandthe responset exogenousEPOin criticallyillpatients.
36criticallyillpatientswith haemoglobinl velsf<11.2g/dl,rin caseofc rdiacdisease,<12.1g/dlwere includednthstudy.St yubj cts wererandomlyselect dtor ceiveint ¬ venous(iv)folicacidcontrolgr p),i folicacidnivrosaccharate(iron group),orivfolicacidr n saccharatendEPO(Egroup). APACHEIIscore,totalbl dcount, reticulocytecount,EPOoncentration, serumtransferrinr c ptors,serui on, transferrinandserumferritinw e measured.Zinc,vitaminB12foliac , creatinineandr ct vproteinwer measuredawell.






CorwinProspective, (Corwirandom sed,double nblind,placebo- 2001c)controled, multicentertrialo determinewhether theadministration ofEPOtcritically illpatientswould reducethenumber ofredbl ocell transfusions.
160Patientswereincludedthstu yoICUday 3.SubcutaneousEPOorpl cebowasadministered andco tinuedd ilyf r5ys.Thsubsequent dosingschedulewaseveryoth ray,minimumf r 2weeksoruntilICUdischarge.Allpatients receivedoralir nstu ydayn .Alpatients werefollowedup6w eks.Blootransfusion requirementsw recompar d.The snosp cific transfusionprotocol.
Thecumulativenumberofni s
ofredbl ocelltransfusedwas significantlylessintheEPO groupthanint epl c boroup. Thefinalhaematocrit concentrationfthEPOgroup wassignificantlygreaterth nin placebogroup.Therewerno significantdifferen esbetwee thewogroupseitherinm rtality orinthefrequ ncyfadv rse events.
CorwinAp ospective,
etal.randomised,double (Corwiblind,placebo- netal.controlled,mul i- 2002)centretrialo evaluatethe efficacyofa weeklydosf EPOtodecrease redc lltransfusion incriticallyll patients.
1302criticallyillpatientswhostayed>daysn ICUwereincludedthstudy.650pati ntswere randomisedtrece vew eklydosfEPOf r3 weeksandifnypatientstayednthICU>3 weekshe/sherec iv da4thdos .652patientsw re includednaplac bogroup.Irontherapywasiv n dailyfromtheirstfstudyinfor( al oriv),whichaselltoler tedbyaindividua . Treatmentwasithheldifthha matocrit 38%.Patientswerefollowedupt28d ys. Transfusionthresholdwassimilaribothgroups, althoughtherewasntra sfusionprotocol.T meanpre-transfusionHbw85.7g/Linthe placebogroupand85.3g/LinthEPOgroup.
Duringthestudyperiod,blood transfusionwassignif cantly lowerinEPOgroup.50.5%of patientsinEPOgroupreceived redc lltransfusioncompared 60.4%inplaceboandtherewas 19%reductionintotaledc l unitstransfusediEPOgroup.Hb concentrationincreasedmore significantlyinEPOgroup.There wasnosignificantdifferencei 28-daymortalit ,e i nleng h ofhospital&ICUtays,and mechanicalventilator-freedays.
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BLOOD TRANSFUSION IN CRITICALLY ILL PATIENTS
There are arguments both for and against the use of red blood cell transfusion to
maintain a high haemoglobin concentration in the critical care setting (Jean-
Francois 2001). Table (2.12) summarize the potential benefits and adverse effects
of red cell transfusion in this group of patients.
Table (2.12): Benefits and adverse effects of red cell transfusion in the critical
care setting (Jean-Francois 2001).
Benefits





■ Increase the safety margin
for bleeding.
■ Improve cardiac function.
PREVALENCE OF BLOOD TRANSFUSION IN THE CRITICAL CARE
SETTING
The decision to transfuse a critically ill patient can be considered under two
headings: a) patient factors and b) physician factors (Hebert, Wells, Martin et al.
Adverse effects
Immunomodulation.
Potential for increasing organ
failure and mortality.
Effects due to red blood cell
storage lesion.
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1998; Van Der 2001). Table (2.13) shows factors that may influence blood
transfusion decisions in ICU.
Table (2.13): Factors influence prevalence ofblood transfusion in ICU (Hebert et
al. 1998).
Patients' factors Physician's factors
■ Age. ■ Experience.
■ Severity of the disease. ■ Speciality.
■ Presence of pre-admission ■ Type of ICU e.g. medical
bleeding or anaemia. and/or surgical.
■ Co-morbidity. ■ Country.
■ Cardiac status e.g. ischaemic ■ Transfusion threshold policy.
heart and congestive heart
failure.
■ Pulmonary condition e.g.
COPD
■ Special disorders e.g.
haemostatic and blood
disorders.
Some studies reported the rate ofblood transfusion among critically ill patients.
Vincent et al. studied 3534 patients and showed that 37% of this cohort were
transfused during their ICU stay, von Ahsen studied 96 patients and showed that
39% of them received red cell transfusion. These results were very similar to a
study carried out by Walsh et al, which found that 39.5% of ICU admissions
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were transfused (Hebert, Szick 2000; von Ahsen, Muller, Serke, Frei, Eckardt
2001; Vincent et al. 2002; Walsh, Lee, Maciver, Garrioch, McClelland 2003a).
Table (2.14) shows some of published studies that have been carried out in
different ICUs to explore transfusion practice.
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Table(2.14):Summaryofpublisheddata outbl odtr nsfusioni criticalarese ting. Author.Typeofpatients.PercentagefTransfusionthr shold.Reaf rtr n fu ion. patientstransfused. ChohanS.SMedico-surgical.52%fpatientsMedianHb78g/L18%Haemorrhage,0reduced
etwhos ayed>24physiologicalres rves,11%t al.(Chohan,hoursinICU(=reasonwasnotrecorded,an McArdle,176).%duetooth rca s s. McClelland, Mackenzie, Walsh2003) MaciverC.R. et al.(Maciver, Walsh,Lee, MacKirdy, Garrioch, McClelland 2002)Medico-surgical.39%MedianHb78g/L
































Babineauet al.(Babineau, Dzik, Borlase, Baxter, Bistrian, Benotti












Frencht al.(French, Bellomo, Finfer, Lipman, Chapman, Boyce2002)
Multi-centre studyin18 Australianand NewZealand ICUs.
19.8%
Median,rangeHb 82,44-187g/L 79,54-119g/L 82,44-118g/L 81,78-94g/L 90,53-129g/L
Acutebloodloss(60.1%).





84±1g/L 84±10g/L 84±12g/L 87±9g/L 84±12g/L
Acutebleeding(55.5%).
1physiologicalre erves(28%). Alteredtissuep rf sion(16.8%). Coronaryarterdisease(8.2%). Others(11.2%).
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Rao et al. studied red blood cell transfusion practice in critically ill patients in
London hospitals and found that the average pretransfusion haemoglobin
concentration was < 90 g/L in 75% of transfusion episodes. The common indications
for transfusion were low haemoglobin (72%) and haemorrhage (25%) (Rao,
Boralessa, Morgan et al. 2002).
Vincent et al. showed that transfusion rates differed significantly by hospital
type, with community hospitals transfusing at a rate of 36.4%, regional hospitals
at a rate of 39.8%, and academic hospitals at the highest rate of 44.2%. This was
attributed to differences in illness severity for patient populations (Vincent et al.
2002). In a review by Corwin et al., the authors reported that in the USA,
approximately 25% to 30% of transfusions occur in critically ill patients (Corwin
2001a).
A Canadian study by Hebert et al. found that transfusion practice in ICU varied
between practitioners. The authors found an association between having an
academic affiliation and transfusing patients at lower Hb concentrations. In this
study, the number of years spent working in ICU; year of graduation, and
primary speciality did not have significant effect on transfusion practice (Hebert
et al. 1998).
HOWMANYRBC TRANSFUSIONS ARE GIVEN TO THE CRITICALLY
ILL?
The amount ofblood transfused to critically ill patients is influenced by factors
such as the patient case mix, and the transfusion practice of the clinicians.
72
In a prospective study by von Ahsen and colleagues77% of the patients received
blood transfusions. The authors showed that, for the transfused patients, the
number of red blood cell transfusions in individual patients varied between one
and 32. Of these patients, 40% received >5 units (von Ahsen, Muller, Serke, Frei,
Eckardt 2001).
Corwin et al. studied all patients who stayed in a tertiary care center ICU for
more than a week over a one-year period. 141(23%) patients stayed more than
one week. Of these patients, 121 (85%) patients received blood transfusion at a
mean rate of 9.5 units per patient. 40% ofRBCs were transfused during the first
week of admission; thereafter transfusion requirement was 2 to 3 units per patient
per week (Corwin, Parsonnet, Gettinger 1995).
In a Canadian cohort study, Hebert et al. compared two cohorts of ICU patients
from 23 centres, before and after the introduction of routine leukodepletion. They
included all patients admitted to these hospitals during the study period (14 786
patients) who received blood transfusion. The authors recorded the number of red
cell units transfused and reported the subgroup ofpatients who received the
transfusion. They found that the mean number of units transfused (leukoreduced
vs control periods) was the same (3.5 units) for cardiac/surgical patients; 5.4 vs
5.6 units for critically ill/multiple trauma patients; and 2.6 vs 2.5 units for
patients with hip fracture (Hebert, Fergusson, Blajchman et al. 2003). These data
related entire hospital admission, rather than ICU stay alone.
In the UK, Chohan et al. prospectively collected transfusion data in a large
medico/surgical UK teaching ICU over a 6-months period. They found that total
red cell use was 3.1 units per admission, comprising 1.6 units and 1.2 units per
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admission for reduced physiological reserve and haemorrhage respectively, (0.47
units per patient day). The median number ofunits per transfusion episode was 2
units (Chohan, McArdle, McClelland, Mackenzie, Walsh 2003). Walsh et al.
showed in a multi-centre study of 10 Scottish ICUs that the overall transfusion
rate was 1.9 units per ICU admission (0.34 red cell units/24 hours). The authors
showed that 1023 critically ill patients in these 10 ICUs utilized a total of 1890
red cell units in 100 days (Garrioch, Walsh, Maciver, McClellan 2002; Maciver,
Walsh, Lee, MacKirdy, Garrioch, McClelland 2002).
In another multi-centre Australian and New Zealand study French et al. studied
1808 critically ill patients, 19.8% admissions (357 patients) received blood
transfusion. The rate of RBCs transfusion in ICU was 2.5-units/ICU transfusion
days (French, Bellomo, Finfer, Lipman, Chapman, Boyce 2002).
Massive red cell transfusion
Vaslef, Steven N et al did a five years, retrospective chart review of 7734 trauma
patients admitted to a trauma centre. They found that 0.6% of the patients who
had been admitted to the centre's intensive care unit received >50 units of red
cell units on the first day of admission. Of these admissions, 36.4% patients
received >75 RBCs units and 63.5% received > 25 RBCs units. The greatest
number of transfused blood products over 24 hours in a survivor was 116 units
(Vaslef, Knudsen, Neligan, Sebastian 2002).
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POSSIBLE COMPLICA TIONS OF TRANSFUSION THATARE OF
CONCERN IN CRITICALLY ILL PA TIENTS
Immunomodulation
An immunosuppressive effect ofblood transfusion may be clinically beneficial in
selected patients (e.g., renal transplant recipients). However, in other settings it
could have adverse effects such as increased cancer recurrence and increased
rates of post-operative infection. Because considerable morbidity and mortality is
related to infection in the ICU population, transfusion related
immunosuppression is an issue of concern. The incidence of infection appears to
increase with the number of transfused red blood cell units, and in some studies
red cell transfusion remains associated with infection even after adjusting for
confounding factors (Corwin 2001a).
The immunomodulatory effect of red cell transfusion has been investigated in
cohort studies, randomised controlled trials, and meta-analysis. Some of these
studies compared this effect in transfused and non-transfused patients; other
studies compared transfusing leukodepleted and non-leukodepleted red blood
cells.
a) Cohort studies
Taylor et al. investigated retrospectively whether critically ill patients who
receive allogeneic packed red blood cell transfusions are at increased risk of
developing nosocomial infections during hospitalisation. Nosocomial infection
rates were compared among three groups: 1) the entire cohort, 2) the transfusion
group, and 3) the non-transfusion group. The nosocomial infection rate for the
entire cohort was 5.94%, and for the transfusion group and the non-transfusion
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group were 15.38% and 2.92%, respectively. There was an association between
an increased number of units ofRBCs transfused and the chance of infection.
The transfusion group was six times more likely to develop nosocomial infection
compared with the non-transfusion group. The mean number ofRBC units
transfused for patients with nosocomial infection was almost four times greater.
Mortality rate for the entire cohort was 13.6%. In the transfusion group, mortality
was 24.3%, while mortality in the nontransfusion group was 10.2%. The length
of ICU stay and hospital stay were significantly longer in the transfused group
compared with the nontransfused group (Taylor, Manganaro, O'Brien, Trottier,
Parkar, Veremakis 2002). As it was a retrospective cohort, the significance of
these associations is unclear.
Leal-Noval et al showed similar results in their cohort study when they
investigated the influence ofblood derivatives on the occurrence of severe
postoperative infection in patients undergoing heart surgery. 738 patients were
included in the study from a postoperative ICU of a tertiary-level university
hospital. The authors studied the influence of 36 variables on the development of
severe post-operative infection in general and individually for pneumonia,
mediastinitis, and/or septicemia. The influence of red blood cells and blood
derivatives (plasma and platelets) on infections was assessed. 9.4% had severe
post-operative infections. Using multivariate analysis, the variables associated
with severe post-operative infection were reintubation, sternal dehiscence,
mechanical ventilation, reintervention, neurologic dysfunction, transfusion of> 4
units of red blood cell, and systemic arterial hypotension. The mortality rate and
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the length of ICU stay were greater in transfused patients (Leal-Noval, Rincon-
Ferrari, Garcia-Curiel et al. 2001).
b) Randomised controlled trials
Flebert et al did a multi-centre study to evaluate a national pre-storage
leukoreduction program. They studied different types of patients such as cardiac
surgery, repair of hip fracture, intensive care patients and multiple traumas. In the
study they classified the patients into three groups; patients transfused with
leukodepleted blood, a second group received non-leukodepleted and non-
transfused groups (control group). The mean number of units transfused was the
same. In the leukodepleted group, the proportion of patients with fever episodes
was lower, and the use of antibiotics also decreased. However, serious
nosocomial infections did not decrease (Hebert et al. 2003).
In a randomised trial by Tartter et al. the incidence of postoperative infections,
hospital stays, and hospital charges of gastrointestinal surgery patients transfused
with packed red cells (non- leukocyte-depleted) or leukocyte-depleted cells were
compared. 221 patients were included in the study. Of these 59 (27%) patients
received blood transfusion. The authors found that operative site and nosocomial
infections, postoperative stays, and hospital charges were significantly more
frequent in patients transfused with packed red cells compared with patients
transfused with leukocyte-depleted red cells (Tartter, Mohandas, Azar, Endres,
Kaplan, Spivack 1998).
Another retrospective study by Baron and colleagues was done to evaluate the
effect of universal leukodepletion of packed red blood cells on postoperative
infections in high-risk patients undergoing abdominal aortic surgery. They
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studied 2 groups of patients; leukodepleted group (195 patients) and non-
leukodepleted group (192 patients). The mean number of units received in both
groups was nearly the same. There was no significant difference in morbidity or
mortality between the two groups and cardiovascular and respiratory outcomes
were not significantly different between the control and leukodepleted groups.
The incidence ofpostoperative infections, severe infectious complications, and
multiple organ failure was not significantly different (Baron, Gourdin, Bertrand
et al. 2002).
c) Meta-analysis
Several meta-analyses of randomised controlled trials that compared the risk of
post-operative infection in patients receiving allogeneic blood transfusion have
been done.
Hill GE et al. reviewed 20 articles published over 4 years with a total of 13 152
patients included in the analysis (5,215 in the blood transfused group and 7,937
in the non-transfused group). The common odds ratio for all studies included in
this analysis evaluated the association of allogeneic blood transfusion with post¬
operative bacterial infection. The authors found that allogeneic blood transfusion
was a significantly associated risk factor for the development of post-operative
bacterial infection in surgical patients. Blood transfusion was a greater risk factor
in trauma patients compared to elective surgical patients and this may be due to
larger number of units received by this group of patients (Hill, Frawley, Griffith,
Forestner, Minei 2003).
Vamavakas EC did a meta-analysis to investigate the association between
allogeneic blood transfusion and mortality when transfusing leukocyte-depleted
78
and non- leukocyte-depleted blood. The author reviewed 14 studies, which
recorded mortality as primary or second outcome. Summary odds ratios of
mortality in the group that received non-leukocyte-depleted red cells versus the
leukocyte-depleted group were calculated from the studies. The author found that
there was no association between allogeneic blood transfusion and either long
term or short-term mortality. However, in a sub-group (open heart surgery
patients) the author found that the association between non-leukocyte-depleted
blood and short term-mortality might exist which could be improved by filtering
the allogeneic blood from the white blood cells before transfusion (Vamvakas
2003).
Another meta-analysis by Vamavakas EC was done to compare the risk of
postoperative infection between recipients of allogeneic and autologous blood
transfusion. In this meta-analysis the author calculated the odds ratios of post¬
operative infection in patients who received allogeneic blood transfusion versus
autologous blood. He found that there was no difference in reducing the risk of
post-operative infection (Vamvakas 2002).
The evidence is controversial, but there is a strong suggestion from many studies
and meta-analysis that leucocytes in the transfused blood have effects on
infection and possibly mortality. It is not known if leucodepleted blood has
significant immunomodulation effects.
Storage lesion
Transfusing packed red blood cells to maintain a normal haemoglobin
concentration has been proposed to represent the most effective means of
increasing systemic oxygen delivery in critically ill patients with sepsis. If sepsis
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is characterized by inadequate tissue oxygenation secondary to inadequate
delivery, increasing arterial oxygen content with RBC transfusion should be
accompanied by an increase in systemic oxygen uptake (Marik, Sibbald 1993). It
has been suggested that in some circumstances, transfused blood may actually
have adverse effects in critically ill patients. Temporarily decreased
concentrations of 2,3-DPG and ATP, caused by storage of blood, impair red
blood cell deformability and interfere with the ability of the red blood cell to
unload oxygen (Corwin 2001a).
Some studies investigated the effect of the age of transfused blood in the surgical
and critical care settings. Marik et al studied the effect of red blood cell
transfusion on gastrointestinal and whole-body oxygen uptake in ventilated
critically ill patients with sepsis within 48 hours of developing sepsis. The
measured systemic oxygen up take did not increase significantly during the
study. The authors found an inverse association between the change in gastric
intramucosal pH and the age of the transfused blood. In those patients receiving
blood that had been stored for more than 15 days, the gastric intramucosal pH
consistently decreased following the red blood cell transfusion. These data
suggested that patients receiving old transfused red blood cells developed
evidence of splanchnic ischaemia (Marik, Sibbald 1993).
Offner et al. did a prospective cohort study to determine the consequences of
massive transfusion on traumatized critically ill patients. They studied patients
who survived longer than 48 hours who were transfused with 6 to 20 U of red
blood cells in the first 12 hours after injury. The age of each unit of blood was
determined. They found that transfusion of older blood was associated with
subsequent infection; patients who developed infections received 11.7 and 9.9 U
of red blood cells older than 14 and 21 days, respectively, compared with 8.7 and
6.7 in patients who did not develop infections. Multivariate analysis suggested
that age ofblood was an independent risk factor for major infections (Offner,
Moore, Biffl, Johnson, Silliman 2002).
Some data from other studies suggests that this is not the case with leucodepleted
red cells. Walsh et al. did a prospective double blind randomised study to
detennine if transfusion of red cells either <5 days or >20 days from donation
alters tonometric indices of gastric mucosal oxygenation or global oxygenation
parameters, in euvolemic anaemic critically ill patients without ongoing
haemorrhage. In this study, patients were randomised to receive 2 units of
leucodepleted red cells that were either <5 days (10 patients) or >20 days (12
patients). Changes in gastric to arterial PCO2 gap (Pg-PaC02 gap), gastric
intramucosal pH (pHi), arterial pH, arterial base excess, and arterial lactate
concentrations were measured during baseline (2.5 hours), during transfusion (3
hours), and for 5 hours after transfusion. Mean age of red cells stored <5 days
was 2 days; red cells stored >20 days, 28 days. Haemoglobin concentration
increased by 150g/Land 166g/L respectively in the fresh and stored groups.
There were no significant differences between the groups either using treatment-
by-time analysis or comparing the pre- and post-transfusion periods either for Pg-
PaC02 gap or pHi. The mean change within each group from pre- to post¬
transfusion period for Pg-PaCCh gap and pHi respectively were: "fresh" red cells
0.56 kPa and -0.018 pH units, and "stored" red cells 0.52 kPa and -0.033 pH
units. There was no statistically or clinically significant improvement in any
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other oxygenation index over time for either group in comparison to baseline
values. This study suggests that the age ofblood does not significantly affect the
global indices of tissue oxygenation parameters in euvolemic anaemic critically
ill patients.(Walsh, McArdle, McLellan et al. 2004)
Organ failure and effect on mortality
Augmenting systemic oxygen delivery using various treatment modalities,
including red cell transfusion, may decrease mortality in critically ill patients.
Increasing haemoglobin concentrations using allogeneic red cell transfusion
could result in this positive effect by improving arterial oxygen content. Few
studies have investigated the effect of age of transfused red cells on the patients'
outcome. One of these studies carried out by Purdy et al. determined,
retrospectively, the age of packed red blood cells transfused to critically ill
patients admitted to the ICU and correlated this variable with patients' outcome.
They recorded the number and the age of red blood cell units transfused to
patients, who had been admitted during a one-year period of time. The authors
found a correlation between mortality and the age of the transfused red blood cell
units. They concluded that the cause of this association was unclear, but could
indicate an adverse effect from transfusion (Purdy, Tweeddale, Merrick 1997).
This study was carried out when all red cells were non-leucodepleted.
Maetani, investigated the role ofblood transfusion in organ system failure
following major abdominal surgery. He included many factors that could
contribute to organ system failure such as blood transfusion, age, pre-operative
haematocrit, organ failure risk (respiratory failure, gastrointestinal stress
bleeding, renal failure, non-obstructive, non-hepatitic jaundice, and
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coagulopathy), operative time, blood loss, and post-operative highest
haematocrit. He found that except for preoperative haematocrit, all the factors
were statistically significant contributors and that blood transfusion was the most
significant (Maetani, Nishikawa, Tobe, Hirakawa 1986). As with other
retrospective cohort studies, the significance of this result is uncertain.
Vincent et al. compared mortality rates for transfused and non-transfused patients
during ICU stay after using statistical techniques to match patients for other risk
factors. The authors found that ICU mortality was 13.5% and 28-day overall
mortality was 20.2%. Both ICU and overall mortality rates were significantly
higher for transfused versus non-transfused patients (ICU: 18.5% vs 10.1%,
respectively; overall: 29.0% vs 14.9%, respectively). Transfused patients had
longer ICU length of stay, more severe organ failure, and higher mortality rates
than non-transfused patients (Vincent et al. 2002). Another study also showed
that transfused patients had a greatermortality rate (13.3% vs 8.9%, respectively)
and a longer mean stay in the ICU (6.1days vs 3.7 days, respectively) than those
not transfused (Leal-Noval et al. 2001).
Corwin et al. did some studies investigated the use of erythropoietin in ICU.
Mean haemoglobin concentrations for patients who received EPO treatment were
similar compared to patients who received blood transfusions. Mortality rate was
the same in both groups (Corwin, Gettinger, Rodriguez et al. 1999; Corwin
2001a; Corwin 2001c). These studies provide indirect evidence against an
adverse effect from RBC transfusion, but were not powered to detect this.
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In summary, there are no large randomised control trials investigating the
association between the storage age of transfused blood and patient outcome
(McLellan, Walsh, McClelland 2002).
TRANSFUSION TRIGGERS IN THE CRITICAL CARE SETTING
Few large clinical studies have been done aiming to find the optimal Hb
concentration and transfusion triggers in critically ill and high-risk patients.
Bracey AW et al. did a study to determine if lowering the haemoglobin threshold
for red cell transfusion to 80g/L after coronary artery bypass graft surgery would
reduce blood use without adversely affecting patient outcome. The authors
compared the study group (received blood transfusion post-operatively when Hb
< 80 g/L) to a control group (patients who were transfused when their post¬
operative Hb < 90 g/L). There was no difference in clinical outcome, including
morbidity and mortality rates, in the two groups. A haemoglobin transfusion
trigger of 80g/L did not adversely affect patient outcome after the procedure
(Bracey, Radovancevic, Riggs et al. 1999).
TRICC study (Transfusion Requirements In Critical Care) (Hebert, Wells,
Blajchman et al. 1999)
The TRICC study is the key background study that investigated red cell
transfusion in critically ill patients. It was a multi-centre, randomised, controlled
clinical trial to compare the effect of a restrictive strategy of red-cell transfusion
with a liberal strategy on critically ill patients. The authors included patients who
were expected to stay in ICU > 24 hours and had a Hb < 90 g/L within 72 hours
after admission. 838 patients were randomised to one of two groups: a) 418
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patients in a restrictive strategy group, these patients were transfused one RBC
unit when their Hb fell below 70 g/L. Hb levels were maintained in the range of
70 to 90 g/L. b) 420 patients in a liberal strategy group, patients were transfused
when Hb was < 100 g/L and was maintained between 100 and 120 g/L.
The mean APACHE II score was 21 for all patients with no significant difference
between the two groups. Table (2.15) summarises the main findings of the study.
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Table (2.15): Summary of the main findings in the TRICC study (Hebert et al.
1999)
Restrictive strategy Liberal strategy group
group N= 418 N = 420
Average daily Hb 85 g/L 107 g/L
Red cell units 2.6 5.6
transfused per patient
Percentage of patients 33% 0%
not transfused
30 days mortality after 18.7% 23.3%
admission.
Mortality rate during 22.2% 28.1%
hospitalisation
Mortality rate during 13.9% 16.2%
the entire ICU stay.






Multi-organ failure 37% 32%
(more than 3 organs)
30 days mortality rate
in subgroups
Cardiac patients 20.5% 22.9%
(n =151)
Septic patients 22.8% 29.7%
(n= 141)
Trauma patients 10% 8.8%
(n = 100)
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The authors suggested that critically ill patients with Hb < 70g/L should be
transfused to keep their Hb between 70 and 90 g/L as a restrictive strategy of red
cell transfusion is at least as effective as and possibly superior to a liberal
transfusion strategy (Hebert et al. 1999).
The authors published details of a sub-group of patients who were mechanically
ventilated to show the effect of blood transfusion on their outcome. This study
has been discussed in details in a previous section (detail see page 59) (Hebert et
al. 2001). The authors published details of another sub-group of patients who had
coronary artery disease (detail see page 55) (Hebert et al. 1997).
A Cochrane review by Hill et al. concluded that in patients who do not have
serious coronary heart disease, transfusion can be withheld in the presence of
haemoglobin concentration as low as 70g/L if there is no obvious bleeding. More
large clinical trials should include critically ill patients with renal and cardiac
diseases to assess the impact of lower transfusion threshold on their clinical
outcome and quality of life (Hill, Carless, Henry et al. 2002).
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MATERIAL AND METHODS
RETROSPECTIVE STUDY INVESTIGATING THE PREVALENCE OF




To determine the prevalence of anaemia among ICU survivors who were managed
with conservative transfusion triggers during ICU stay at the time of discharge home
from hospital.
SECONDARYAIM
To describe the pattern of anaemia at hospital discharge.
To determine factors, during ICU stay, that are associated with anaemia at hospital
discharge.
PATIENTS STUDIED
Two cohorts of general ICU patients were included in this study. Both cohorts of
patients had been studied previously during their ICU stay as part of prospective
blood transfusion audits
First cohort period: between 27/1/2000 and 08/7/2000.
Second cohort period: between 4/6/2001 and 12/9/2001.
FIRST COHORTPERIOD
Data were prospectively collected daily for the study period on haemoglobin
concentration, red cell transfusion and indications for transfusion during ICU stay.
Only patients who stayed in ICU more than 24 hours were included in the analysis.
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For non-haemorrhage transfusion episode, the median pre-transfusion Fib
concentration was 78 g/L (interquartile range: 74-84 g/L).
SECOND COHORTPERIOD
During the study period, data were prospectively collected in a similar way as for the
first cohort. All patients were included in this audit during the ICU stay. The median
pre-transfusion Fib was 78 (interquartile range: 73-85 g/L).
In the present study all patients were included [not only patients who stayed > 24
hours]. General characteristics of the study population and ICU demographic data
were described for the combined cohorts. Transfusion thresholds were low and
identical during both periods. The results indicate that ICU clinicians followed a
conservative transfusion strategy during the periods ofboth cohorts.
STUDY DESIGN





The studies were carried out in the form of audit. No interventions were carried out
and patient management was not altered in any way on the basis of the data
collected. We obtained clear guidance from the Local Regional Ethics Committee
that ethical review was not required. Guidelines from the data protection act were
followed and anonymisation of data after linkage was carried out. Patients'
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Each dataset was obtained in excel files.
ICUDATASET
For both cohorts, the following identifiers were obtained from the ICU database
(Scottish Intensive Care Society (SICS) Audit Group database). Each dataset
contained demographic and outcome data for all patients admitted to the unit during
the study periods. Table (2.16) shows the fields which were extracted from SICS
database [ICU dataset]. The two cohorts were merged in one excel file to obtain one
ICU dataset.
HAEMA TOLOGYDATASET
From the hospital haematology database, the haematological results were obtained
for all patients who were in the Royal Infirmary, Edinburgh between 01/01/2000 &
31/10/2000 and 01/06/2001 & 30/11/2001. The following data were extracted from
the hospital haematological laboratory database for each patient table (2.17).
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Table (2.16): The extracted fields from SICS database [ICU dataset]
Field Content







Date ofDischarge from ICU
Date of discharge from hospital
APACHEII score
ICU length of stay
ICU outcome
Hospital outcome
Destination on discharge from ICU
Outcome on discharge from hospital
Destination on discharge from hospital
Type of destination on discharge from
hospital
Numeric value
Alpha characters <30 characters









Alpha characters <30 characters
Alpha characters <30 characters
Alpha characters <30 characters
Alpha characters <30 characters
Alpha characters <30 characters
Alpha characters <30 characters
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Table (2.17): The extracted fields from the hospital haematology laboratory database
[haematology dataset]
Field Content
Hospital ID ISD Hospital code
Surname Alpha characters <30 characters
Forename Alpha characters <30 characters
Sex M/F
Date ofbirth dd/mm/ccyy
Sample request date dd/mm/ccyy
Haematological results
Haemoglobin concentration (g/L) Numeric value
Mean red cell corpuscular volume (MCV) Numeric value
Mean red cell corpuscular haemoglobin Numeric value
concentration (MCHC)
White blood cell count Numeric value
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LINKAGE
This process involved the linking of each ICU patient's record, using the patient
identifier (surname, forename, date of birth, hospital number, and sex) to an extract
from the haematological laboratory database. This extract contained the specified
patient denomination data in order to carry out the linking between the two
databases. The process of linkage is described in detail in appendix (I).
STUDY DATABASE
From the linkage of ICU dataset and the haematology dataset, a study database was
prepared consisting of complete records of each patient containing the data shown in
table (2.18)
From the final study database, the following parameters were extracted and
calculated for each patient table (2.19). The definitions of each parameter, which
were used to extract the data points, are shown.
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Table (2.18): Fields of the study database
Fields Contents







Date ofDischarge from ICU
Date of discharge from the Hospital
APACHEII score






Mean red cell corpuscular volume
(MCV)
Mean red cell corpuscular haemoglobin
concentration (MCHC)
White blood cell count
Numeric value
Alpha characters <30 characters









Alpha characters <30 characters







Table (2.19): Different parameters used in the study and their definitions
Haematological result & dates
Last haemoglobin concentration prior to
discharge from ICU
Last haemoglobin concentration prior to
discharge from hospital
Last mean cell volume (MCV) prior to
discharge from hospital
Last mean corpuscular haemoglobin
concentration (MCHC) prior to discharge
from hospital
Number of days before ICU discharge
last haemoglobin was requested
Number of days before hospital
discharge last haemoglobin was
requested
Definition (defined by sample request
date)
The nearest haemoglobin record before
ICU discharge date.
The nearest haemoglobin record before
hospital discharge date.
The nearest MCV record before hospital
discharge date
The nearest MCHC record before
hospital discharge date
ICU discharge date - last haemoglobin
request date before ICU discharge.
Hospital discharge date - last
haemoglobin request date before hospital
discharge.
Number of days in hospital post ICU Hospital discharge date - ICU discharge
discharge date.
Mean haemoglobin concentration during post ICU stay
Number of haemoglobin concentrations recorded during post ICU stay
Minimum haemoglobin concentration during post ICU stay
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SPREADSHEET FOR ANALYSIS
From the study database, a spreadsheet was prepared for primary analysis.
Table (2.20) shows the final spreadsheet used for analysis. Figure (2.1) illustrates the
management of the datsets used in the study to obtain final spreadsheet for analysis.
ANALYSIS
For analysis, tables were created summarising
Patients' demographic data.
Haemoglobin levels in bands for all patients at the time of ICU discharge.
Haemoglobin levels in bands at the time ofhospital discharge for all patients
who discharged home.
Different types ofRBCs indices at the time of hospital discharge.
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Table (2.20): The contents of the final spreadsheet used for analysis
ICU Key Number
Hospital Number
Date of admission to ICU
Date of discharge from ICU
Date of discharge from hospital
ICU outcome
Destination on discharge from ICU
Outcome on discharge from hospital
Destination on discharge from hospital
Type of destination on discharge from hospital




Last haemoglobin concentration prior to discharge from ICU
Number of days before ICU discharge last haemoglobin was requested
Number of days in hospital post ICU discharge
Number of haemoglobin concentrations recorded during post ICU stay
Mean haemoglobin concentration during post ICU stay
Minimum haemoglobin concentration during post ICU stay
Last haemoglobin concentration prior to discharge from this hospital
Last mean cell volume prior to discharge from this hospital
Last mean corpuscular haemoglobin prior to discharge from this hospital












Figure (2.1): How chart illustratingmanagement ofthe datasets used in the study
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PROSPECTIVE STUDY INVESTIGATING THE PREVALENCE OF
ANAEMIA AMONG SURVIVORS OF CRITICAL ILLNESS MANAGED
WITH CONSERVATIVE TRANSFUSION TRIGGERS
AIMS
PRIMARYAIM
To determine the prevalence of anaemia during recovery from critical illness for
patients who survived ICU and post-ICU hospital stays.
SECONDARYAIM
To describe the pattern of anaemia at hospital discharge.
To describe transfusion practice in patients after ICU discharge.
PATIENTS STUDIED
All patients who were discharged from the ICU between 19/11/2002 and 06/03/2003
were included in the study. During both periods, ICU clinicians used evidence based
transfusion practice; the median pre-transfusion Hb concentration was 78 g/L (IQ:
74-84 g/L) during the first period and 78 (IQ: 73-85 g/L) during the second period.
EXCLUSION CRITERIA
Patients who were discharged home directly from ICU.
Patients who were discharged to another hospital (acute or rehabilitation)
directly from ICU because final Hb at the time of discharge home was not
known.
Patients who died in ICU.
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DATA COLLECTION
All patients who were discharged alive from ICU to a ward in the hospital were
followed up daily during their hospital stay until death or discharge from the
hospital.
Data that were collected during the follow up period:
Patient's ICU demographic and outcome data.
Haematological data.
Transfusion-related data.
Patients' demographic and outcome data for all patients were collected from the
Scottish Intensive Care Society (SICS) Audit Group database via dedicated ward-
based desktop computer terminals.
Haematological data were collected daily from the case notes and the hospital
haematology database via dedicated ward-based desktop computer terminals.
Transfusion data were collected from the case notes.
The data were collected in excel file.
Table (2.21) shows the data that were collected in different categories.
EXCLUDED DATA
All haematological and transfusion data during ICU stay were excluded from the
study, because this was already well characterised for the first part of the study.
Readmissions: if a patient was readmitted to the ICU during the same hospital
admission, all the haematological and transfusion data during this period were
excluded from the study.
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DATA QUALITY
After completion of the study spreadsheet, multiple checks were done to fill some
missing Hb values from the haematology database terminals in the ICU.
ANALYSIS
Tables were created for analysis summarising
Patients' demographic data and outcome.
Haemoglobin levels in bands at the time of ICU discharge.
Haemoglobin levels in bands at the time ofhospital discharge.
RBCs indices at the time of hospital discharge for patients who were
discharged home.
Transfusion data.
ANALYSIS OF COMBINED DATASET
We combined all data from the retrospective and prospective cohorts. From this
dataset we calculated the overall prevalence of anaemia at hospital diacharge for all
patients discharged home after survining ICU and hospital stay. We further explored
the relationships between various characteristics of ICU stay, namely the last Hb
before ICU discharge, gender, age, APACHE II score, and the length of ICU stay,
and the probability of dicharge from hospital with a Hb < lOOg/L. This analysis was
done using logistic regression in collaboration with Mr Robert Lee, Medical
Statistics Uint, Edinburgh University.
Multi-variable logistic regression was used to identify which variables were
statistically significant independent predictors of a last Hb prior to hospital discharge
<100 g/L. Two-way interactions between the potential predictors were examined in
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addition to the main effects. A p-value <0.05 was regarded as statistically significant.
As there was no evidence of non-linearity in the relationships between a logistic
transformation of the response probability and APACHE II score, length of ICU stay,
or last Hb before ICU discharge these were included as continuous variables in the
logistic regression models. Since there was strong evidence of a non-linear
relationship between a logistic transformation of the response probability and age on
admission to ICU this variable was divided into quarters and included as a
categorical variable in the logistic regression models.
102
Table (2.21): Collected data during the prospective study
Patient's demographic data and outcome








ICU length of stay.
APACHEII score.
ICU outcome
Destination after ICU discharge.
Haematological data
Last haemoglobin before ICU discharge.
Every Hb concentration measured during hospital stay after ICU discharge.




Number of red cell units transfused.
Pre-transfusion Hb level.
The number of the transfusion episode.
Specialty of the consultant who prescribed the transfusion.
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RESULTS
RESULTS OF THE RETROSPECTIVESTUDY
ICU dataset
A total of 489 admissions were obtained from the SICS database for the two cohorts
comprising all patients admitted to ICU between 27/1/2000-08/7/2000 (N=284) and
4/6/2001-12/9/2001 (N=205).
Of 489 ICU admissions: 321 were discharged alive (2 directly home), 77 patients
were transferred to other hospitals after ICU discharge and 31 died, leaving 211
patients discharged home; of these 56.9% (N=120) were males and females 43.1%
(N = 91). Figure (2.2) illustrates the outcome in all patients after ICU discharge until
the time ofhospital discharge.
The study group comprised 211 patients who were discharged home from hospital
after surviving ICU and hospital stays. Demographic characteristics of these patients
are shown in table (2.22).
Table (2.22): Patients' demographic data (N = 211)
Variable Mean SD Median Range Ql Q3
Age 52.2 19.1 55 13-92 35 66
APACHE II 17.8 6.4 18 3-35 14 22
ICU stay (days) 4.2 7.7 1.5 0-52.9 0.8 3.7
Number of days in 5.2 7.8 2 1-54 2 5
ICU




A total of 1,102,676 haematological results from 220,717 blood samples in the
period between 01/01/2000 and 31/10/2000 were obtained. A total of 688,522 results
from 137,836 blood samples were obtained for the period between 01/06/2001 and
30/11/2000. These 2 datasets contained all patients who had been in the hospital
during the study periods and were linked to patients' dataset.
Haemoglobin concentrations at the time of ICU discharge
4 patients (3 females & 1 male) had no haematological records at the time of ICU
discharge. Last Hb values recorded in ICU were considered as ICU discharge Hb
because these values were available to ICU physicians at the time of ICU discharge.
Table (2.23) shows the number of patients in different Hb bands at the time of ICU
discharge. Figure (2.3) shows the number ofmales and females in different Hb
bands. Figure (2.4) shows Hb levels for all patients.
85.3% of all patients were discharged anaemic from ICU with a haemoglobin
concentration below the hospital laboratory reference range (males <130 g/L &
females <115 g/L). The prevalence of different degrees of anaemia ("mild" <
laboratory reference range, "moderate" Hb< 100 g/L, and "severe" Hb< 90 g/L) at
ICU discharge is shown in table (2.24).
Table (2.24): Prevalence of different degrees of anaemia at ICU discharge
Hb Males 120 Females 91 Total 211
N (%) N (%) N (%)
< 90g/L 35 (29.2%) 32 (35.2%) 67 (31.8%)
<100g/L 66 (55%) 40 (44%) 116(55%)
< Reference range 107 (89.2%) 73 (80.2%) 180 (85.3%)
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Haemoglobin concentrations at the time of hospital discharge
Out of 211 patients (the study group), 20 patients had no haematological results after
ICU discharge (during their post-ICU hospital stay). The median (IQR) and [range]
of post-ICU hospital stay for these patients were 2(1-4) and [1-18] respectively. For
these patients, last Hb recorded in ICU was used as hospital discharge Hb. 191 had at
least one haematological result during their post-ICU stay in the hospital.
81.5% of all patients who were discharged to their normal residency (n = 211) had a
haemoglobin concentration below the hospital laboratory reference range at hospital
discharge. Table (2.25) shows the number of patients in different Hb bands, figure
(2.5) shows number ofmales and females, and figure (2.4) shows the distribution of
all patients in different Hb bands at hospital discharge.
12.8% of the patients were discharged from the hospital to their nonnal residency
with Hb <90g/L, and 35.5% with Hb <100g/L. Table (2.26) shows the prevalence of
different degrees of anaemia at hospital discharge in detail.
Table (2.26): Prevalence of different degrees of anaemia at hospital discharge.
Hb Males 120 Females 91 Total 211
N (%) N (%) N (%)
< 90g/L 10(8.3%) 16(17.6%) 27 (12.8%)
<100g/L 40 (33.3%) 35 (38.5%) 75 (35.5%)
< Reference range 104 (86.7%) 68 (74.7%) 172 (81.5%)
Table (2.27) summarises Hb characteristics during ICU and post-ICU hospital stays.
Incidence of different types of anaemia at hospital discharge
83% of anaemic male patients and 80% of anaemic females, with Hb concentration <
hospital laboratory reference range, had normocytic normochromic anaemia at
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hospital discharge when using patients' MCV and MCHC to identify different types
of anaemia (the hospital laboratory reference range for normal levels ofMCV and
MCHC are 76 to 100 fl and 31 to 35g/dl, respectively). 2 MCHC values were missing
for male patients with hospital discharge Hb < reference range and 4 values for
females. Table (2.28) shows the prevalence ofdifferent types of anaemia for males
and females with Hb < reference range at hospital discharge and figure (2.6) for all
patients.
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Figure (2.2): Flow chart illustrating outcomes in patients studied [retrospective
cohort]
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Haemoglobin level for all patients at hospital discharge
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Table (2.28): Prevalence of different types of anaemia for males and females with
Hb< reference range at hospital discharge
Anaemic patients (n=166)
Types of anaemia Male n=102 Female n=64
N (%) N (%)
Normocytic (MCV 76-100 fl) +
85(83.3) 51(79.7)
normochromic (MCHC 31 -35g/dl)
Normocytic + hypochromic 8 (7.8) 10(15.6)
Macrocytic + hyperchromic 2(1.9) 0
Macrocytic + normochromic 6 (5.9) 1(1.5)
Microcytic + normochromic 1(.9) 1(1.5)
Macrocytic + hypochromic 0 1(1.5)
Figure (2.6): Prevalence of different types of anaemia for all patients




















RESULTS OF THE PROSPECTIVE STUDY
192 admissions (185 patients) were discharged alive from the ICU during the study
period [19/11/2002 to 06/03/2003]; 117 males (61%) and 75 females (39%). Mean ±
SD, median [Ql, Q3], and range of last Hb (g/L) result before ICU discharge were
101 ± 21, 99 [86, 117], and (63-151). Demographic characteristics of the 185 patients
are shown in table (2.29).
Of the 192 admissions, 66 died in ICU, 7 and 4 were discharged directly from ICU to
another acute hospital and home respectively. 7 patients were re-admitted to ICU
during the same hospital stay; their haematological and transfusion data during the
second ICU admission were not collected, but post-ICU data after the 2nd admission
were included. 72 patients comprised the study group, 41 (57%) patients were males
and 31 (43%) were females. These patients survived ICU and hospital stays and were
discharged home. Figure (2.7) illustrates the outcome in all admissions after ICU
discharge.
Table (2.29): Patients' demographic data (N= 185)
Variable Mean SD Median Range Ql Q3
Age 57.5 18.1 58 16-90 45 73
APACHE II 19.4 9.6 19 0-45 13 26
ICU stay (days) 5.5 11.8 1.3 0-88.9 0.8 4.2
Days in hospital
after ICU
14.8 16.0 11 2-101 5 17.8
Haemoglobin concentrations at ICU discharge
Out of 185 patients who were discharged from ICU during the study period, 23
patients (12%) did not have ICU discharge Hb records. The last Hb values recorded
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in the ICU were used as ICU discharge Hb.145 patients had their last ICU Hb
measured on the day of ICU discharge, 13 patients one day before discharge, and 4
patients two days before discharge.
Out of the 72 patients (the study group), 2 patients had their last ICU Hb values were
measured one day before ICU discharge. The study group demographic data and
haemoglobin characteristics at the time of ICU discharge are shown in table (2.30).
The numbers of patients in different Hb bands at the time of ICU discharge are
shown in table (2.31). Figure (2.8) shows the numbers ofmales and females in
different Hb bands and figure (2.9) shows the number of all patients at the time of
ICU discharge.
87.5% of the patients had Hb concentration < reference range, 54.16% < 100, and
36.11% < 90g/L. Table (2.32) shows the prevalence of different degrees of anaemia
at the time of ICU discharge.
Table (2.32): Prevalence of different degrees of anaemia at ICU discharge.
Hb Males (n=41) Females (n=31) Total (n=72)
N (%) N (%) N (%)
< 90 g/L 13 (31.7) 13 (41.9) 26 (36.1)
<100g/L 18 (43.9) 21 (67.7) 39 (54.2)
< Reference range 37 (90.2) 26 (83.9) 63 (87.5)
Haemoglobin concentrations at the time of hospital discharge
2 patients out of 72 patients did not have post-ICU Hb results. For these patients, last
ICU Hb values were used as hospital discharge Hb. Mean ± SD, and median (Ql,
Q3) last Hb (g/L) before hospital discharge were 111 ± 18.7, and 110.5 (94, 122)
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respectively. Table (2.33) shows the number of patients in different Hb bands at
hospital discharge. Figure (2.10) shows the number ofmales and females in different
Hb bands and figure (2.9) shows the number of all patients at the time of hospital
discharge.
72.2%, 12.5%, and 33.3% had Hb concentration < reference range, <90g/L, and
<100g/L respectively. Table (2.34) shows the prevalence of different degrees of
anaemia at the time ofhospital discharge.
Table (2.34): Prevalence of different degrees of anaemia at hospital discharge.
Hb Males (n=41) Females (n=31) Total (n=72)
N (%) N (%) N (%)
< 90 g/L 6(14.6) 3 (9.7) 9(12.5)
<100g/L 13 (31.7) 11 (35.5) 24 (33.3)
< Reference range 34 (82.9) 18 (58.1) 52 (72.2)
Prevalence of different types of anaemia at hospital discharge for anaemic
patients with Hb concentration < reference range
According to patients' last MCV and MCHC with Hb level < reference range, 80%
ofmales and 88% of females had nomocytic normochromic anaemia at the time of
hospital discharge. Table (2.35) shows the numbers and the percentages ofmales and
females discharged to their nonnal residency with different types of anaemia and
figure (2.11) shows the percentages of all patients.
Transfusion practice during post-ICU hospital stay
Of all patients discharged alive from ICU (N = 185), 21 (11%) patients received red
blood cell transfusion (12 males and 9 females) during their hospital stay: 19
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surgical, 1 medical and 1 renal. Of the 21 transfused patients, 11 (52%) patients were
discharged from the hospital to their normal residency, 5 (24%) died, 2 (10%) were
discharged to another acute hospital and 3 (14%) to a rehabilitation hospital.
4 patients had been re-admitted to ICU during the same hospital stay and they
represented 57% of total re-admissions during the study period.
10 (48%) patients had one transfusion episode, 4 (19%) patients had two transfusion
episodes, 4(19%) patients had three transfusion episodes and 3 (14%) had four
transfusion episodes. Characteristics of patients during their first ICU admission who
received red cell transfusion after ICU discharge are shown in table (2.36). The
median pre-transfusion Hb for all patients was 74 g/L (inter-quartile range: 68-76
g/L). Characteristics of pre-transfusion Hb for each transfusion episode are shown in
table (2.37).
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Figure (2.7): Flowchart illustrating outcomes in
patients studied [prospective cohort]
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Figure(2.10):Numb rofal sandfe ldiffe nthaemoglobinb sf patie tswhoredischarg d homeaftersurvivingICU.
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Table (2.35): Prevalence of different types of anaemia for males and females with
Hb< reference range at hospital discharge
Anaemic patients (n= 52)
Types of anaemia Male (n=34) Female (n=18)
N (%) N (%)
Normocytic (MCV 76-100 fl) +
normochromic (MCHC 31 -35g/dl)
27 (79.4) 16(88.9)
Normocytic + hypochromic 4(11.8) 1(5.6)
Normocytic + hyperchromic 1(2.9) 0
Microcytic + hypochromic 0 1(5.6)
Macrocytic + nonnochromic 2 (5.9) 0
Figure (2.11): Prevalence of different types of anaemia for patiens
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SUMMARY FOR COMBINED COHORTS
There were a total of 681 admissions to ICU in the study cohorts. Of these 441
patients were discharged alive from ICU. Of these 283 patients were discharged from
ICU to a ward in the hospital and then discharged to their normal residence. 122
(43%) were females and 161 (57%) were males.
The median (IQR) of last Hb before ICU discharge was 99 g/L (87 to 114 g/L). Table
(2.38) shows the number (%) of patients with last Hb before ICU discharge below 90
g/L, 100 g/L, and < reference range.
The median (IQR) of last Hb before hospital discharge was 108 g/L (96 to 120 g/L).
Table (2.39) shows the number (%) of patients with last Hb before hospital discharge
below 90 g/L, 1 OOg/L, and < reference range. Table (2.40) shows the number (%) of
patients who were discharged home with different degrees of anaemia in different
bands of age, APACHE II score, length of ICU stay, and last Hb before ICU
discharge.
There were 219 patients who were discharged to their normal residence and had their
last Hb before hospital discharge below the reference range. Table (2.41) shows the
prevalence of different types of anaemia according to their last MCV and MCHC
results.
MULTI-VARIABLE LOGISTICREGRESSIONFOR THE COMBINED
RETROSPECTIVEAND PROSPECTIVE COHORTS
There was very strong evidence that a lower last haemoglobin before ICU discharge
is associated with an increase in the odds of a last Hb prior to hospital discharge
<100 g/L (table 2.42). There was also strong evidence of an association between age
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on admission to ICU and a low Hb prior to hospital discharge. The 38-53 year olds
and 54-65 year olds having considerably increased odds of a last Hb prior to hospital
discharge <100 g/L compared to the under 38 year olds. The association between an
increase in APACHE II score and an increase in the odds of a last Hb prior to
hospital discharge <100 g/L was almost statistically significant. Although each one
day increase in the length of ICU stay was estimated to increase the odds of a last Hb
prior to hospital discharge <100 g/L by only a small amount this did approach
statistical significance. Even though the odds of a last Hb prior to hospital discharge
<100 g/L were greater for female patients than male patients, the unadjusted odds
ratio was not statistically significantly different from one.
There was no evidence from the multi-variable analysis that, after considering the
last haemoglobin before ICU discharge, any of the other variables were independent
predictors of a last haemoglobin prior to hospital discharge <100 g/L (table 2.42). In
addition there was no evidence that the relationship between the last haemoglobin
before ICU discharge and a last Hb prior to hospital discharge <100 g/L was
different for males and females (p=0.18), modified by age on admission (p=0.57),
modified by APACHE II score (p=0.55), or modified by length of ICU stay (p=0.18).
Some caution should be shown when interpreting the multi-variable analysis results
since the confidence intervals for some of the adjusted odds ratios are quite wide. In
particular the upper limits do not exclude what would be fairly strong independent
associations between gender or age on admission and a last haemoglobin prior to
hospital discharge <100 g/L.
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SUMMARY OF THE FINDINGS
A total of 681 ICU admissions were studied in both the retrospective and prospective
cohorts. 441 (64.75%) patients were discharged alive from ICU. Of these 283
(64.17%) patients survived post-ICU hospital stay, were discharged to their normal
residence, and comprised the final study group. 57% were males, the mean ± SD age
was 52 ± 18.3 years, and mean APACHE II score was 17.2 ± 6.5.
84.8% of all patients in the study group were discharged anaemic from ICU with Hb
levels below the normal reference range. 52.3% were discharged with Hb< 100 g/L
and 29.3% with Hb <90 g/L. 77.4% were discharged to their nonnal residence from
hospital with Hb levels below reference range. 32.5% were discharged with Hb <100
g/L and 11.3% with <90 g/L. Red cell morphology showed that normochromic
normocytic indices were present in 82% of all anaemic patients with Hb level less
than reference range when discharged home.
There was a strong association between last Hb before ICU discharge and the
probability of discharge home with Hb <100g/L. After adjustment, there were no
associations with age, sex, admission APACHE II score, or ICU length of stay. In a
logistic regression model, after including last Hb in ICU, no other parameter was
associated independently with a Hb <100g/L at discharge home.
In the prospective part of the study, 11 % ofpatients received red cell transfusion
after ICU discharge, comprising a total of 42 transfusion episodes (99 red cell units).





The study took place in a large medico-surgical teaching ICU and included three
cohorts of ICU patients. The cohorts accounted for 100% of ICU admissions during
the study periods to obtain large numbers of patients. The cohorts included the entire
ICU case mix so selection bias was unlikely. The cohorts were from three different
years to compare clinicians' practice during different periods. The three cohorts were
from different quarters of the year; therefore variation by time of year was unlikely
to be a source ofbias.
The retrospective cohort
The patient dataset for the retrospective cohort was obtained from the Scottish
Intensive Care Society (SICS) Audit group database, which is accurate, contains all
patients' demographic data, and includes 100% of ICU admissions. This cohort of
patients was previously included in large national (Garrioch, Walsh, Maciver,
McClellan 2002) and single centre (Chohan, McArdle, McClelland, Mackenzie,
Walsh 2003) studies to investigate transfusion practice during critical illness. The
data were prospectively collected at the time of these studies and have been
previously reported, showing that a restrictive transfusion strategy was used during
the ICU stay(Garrioch, Walsh, Maciver, McClellan 2002; Maciver, Walsh, Lee,
MacKirdy, Garrioch, McClelland 2002; Chohan, McArdle, McClelland, Mackenzie,
Walsh 2003; Walsh, Lee, Maciver, Garrioch, McClelland 2003a; Walsh, Lee,
Maciver, Garrioch, McClelland 2003b).
During the above-mentioned prospective studies by Walsh et al., and Chohan et al.,
the daily ICU Hb values were recorded daily from the patients' notes. These Hb
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values were compared to the linked values in our dataset and we found that there
were no differences or missing values as a result of the linkage process when we
compared both datasets (our dataset and the Walsh et al. and Chohan et al. datasets).
Therefore, the accuracy of the linkage process was satisfactory and the chance of
missing any haematological values as a result of the linkage process was small.
Nearly 360,000 records were received from the haematology database. This large
number generated few errors in the linkage process, which were resolved by
repeating the linkage more than once in different ways until satisfactory linkage
results were obtained. A few records in the haematology dataset contained
differences in one or more character in one or more field was that used in the linkage
process for some patients e.g. forename and/or surname, and/or date ofbirth. This
created linkage errors, which were sorted by post-linkage manual checking.
Therefore, errors in the linkage process were unlikely to cause any missing
haematological data.
After completing and checking the linkage process, a manual search in the
haematology database was carried out to find any missing haematological results to
obtain complete records for analysis.
The linkage process was the key element of the study; all of the above-mentioned
methodology in checking the linkage process provided the study with a high quality
dataset for further analysis.
Theprospective cohort
Haematological and transfusion data for the prospective cohort were collected daily.
Patients were followed up on a regular baseis throughout the hospital after ICU
discharge. All Hb results were recorded daily to avoid any missing values and results
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were checked again in the haematology database to obtain a highly accurate dataset.
It is therefore unlikely that significant inaccuracies occurred.
Transfusion data were collected from patients' notes. Reviewing blood transfusion
forms for the number of red cell units transfused in each transfusion episode was
carried out to increase the accuracy of this data. It is therefore unlikely that there
were missing or inaccurate values.
Weaknesses
The retrospective cohort
It was not possible to define post-ICU transfusion practice for this cohort. However,
a pilot trial to obtain this by linkage was carried out. A dataset was obtained from the
blood bank database that contained the number of red cell units issued and returned
to the blood bank. This dataset did not provide information as to whether these red
cell units were actually received by the patients or not. It was also unclear from this
dataset if ICU physicians or other hospital physicians prescribed the red cell units
that were issued within short time after ICU discharge. We concluded that the data
from this linkage were unreliable and did not report them. The only way to obtain
post-ICU transfusion practice was to do a case note review, which was not feasible
for this large number of records. Therefore, the analysis of this part of the study did
not take place, but was included in the prospective cohort.
Theprospective cohort
Haematological data were not collected during ICU stay as the prevalence of
anaemia and transfusion practice during critical illness was already established in the
unit from earlier studies.
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After ICU discharge, a large number of patients were followed up in different wards.
Manual checking from the hospital haematology database was done to check for any
missing values that were not present in hospital notes at the time of visits.
Due to long hospital stay it was difficult to be sure that all post-ICU days were
audited. The SICS database was used to check for missing days as hospital discharge
date is routinely entered. Only one patient was found to have missing days (40 days)
as he stayed in the hospital more than 100 days after ICU discharge. This missing
data is unlikely to have affected the final results.
Transfusion practice was case note dependent; causes for blood transfusion were not
documented and there were difficulties in tracing these causes. This is a well-known
problem in auditing transfusion practice. It was not feasible to interview those
clinicians making transfusion decisions.
The retrospective and the prospective studies
Both studies were observational. ICU discharge Hb and/or hospital discharge Hb for
some patients were not always measured on the day of discharge. For these patients,
the last Hb value recorded in ICU or in the hospital was used as discharge Hb. For
most patients, these Hb values were measured 2-3 days before discharge so it was
unlikely that Hb values changed significantly at the day of discharge. These values
were the last values available and checked by physicians and reflected levels thought
acceptable for discharge. If these levels were not acceptable, the physicians
presumably would have checked them again on the day of discharge or delayed
discharge to investigate or treat the anaemia. Therefore, using last recorded ICU and
hospital Hb values as ICU or hospital discharge Hb were a reasonable reflection of
what clinicians considered compatible with discharge home.
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A small number of patients were readmitted to ICU during the study periods.
Readmission generated a problem in defining the post-ICU period. Post-ICU period
for the retrospective part of the study was defined as the period that followed the
final ICU discharge. However, in the prospective part it was defined as the period
that followed the first ICU discharge in order not to miss any transfusion data in
post-ICU discharge. 7 patients were readmitted to ICU in this part of the study. Five
of these patients died in the hospital and 2 were discharged home. It is unlikely that
these readmissions influenced the estimates of the prevalence of anaemia that were
obtained, or the regression analysis.
APACHE II score for both the prospective and the retrospective studies was obtained
from the SICS database. This score is calculated from physiological variables in the
first 24 hours in the ICU and also incorporates a weighting for age and chronic
health. The SICS database is maintained by senior clinical staff in ICU, however, it is
not externally validated and therefore there is a potential for inaccuracy in the
dataset.
COMPARISON WITH OTHER STUDIES
The general characteristics of the cohorts were similar as regard the percentages of
males and females, mean age, APACHE II score, ICU and hospital length of stays to
other recent studies by Walsh et al. and Garrioch et al (Garrioch, Walsh, Maciver,
McClellan 2002; Walsh, Lee, Maciver, Garrioch, McClelland 2003b) and are typical
ofUK ICUs with high illness severity at admission. Our estimates may not be
applicable to ICU populations with lower illness severity.
Recent transfusion guidelines emphasise the evidence in favour of avoiding red cell
transfusions during hospital treatment of critically ill and peri-operative patients by
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using conservative transfusion triggers. Several cohort studies have confirmed that
conservative transfusion triggers are being used in the ICU, and that anaemia is
prevalent during critically illness(Hebert et al. 1998; Garrioch, Walsh, Maciver,
McClellan 2002). Our data show that this approach results in a large number of
anaemic patients who are recovering from critical illness being discharged in to the
community. In most patients the anaemia has morphological characteristics similar to
anaemia of chronic disease.
Several recent studies showed that the anaemia critical illness has similarities to the
anaemia of chronic disease which is characterised by normocytic normochromic
blood indices (Rodriguez, Corwin, Gettinger, Corwin, Gubler, Pearl 2001; Hobisch-
Hagen et al. 2001; Corwin 2001b). Bone marrow suppression due to direct effect of
circulating cytokines and inadequate EPO concentrations play an important role in
the course of this type of anaemia(Rogiers et al. 1997; Goodnough 2001; Eckardt
2001; Corwin 2001a; Corwin 2001b). Our findings showed that most patients
recovering from critical illness were discharged home with nonnocytic
normochromic anaemia. This may indicate marrow suppression,
inadequate/ineffective EPO, or functional iron deficiency. Rodriguez et
al.(Rodriguez, Corwin, Gettinger, Corwin, Gubler, Pearl 2001), von Ahsen et al.(von
Ahsen, Muller, Serke, Frei, Eckardt 2001), and Van Iperen et al.(van Iperen,
Gaillard, Kraaijenhagen, Braam, Marx, van de 2000) showed that this is the case
during ICU stay. However, there is no reported data investigating whether this
continues after ICU discharge or for how long. Further studies are needed to define
factors contributing to delayed recovery from anaemia after ICU discharge.
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Our data suggest that anaemia associated with critical illness may persist for a
considerable time. Improved understanding of the causes of this may enable the
rational use of new treatments such as erythropoietin. Exogenous erythropoietin has
been used in the treatment of the anaemia of critical illness. However, there are many
arguments about its efficacy during the course of the disease. Krafite-Jacobs et al.
(Krafte-Jacobs, Levetown, Bray, Ruttimann, Pollack 1994), and Van Iperen et
al.(van Iperen, Gaillard, Kraaijenhagen, Braam, Marx, van de 2000) showed that
there is a blunted response to exogenous EPO during critical illness. Other studies
suggested that there is association between the level of circulating inflammatory
mediators and bone marrow response to EPO. Defining which patients may benefit
from treatment, and what stage in their illness, is important before EPO should be
considered for widespread use.
POSSIBLE IMPLICATIONS OF ANAEMIA AFTER CRITICAL ILLNESS
Treatment of the anaemia of critical illness is potentially important. Some studies
show that anaemia has adverse effects on different body organs. Deicher et al.
(Deicher, Horl 2003), Hus et al.(Schuster, Rowley, Feinstein, McGue, Zuckerman
1984), and Astor et al. (Kovesdy, Astor, Longenecker, Coresh 2002)showed that
anaemia is a risk factor for the progression of chronic renal disease. Ezekowitz et
al.(Ezekowitz, McAlister, Armstrong 2003), Weiskopf et al.(Weiskopf et al. 1998;
Weiskopf, Feiner, Hopf et al. 2003), Carson et al.(Carson et al. 1996), and Sandgren
et al (2003, Abstracts of the American Geriatrics Society Annual Meeting, page 363)
showed that anaemia is common in heart disease and associated with poor outcome.
Granberg et al.(Granberg Axell 2002) and Weiskopf et al. (Weiskopf et al. 2000)
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showed that anaemia can have adverse effects on the central nervous system
functions.
It is unclear if anaemia of critical illness is a long-term disorder, can persist after
ICU and hospital discharge, and whether it has similar negative impacts on different
body organs and quality of life. Our literature review identified no studies
investigating the prevalence of anaemia during recovery from critical illness, or its
long-term effect on patients' health. There is also no information about whether there
is an association between this type of anaemia and quality of life. However, there is
clear evidence that anaemia is associated with poor quality of life in chronic renal
failure(Seidenfeld, Piper, Aronson 2002), chronic inflammatory diseases(Peeters,
Jongen-Lavrencic, Bakker, Vreugdenhil, Breedveld, Swaak 1999),
cancer(Littlewood, Cella, Nortier 2002), and chronic heart failure(Horwich,
Fonarow, Hamilton, MacLellan, Borenstein 2002).
Some UK studies showed that easy fatigability and poor quality of life are not
uncommon after recovering from critical illness (Ridley, Wallace 1990; Eddleston,
White, Guthrie 2000). Muscle weakness, cachexia and malnutrition are also common
in patients recovering from critical illness (Elia, Stratton 2000). The presence of
these factors, with anaemia, could worsen the quality of life after ICU and hospital
discharge. Wright JC et al. showed that patients discharged from ICUs have excess
mortality compared to population cohorts for 2-3 years following ICU discharge. The
authors found 33.4% 5 years mortality after discharge from ICU (Wright,
Plenderleith, Ridley 2003).
Factors that are associated with quality of life after critical illness are poorly
understood. It has been shown that increasing Hb levels in another settings such as
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chronic renal failure (1999 European best practice guidelines for the management of
anaemia in patients with chronic renal failure, page 363), cancer (Littlewood, Bajetta,
Nortier, Vercammen, Rapoport 2001), and chronic heart failure has improved quality
of life and patients' outcome (Silverberg, Wexler, Sheps et al. 2001).
There is a need for further trials that can provide a clear idea about the prevalence of
long-term anaemia after ICU discharge, its pathophysiology and causes, and its
impact on quality of life. An interventional trial should follow to investigate the role
of treating post-ICU anaemia in enhancing patients' recovery and improving quality
of life after ICU and hospital discharge.
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CHAPTER THREE
RED CELL 2,3-DIPHOSPHOGLYCERATE [RBC 2,3-DPG] AND P50 ~~~~
DURING CRITICAL ILLNESS: PROSPECTIVE OBSERVATIONAL
STUDY.
The discovery of the role of red blood cell 2,3-diphosphoglycerate (RBC 2,3-DPG)
in oxygen transport and its effect on the oxygen dissociation curve (ODC) has
changed many thoughts in several areas of clinical medicine.
THE OXYHAEMOGLOBIN DISSOCIATION CURVE AND P50
The oxyhaemoglobin dissociation curve describes the relation between the oxygen
saturation or content of haemoglobin and the oxygen tension at equilibrium. Affinity
of haemoglobin for oxygen is expressed by P50 value. P50 represents the partial
pressure of oxygen (P02) at which 50% of the haemoglobin is saturated under
standard conditions of temperature and pH. Normally, the P50 is 27 mmHg for adult
haemoglobin (figure: 3.1) (Eaton, Brewer, Schultz, Sing 1970; Hsia 1998).
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Arturson et al determined the oxygen affinity of human blood in vivo under standard
conditions. The authors studied 12 males and 15 females. All the subjects were
healthy with age range 20-48 years. A venous blood sample was taken from each
individual while at rest. Immediately after the blood samples were drawn, Hb,
oxygen saturation, HbCo, P02, PCO2, pH, and RBC 2,3-DPG were measured. This
study allowed the authors to plot the relation between P02, and oxygen saturation
under actual condition conditions with respect to pH, PCO2, RBC 2,3-DPG, and
HBCo in apparently healthy humans. The authors suggested that it is possible to
obtain measurements of the whole blood oxygen affinity by this technique (Arturson,
Garby, Robert, Zaar 1974a).
DETERMINA TIONOFP50
There are two main approaches to measure P50: a) in vivo, this approach allows to
estimate the P50 as it is in the real conditions in the body at the time of taking the
blood sample, once the sample is drawn from the subject and maintained in
anticoagulant, its pH, PCO2, and temperature may change. This method adjusts for
these variables, to estimate the in vivo state using special devices, or can be
calculated using Siggaard-Andersen or Samaja et al. equations (discussed later in
detail), b) in vitro, P50 is estimated under standard conditions of pH, PCO2, and
temperature. Many equations have been derived and it is often called standard P50.
The use of these equations as been to estimate a P50 value from arterial oxygen
saturation (S02) and partial pressure of oxygen Pao2 alone, but assumes other factors
(pH, PCO2, and temperature) are within normal ranges.
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Most studies concerning P50 used equations to calculate its value. Very few studies
have measured the actual in vivo P50.
In vivo P50 (oxygen dissociation curve analyser)
Duvelleroy et al described a method of plotting the ODC from a sample of whole
blood (5-10 ml). The method used a special device that allowed diffusion of a
known volume of O2 to a known volume of deoxygenated blood (deoxygenated using
a tonometry for 30-45 min at 37 °C with humidified mixture of 95% N2 and 5% CO2)
and measured blood Po2 and 02 content continuously using a closed chamber. pH
and PCO2 were determined with appropriate electrodes maintained at 37 C before and
after the completion of the process. The device used allowed the authors to plot a
graph showing the relationship between blood P02 mmHg (y axis) and 02 content (X
axis). After analysing the data, the authors found that the mean P02 at 50% saturation
at pH = 7.40 was 26.53 ± 0.48 mmHg (Duvelleroy, Buckles, Rosenkaimer, Tung,
Laver 1970).
In vivo P50 can be also calculated using the Siggaard-Andersen or the Samaja et al
formulas.
Siggaard-Andersen described a very complex formula that contains measured and
calculated values. A special software computer program is needed to estimate the in
vivo P50 using this fonnula (Siggaard-Andersen, Wimberley, Fogh-Andersen,
Gothgen 1988).
Smaja et al. described another formula to estimate in vivo P50 as follow (Samaja,
Mosca, Luzzana, Rossi-Bernardi, Winslow 1981):
1) Log P50 was estimated from known values of PCO2 and RBC 2,3-DPG/Hb
(molar ratio) at definite value of pH using a special formula.
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2) The authors suggested that because log P50 is always a linear function ofpH
in the range 6.9 to 7.6, its value at any pH in this range can be interpolated by
using the formula:
Log P50 (pH) = [(pH - 7.0) X (log P50 (7.6) - log P50 (7.0)] / 0.6
+ log P50 (7.o)
3) This empirical relationship allowed the authors to estimate in vivo P50 at any
given pH (range 6.9 to 7.0), Pco2 (range 20 to 90 mmHg), and RBC 2,3-
DPG/Hb ratio (range 0.3 to 2.5), with 0.73 mmHg SD.
In vitro P50 (standard P50 or P507.4)
The key equation used to calculate P50 was described by A.V. Hill.
The Hill equation is (Willford, Hill, Moores 1982):
S = Po2n/(Po2n + P50")
Where S is the fractional saturation, Po2 is the partial pressure of oxygen, and n is the
haem-haem interaction or a quantitative expression of the shape of the ODC (Hill
factor = 2.7 for human normal blood).
Some authors have derived other formulas based on the same principles ofHill's
formula such as Willford et al. and Samaja et al.
Willford et al. formula (Willford, Hill, Moores 1982):
P50 = Pao2 X 1 - (Sa — Sv) X l'/n
1 + (Sa- Sv)
Where Pao2 is partial pressure oxygen, Sa is arterial oxygen saturation, Sv is venous
oxygen saturation, and n is Hill factor (2.7).
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Samaja et al. formula (Hill's transformation)(Samaja, Mosca, Luzzana, Rossi-
Bernardi, Winslow 1981):
Log P50 = log Pao2 + [log (S02 /(100 - S02)]/n
Comparison between in vivo versus standard P50
Ekeloef et al. compared 114 arterial or venous blood samples that were analysed
using the Sigaard-Andersen oxygen status algorithm (in vivo P50) and Doyle's
method based on Hill's equation (standard P50 or in vitro P50). The authors
suggested that the Siggaard-Andersen oxygen status algorithm is the most clinically
useful single-point method of P50 calculation. The authors added that Doyle's
formula slightly overestimated the P50 by a value of 0.04 kPa (Ekeloef, Eriksen,
Kancir 2001).
Samaja et al measured the actual in vivo P50 in 63 blood samples using a special
tonometer. The authors calculated the in vivo P50 and the in vitro P50 using their
own equations (mentioned above) and compared the results to the actual measured in
vivo P50 using the special tonometer. They found that precision was slightly
improved if the in vivo equation was used (r = 0.9938) compared to the in vitro
standard P50 (r = 0.9853). They suggested that the calculated in vivo P50 was more
accurate at lower and upper extremes (Samaja, Mosca, Luzzana, Rossi-Bernardi,
Winslow 1981).
Factors affecting P50
The factors that are known to influence the dissociation curve and subsequently P50:
a) arterial pH, b) Pco2, c),body temperature and d) RBC 2,3-DPG (Stryer 1981;
Beutler, Lichtman, Coller, Kipps, editors 1995).
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Bohr effect (Pco2 andpH)
Reducing the oxygen-binding affinity of haemoglobin by the addition of hydrogen
ions or carbon dioxide to blood is known as Bohr effect. Conversely, oxygenation of
haemoglobin reduces its affinity for carbon dioxide; this is known as Haldane effect.
Because changes in pH rapidly affect the haemoglobin molecule's ability to bind
oxygen, this mechanism has been postulated to be an important early adaptive
response to anaemia. However, the equations describing the physical process indicate
that a very large change in pH is required to modify the p50 by a clinically important
amount ([almost equal to] 10 mmHg). As a result, the Bohr effect is unlikely to have
important consequences (Hsia 1998; Hebert, Szick 2000).
There were early attempts to investigate the effect of the above-mentioned
parameters on ODC. Winslow at al. analyzed 56 ODCs of fresh human blood, each
from 0 to 150 Torr Po2. The data were collected over ranges of values for the 2,3-
diphosphoglyceric acid-to-hemoglobin concentration ratio [DPG]/[Hb] of 0.2-2.7, for
pH of 7.0-7.8, and for Pco2 of 7-70 Torr. This study provided a tool to study the
affinity ofHb for 02 within the red blood cell and to predict the shape of the 02
equilibrium curve in various physiological and pathological states. Other attempts to
predict blood 02 affinity have considered only P50 or have provided too little data
for continuous simulations. The authors did not make a physical interpretation of the
reactions of these variables within the red blood cell as they sated that more data
were required (Winslow, Samaja, Winslow, Rossi-Bernardi, Shrager 1983).
Most of the studies that investigated the effect of different parameters on ODC and
P50 are very early studies around 1930s and 1960s.Thomas et al. reviewed very early
studies and noted that P50 corrected to pH 7.4 correlated with levels of RBC 2,3-
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DPG, when 2,3-DPG was altered by in vitro or in vivo alterations of acid base status.
The authors clarified that pH has dual effect on the position of the ODC by a direct
effect and through alteration ofRBC 2,3-DPG. In the same review the authors noted
that carbon dioxide affects the ODC by changing pH and forming carbamino
compounds (Thomas, III, Lefrak, Irwin, Fritts, Jr., Caldwell 1974).
Temperature
Reeves investigated the effect of temperature on the ODC. The author measured the
oxygen affinity of human blood over six degree temperature intervals from 13 to
43 C. The results were expressed in standard pH and carbon dioxide. Table (3.1)
shows P50 values that correspond to different values of temperature.
Table (3.1): P50 values that correspond to different vales of temperature Reeves
results (Reeves 1980)







The author stated that the shape of the ODC was invariant with temperature.
However, the measured C02-Bohr coefficient (A log P50/ A pH) ranged from -0.46
to -0.51 and was not temperature dependent (Reeves 1980).
RED BLOOD CELL 2,3-DIPHOSPHOGLYCERATE [RBC 2,3-DPG]
Red blood cell 2,3-Diphosphoglycerate (RBC 2,3-DPG) is the main acid-soluble
constituent of the erythrocyte ofmost mammals [Table (1)], occurring in the human
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at high concentration, compared with adenosine tri-phosphate (ATP) and
orthophosphate (Pi) (Rose 1970). Table (3.2) summarises concentrations of the
glycolytic intermediates in erythrocytes(Stryer 1981).



















The discovery of the effect of red blood cell RBC 2,3-DPG and ATP on the oxygen
dissociation characteristics ofhaemoglobin has greatly increased appreciation of the
association between red cell metabolism and function. Recent evidence makes it
clear that, through variations in the levels ofATP and RBC 2,3-DPG, the metabolism
of the human red cell may help maintain normoxia (Eaton, Brewer, Schultz, Sing
1970).
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RBC 2,3-DPG reduces the affinity of haemoglobin for oxygen by two mechanisms.
First RBC 2,3-DPG binds preferentially to deoxyhaemoglobin and thereby alters the
equilibrium between oxygen and haemoglobin. A second mechanism is by altering
intraerythrocyte pH relative to plasma pH (Thomas, III, Lefrak, Irwin, Fritts, Jr.,
Caldwell 1974).
Glucose is the normal energy source of the red cell. It is metabolised by the
erythrocyte along two major routes, the glycolytic pathway and the hexose
monophosphate shunt. The steps in these pathways are essentially the same as those
found in other tissues and in other organisms. Unlike most other cells, however the
red cell lacks a citric acid cycle (Stryer 1981; Beutler, Lichtman, Coller, Kipps,
editors 1995). Glucose metabolism of the erythrocyte for RBC 2,3-DPG synthesis
(the direct glycolytic pathway) is shown in figure (3.2).
It has been hypothesised by some authors that red cell DPG may influence red cell
deformability. Waugh et al studied the effect ofRBC 2,3-DPG on the mechanical
properties of the erythrocyte. From their results they confirmed the observations of
early investigators that under some conditions RBC 2,3-DPG acts to destabilize the
erythrocyte membrane. However, this effect is thought not to occur under
physiologic conditions suggesting that the effects ofRBC 2,3-DPG on the











Figure (3.2): Flow chart illustrating red blood cell
2,3-DPG synthesis
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ROLE OF RBC 2,3-DPG IN CONTROLLING RED CELL OXYGEN
AFFINITY
As the usual P50 measurements are done under constant conditions of temperature,
pH, and P02, observed variations in the oxygen affinity are usually related to the
concentration of 2,3-DPG. The P50 ofwhole blood or haemoglobin solutions
increases with increasing concentrations of 2,3-DPG (Mollison, Engelfriet,
Contreras, editors 1993).
In human red cells DPG and Hb are nearly equimolar. DPG profoundly lowers the
affinity of Hb for oxygen at concentrations commonly found in the red cells. One
mol ofDPG combines with one mol of deoxy-Hb to fonn a complex, which has a
low oxygen affinity. If 2,3-DPG is displaced it becomes easier for the Hb molecule
to undergo the allosteric transition to the tense (oxy) state with a higher oxygen
affinity (Mollison, Engelfriet, Contreras, editors 1993) (Benesch, Benesch 1969).
2,3-DPG binds in an electrically charged pocket between the (beta) chains of
hemoglobin, stabilizing the tense conformation and reducing oxygen affinity. The
binding of RBC 2,3-DPG also lowers the intracellular pH and further enhances the
Bohr effect. The P50 increases directly with the RBC 2,3-DPG concentrations. The
RBC 2,3-DPG concentration is reduced in aging red cells and under conditions of
hyperoxia or inhibition ofglycolysis (by acidosis or hypophosphatemia). Other
organophosphates and anions, such as chloride, also compete with RBC 2,3-DPG for
binding sites on hemoglobin. Hence, their presence can reduce the regulatory effect
of RBC 2,3-DPG on oxygen affinity (Hsia 1998).
Fairweather et al related the ODC to RBC 2,3-DPG in patients with acute and
chronic respiratory failure. The authors studied 27 patients, in vivo P50 was
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measured using a special tonometer [Edward and Martin] and RBC 2,3-DPG was
measured using an enzymatic method. The authors found that the average values of
RBC 2,3-DPG was 15.2 ± 3.5 x 10"6 mol/g Hb (normal reference range reported 8.5
to 20.5 pmol/g Hb) and P50 was 27.4 ± 2.3 mmHg (normal reference range reported
23-32 mmg). These values were within normal reference ranges despite hypoxia. The
authors found that P50 values correlated positively with RBC 2,3-DPG (r = 0.418, P
< 0.05). Multiple-regression analysis showed that the relationship between P50 and
RBC 2,3-DPG can explain 17.9% of the variance in P50. The authors suggested that
RBC 2,3-DPG was one of the most relevant variables that affected P50 in patients
with respiratory failure (Fairweather, Walker, Flenley 1974).
FACTORS AFFECTING THE CONCENTRA TION OFRBC 2,3-DPG INRED
CELLS IN VITRO
Most studies concerned with RBC 2,3-DPG in vitro were carried out to investigate
different medias for storing blood (discussed in a later section in detail). Deuticke et
al. found that RBC 2,3-DPG content of human red cells can be elevated in vitro by
incubating the red cells in media containing inosine, pyruvate, and inorganic
phosphate. The authors suggested that pH was the main factor that affected RBC 2,3-
DPG through its effect on the synthetic pathway (Deuticke, Duhm, Dierkesmann
1971).
Bevington at al. showed that change in temperature over a short time had no
significant effect on RBC 2,3-DPG in vitro. Blood samples were taken from normal
healthy individuals. RBC 2,3-DPG was measured immediately after the blood
samples were withdrawn, 30, and 60 minutes later. The samples were kept in ice.
The authors did not mention the actual temperature of the blood samples. The mean
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± SD of baseline RBC 2,3-DPG levels was 4.77 ± 0.29 mmol/1, after 60 min. 4.89 ±
0.27 mmol/1, and after 90 min. 4.86 ± 0.31 mmol/1 (Bevington, Asbury, Preston,
Russell 1985).
Rose et al did a laboratory study to investigate the enzymes controlling RBC 2,3-
DPG in human erythrocytes by purifying the enzymes responsible for synthesis
(diphosphoglycerate mutase) and breakdown (diphosphoglycerate phosphatase).
They found that diphosphoglcerate mutase is inhibited by low levels ofRBC 2,3-
DPG by a competitive inhibition with 1,3 diphosphoglycerate. Inorganic phosphate
inhibits the mutase enzyme as it acts as an inhibitor competitive with
monophosphoglycerate. The activity of the phosphatase enzyme is stimulated by the
presence of both chloride and phosphate. Phosphate in the absence of chloride has
very little effect. Chlorides ofNa, K, and Mg are equally effective as activators. The
authors found very high concentrations of chloride and/or phosphate have equal
inhibitory effects on the phosphatase enzyme (Rose 1970).
FACTORSAFFECTING THE CONCENTRATION OFRBC 2,3-DPG INRED
CELLS IN VIVO
FACTORS INFLUENCING ENZYME ACTIVITY
Studies of the physiology of red blood cells indicate that large increases or decreases
in RBC 2,3-DPG concentrations can occur in response to changes in oxygen
demands. The concentration of 2,3-diphosphoglycerate (DPG) depends on the
balance between its rate of fonnation from 1,3-DPG by diphosphoglycerate mutase
and its degeneration by diphosphoglycerate phosphatase (Rose, Liebowitz 1970;
Eaton, Brewer, Schultz, Sing 1970).
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Rose and Liebowitz performed another laboratory study, which confirmed that
phosphate and phosphoglycerate levels are important for determining the rate of
hydrolysis of RBC 2,3-DPG. The authors found that in human RBCs the maximum
velocity of the enzyme occurred at pH 6.4. Hydrogen ions have been shown to
inhibit the diphosphoglycerate mutase reaction and stimulate the phosphatase
reaction. It appears that red cell 2,3-DPG levels are exquisitely sensitive to pH: a rise
in pH causes a rise in 2,3-DPG levels, while acidosis results in RBC 2,3-DPG
depletion. Rose proposed that end-product inhibition of RBC 2,3-DPG mutase is
decreased by increased binding ofRBC 2,3-DPG by deoxyhaemoglobin. It was
suggested that decreased inhibition leads to an increase RBC 2,3-DPG levels (Rose,
Liebowitz 1970; Thomas, III, Leffak, Irwin, Fritts, Jr., Caldwell 1974; Beutler,
Lichtman, Coller, Kipps, editors 1995).
Luque et al. did a study to compare factors that affect the concentration of RBC 2,3-
DPG in human blood. 4ml samples were added to tubes with 1ml of a solution of
citrate and glucose (pH 5.0). Two of these tubes also included tetrathionate or
dithionate. A third sample included dipyridamole. The control sample added
physiological saline. The final pH in all samples was 7.0. They found that the level
ofRBC 2,3-DPG is better maintained during storage in the presence of tetrathionate.
They suggested that the variation ofRBC 2,3-DPG under the influence of these
compounds could be due to direct action on the enzymes responsible for its synthesis
and degradation (Luque, Pinilla, Ventura, Santos-Ruiz 1972).
Jelkmann et al. did an animal study using foetal rabbit red blood cells. They found
that RBC 2,3-DPG was increased during incubation in isotonic saline at 37°C, pH
7.4, glucose, inosine, and pyruvate (Jelkmann, Bauer 1978).
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Table (3.3) summarises factors affecting the enzymatic pathway ofRBC 2,3-DPG
Table (3.3) Factors affecting the enzymatic pathway for RBC 2,3-DPG synthesis
(Rose 1970; Rose, Liebowitz 1970; Deuticke, Duhm, Dierkesmann 1971; Luque,
Pinilla, Ventura, Santos-Ruiz 1972)
Factors decrease synthesis Factors increase synthesis
2,3-DPG Chlorides ofNa, Mg, and Ca
Inorganic phosphate Hydrogen ions
Very high levels of chloride pyruvate
Tetrathionate
THE EFFECT OFAGEAND SEX
There have been few reports suggesting that the chemical composition of the red
blood cell changes during the life of an adult healthy human.
Purcell et al.showed that in a normal population, RBC 2,3-DPG decreased with
advancing in age. They studied a total of 322 (176 males and 146 females) subjects
from 18-97 years of age; anaemic patients were excluded from the study. The
subjects were grouped according to age and RBC 2,3-DPG was measured. A
significant inverse correlation between RBC 2,3-DPG concentration and age was
found. RBC 2,3-DPG decreased significantly (P< 0.05) from a mean of
14.9pmol/gHb for the age group 18 to 24 years to 13.8pmol/gHb for the age group
65 to 74 years (table 3.4). Within each group the mean RBC 2,3-DPG concentrations
in males and females were the same, except in the age group 35 to 44 years, where
the difference between mean concentrations from males and females was significant
(13.6 and 15.2pmol/gHb respectively) (Purcell, Brozovic 1974).
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Table (3.4): The relationship between age and RBC 2,3-DPG concentration (Purcell,
Brozovic 1974).
Age band in years (N) Mean ± SD RBC 2,3-DPG (pmol/gHb)
18-24 (26) 14.9 ± 1.6
25-34 (35) 14.4 ± 1.3
35-44(17) 14.3 ± 1.5
45-54(17) 14.2 ± 1.5
55-64(11) 14.9 ± 1.8
65-74 (56) 13.8± 1.9
75-84(104) 13.9 ±2.4
>85 (16) 12.8 ±2.0
In children, the mean haemoglobin concentration is lower than in adults. Howard et
al measured RBC 2,3-DPG levels in 20 haematologically nonnal children, one to 12
years of age, and compared it to 15 nonnal adults. These authors found no
differences between children and adults. Moreover, they determined p50 in
conjunction with RBC 2,3-DPGlevels and the results were almost identical (table
3.5) (Pearson 1973).
Table (3.5): Mean ± SD ofRBC 2,3-DPG and P50 in children and adults (Pearson
1973).
Subjects RBC 2,3-DPG (pmol/gHb) P50 (mmHg)
Children 12.98 ± 1.90 27.19 ±0.61
Adults 13.00 ± 1.93 27.16 ±0.72
THE EFFECT OFALTITUDE
The erythropoietic system adapts to high altitude with two major responses: firstly,
by increasing red cell production and, secondly, by shifting the oxygen dissociation
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curve to the right by increasing RBC 2,3-DPG concentrations (Winslow, Samaja,
West 1984; Beutler, Lichtman, Coller, Kipps, editors 1995).
Winslow et al. studied red cell function at extreme altitude on Mount Everest where
they measured haemoglobin concentration, RBC 2,3-DPG, P50 (using special
tonometer), and acid base status in the research team members (26 to 52 years old) at
various altitudes. They found increases in RBC 2,3-DPG, which occurred in
association with modest increases in P50. RBC 2,3-DPG increased to high levels
when the members moved from sea level to 6,300 m, but further increased only
slightly when they reached 8,050 m (table 3.6).
Table (3.6): Red cell function at extreme altitude on Mountain of Everest (Winslow,
Samaja, West 1984)
Altitude Hb pH P50 DPG [DPG]/[Hb]
g/L Torr mol/mol Hb
Sea level 145 ±23 7.399 28.1 0.84 ±0.12 0.84
5400 m 178 ± 10 N/M N/M 1.05 ±0.09 N/M
6300 m 188 ± 15 7.467 29.8 1.04 ±0.12 1.04
8050 m N/M 7.552 29.6 N/M 1.18
8848 M N/M 7.780 27.4 N/M N/M
Mean ± SD [N/M = not mentioned in paper]
The authors suggested that the increase in RBC 2,3-DPG, P50 and left shift of the
ODC was associated with respiratory alkalosis. The authors did not mentioned how
quickly the response occured in relation to altitude, change in acid base balance or
any other variables (Winslow, Samaja, West 1984).
Adams et al did a study to compare the concentration ofRBC 2,3-DPG in 2 cretins
(anaemic individuals due to a decreased red cell production because of low thyroid
hormone production) and 2 nonnal subjects (control group) living at 3700 m. The
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authors found that RBC 2,3-DPG values were higher in cretins than the controls
despite similar levels of inorganic phosphate levels, and there was no correlation
between Hb levels and RBC 2,3-DPG concentrations. Table (3.7) shows the absolute
values of the results for all patients included in the study.
Table (3.7): Absolute valued ofHb and RBC 2,3-DPG in cretins (Adams 1976)
Subjects Age RBC 2,3-DPG Hb
(years) (pm/gHb) (g/L)
Cretin 1 27 12.07 115
Cretin 2 34 11.29 139
Control 1 52 10.29 144
Control 2 36 10.06 166
Nonnal reference range used in the study: RBC 2,3-DPG = 12 ± 1.2pm/gHb, Hb =
not mentioned in the paper.
The number of individuals in the study was too small to make definite conclusions
(Adams 1976).
Yoshino et al. did another study to measure RBC 2,3-DPG levels during high altitude
hypoxia. Five untrained healthy males (20 - 25 years) were submitted to a 4000,
5000 and 6000m simulated altitude chamber. Blood samples from subjects before
and after exposure to each stimulated altitude for 5 hours were analysed for RBC 2,3-
DPG. A correlation was observed between the levels ofRBC 2,3-DPG and the
variation of arterial oxygen saturation. The results were shown in graphs without
numerical values. The authors mentioned that the change in RBC 2,3-DPG
concentration was rapid in response to high altitude and further maintained after
returning to sea level. They suggested that the increase in RBC 2,3-DPG was an
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indication of tissue hypoxia. The authors did not measure or adjust for acid base
status (Yoshino, Hayashi, Katsumata, Mori, Mitarai 1980).
Mairbaurl H et al measured haematological and erythrocyte oxygen transport
parameters in whole blood and density-separated erythrocytes in 11 mountaineers
(mean ± SD age 36.8 ± 10.2 years) before and during 5 days of exposure to high
altitude (4559 m). At high altitude, whole blood in vivo P50 (measured using a gas
mixing pumps called Wosthoff device) remained almost unchanged, whereas
standard P50 (calculated using Hill's equation) and RBC 2,3-DPG increased
significantly. The Bohr coefficient for carbon dioxide was elevated significantly (the
change of oxygen-binding affinity of haemoglobin by the effect of hydrogen ions or
carbon dioxide). The authors suggested that during short-term exposure to high
altitude, the oxygen affinity is decreased only under standard acid-base conditions.
They explained their suggestion by increased levels ofRBC 2,3-DPG as a result of
low oxygen saturation and respiratory alkalosis (Mairbaurl, Schobersberger, Oelz,
Bartsch, Eckardt, Bauer 1990).
THE EFFECT OF EXERCISE
Sports anaemia refers to a decrease in Hb and Hct in highly trained runners. Ricci et
al measured Hb levels in athletes before and after exercise and in a control groups
(healthy individuals) and the mean ± SD valuse were [138 ± 8, 148 ± 8, and 154 ± 6
g/L respectively] (Ricci, Masotti, De, V, Vedovato, Zanotti 1988). This type of
anaemia may be due to increase in red cell destruction, increased iron loss in urine
and sweat, or increased plasma volume due to overshoot re-hydration. Sports
anaemia often occurs during intensive training; a compensatory mechanism was
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demonstrated to increase oxygen delivery to tissues. Elevations in the levels ofRBC
2,3-DPG seem to be involved in adaptation to the stress of prolonged exercise (Ricci,
Castaldi, Masotti, Lupi, Bonetti 1984) (Ricci, Masotti, De, V, Vedovato, Zanotti
1988; Mollison, Engelfriet, Contreras, editors 1993)
Measuring RBC 2,3-DPG and P50 after exercise, Ricci et al. studied 24 non-smoking
well-trained runners and compared them to healthy non-trained volunteers. They
found that in runners, the mean RBC 2,3-DPG was significantly higher than in the
control group (18.9 ± 3.7 and 15.4 ± 2.5pmol/gHb respectively), but the mean P50
values were not significantly different (24.5 ± 1.5 and 24.8 ± 1.2 mmHg
respectively). The authors did not mentioned whether P50 values were in vivo or in
vitro. As the authors found that mean MCV value was significantly higher in runners
than in controls (86 ± 4 and 83 ± 4 fl respectively), they suggested that the increase
of RBC 2,3-DPG was due to increase erythropoietic activity to compensate for mild
haemolysis. The new red cells contained high levels ofRBC 2,3-DPG (Ricci,
Castaldi, Masotti, Lupi, Bonetti 1984).
Meen HD el al. examined changes in RBC 2,3-DPG after exercise. They measured
RBC 2,3-DPG levels in 5 healthy men (25 - 50 years) over a prolonged period of
time after heavy exercise in healthy men, on 3 separate days. They found with 6 min
work, RBC 2,3-DPG was unchanged or slightly reduced immediately after and 15
min after the end of exercise, but then increased 8% above the initial level, 30 min
after the exercise. With more work (12min), RBC 2,3-DPG increased 12% above its
initial values. With an hour ofwork, RBC 2,3-DPG was increased 30 min after
exercise, and rose continuously during the early recovery phase. Table (3.8) shows
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RBC 2,3-DPG values and some other variables measured before and during exercise
and table (3.9) shows the same variables after finishing exercise.
Table (3.8): Mean ± SD RBC 2,3-DPG, pH, lactate, and serum P before and during
exercise (Meen, Holter, Refsum 1981).
Variable Base line 30 min ofwork End ofwork
(60min)
RBC 2,3-DPG 1.86 ± 0.11 2.08 ± 0.20 2.06 ±0.20
(mmol/1)
pH 7.34 ±0.04 7.35 ±0.05 7.39 ±0.04
Lactate (mmol/1) 1.18 ± 0.18 3.65 ± 1.55 3.07 ± 1.33
Serum P (mmol/1) 1.04 ±0.07 1.26 ±0.11 131 ±0.06
Table (3.9): Mean ± SD RBC 2,3-DPG, pH, lactate, and Serum P after exercise (time
in minutes) (Meen, Holter, Refsum 1981)
Variable 15 30 45 60 90 120 210 300
DPG 2.04 ± 2.02 ± 2.00 ± 2.02 ± 2.06 ± 2.00 ± 1.94 ± 2.00 ±
0.17 0.17 0.15 0.19 0.19 0.17 0.17 0.16
pH 7.37 ± 7.37 ± 7.37 ± 7.37 ± 7.34 ± 7.34 ± 7.38 ± 7.39 ±
0.01 0.02 0.03 0.01 0.01 0.04 0.03 0.03
Lactate 1.60 ± 1.25 ± 1.15 ± 1.08 ± 1.12 ± 1.06 ± 1.26 ± 0.95 ±
0.49 0.29 0.23 0.14 0.18 0.13 0.36 0.25
Serum P 1.24 ± 1.19 ± 1.15 ± 1.12 ± 1.11 ± 1.12 ± 1.16 ± 1.17 ±
0.09 0.09 0.07 0.07 0.07 0.08 0.13 0.09
The authors concluded from this study that heavy exercise was followed by a
progressive increase in RBC 2,3-DPG, reaching a new level 30-40 min after exercise.
They suggested that the main cause of the increase in RBC 2,3-DPG was due to
166
increase in serum phosphate. The authors suggested that lactate may have a role
through a decrease in pH (Meen, Holter, Refsum 1981).
Boswart J et al., in a similar study found that after 6 months intense training there
was a small, but significant increase in resting RBC 2,3-DPG. The authors studied 8
athletes (15-25 years). The authors showed the absolute values for all subjects
included in the study at rest before and after 6 months intense exercise (table 3.10).
Table (3.10): RBC 2,3-DPG (mmol/1) values at rest before and after 6 months of
training (Boswart, Kuta, Lisy, Kostiuk 1980).









The authors concluded that physical exercise has an effect on RBC 2,3-DPG level,
but did not suggest a mechanism (Boswart, Kuta, Lisy, Kostiuk 1980).
Ricci G et al. studied the effect of exercise on haematologic parameters, serum iron,
serum ferritin, RBC 2,3-DPG, and serum erythropoietin in 8 long-distance runners
during training (20 - 35 years) and compared them to 8 healthy volunteers (21-42
years). The authors found that there was no increase ofRBC 2,3-DPG observed after
exercise, but it was significantly higher than that in a control group. After exercise
the athletes' erythropoietin was higher than that of controls. Interestingly, there was a
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slight increase in neutrophil count after exercise. Table (3.11) summarises the results
of the study.
Table (3.11): The effect of exercise on the haematological parameters (Ricci,







Before exercise 19.2 ±4.3 19.1 ±4.9 115 ± 78 1.34 ±0.44 3.49 ± 1.6
After exercise
19.6 ±3.0 19.9 ±5.4 130 ± 88 1.58 ±0.59 4.83 ± 1.6
Controls 16.5 ±1.1 21.7 ±5.1 116 ± 63 1.00 ±0.15 3.92 ±0.6
2,3-DPG (pmol/gHg), serum iron (pmol/1), serum ferritin (pg/1), EPO (%),
neutrophils 109/1
The authors did not find a correlation between red cell parameters and RBC 2,3-DPG
in the study group. They did not suggest any explanations for the results (Ricci,
Masotti, De, V, Vedovato, Zanotti 1988).
Katz A et al. studied the effect of intense interval training on RBC 2,3-DPG levels at
rest and after maximal exercise. They found that training caused no significant
difference in RBC 2,3-DPG levels at rest and concluded that the role ofRBC 2,3-
DPG in enhancing tissue oxygenation during increased metabolic demand remains
obscure. The authors showed the results in graphs and not in numerical values (Katz,
Sharp, King, Costill, Fink 1984).
The data of the studies investigating the effect of exercise on RBC 2,3-DPG are
conflicting and most of them are unclear. Some studies suggested that exercise
affects RBC 2,3-DPG through changes in pH or phosphate levels; other studies




Very few studies looked at the oxygen affinity in subjects with diabetes mellitus.
Arturson G et al. studied this relation where they recruited 28 diabetic patients, with
an average duration of the disease of 14 years. No patients were acidotic; 27 healthy
volunteers were used as controls. They determined oxygen affinity ofwhole blood,
including measurements ofpH, Pco2 and RBC 2,3-DPG. They found that the values
ofRBC 2,3-DPG were higher in the diabetic patients than in the control subjects and
no relation between RBC 2,3-DPG values and haemoglobin concentrations in either
group (table 3.12).
Table (3.12): Oxygen affinity in subjects with diabetes mellitus (Arturson, Garby,
Robert, Zaar 1974b)
Subjects Hb pH RBC 2,3-DPG
Diabetics
Males (12) 144 ± 1.4 7.39 ±0.01 5.63 ±0.67
Females (16) 140 ±0.9 7.38 ±0.02 5.71 ±0.53
Controls
Males (12) 147 ±0.7 7.39 ±0.03 4.67 ±0.35
Females (15) 130 ±0.9 7.38 ±0.02 5.08 ±0.49
Mean ± SD Hb (g/1), ph, RBC 2,3-DPG (mmol/1)
The authors did not show numerical values for P50, however they showed 2 figures
for standard P50 and in vivo P50 and mentioned that oxygen affinity could not be
evaluated on the basis of the available data. They referred the higher levels ofRBC
2,3-DPG in the study group than that in the controls due to the presence of HbAie
which has lower oxygen affinity (Arturson, Garby, Robert, Zaar 1974b).
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ANAEMIA
In anaemia the oxygen carrying capacity ofblood is decreased and there are adaptive
mechanisms to maintain adequate oxygen delivery to tissues such as increased
cardiac output, hyperventilation, and increased RBC 2,3-DPG concentration
(Beutler, Lichtman, Coller, Kipps, editors 1995; Szaflarski 1996).
Few studies have investigated the effect of acute and chronic anaemia on RBC 2,3-
DPG, however, some studies have investigated in detail sports anaemia (discussed in
a previous section).
Acute anaemia
Most studies that investigated the effect of acute anaemia were carried out in animal
models. Anaemia was induced by normovolaemic haemodilution.
Cropp et al. studied the role ofRBC 2,3-DPG in oxygen transport in experimental
anaemia. The authors measured RBC 2,3-DPG levels before, during, and after
inducing anaemia by isovolaemic exchange transfusions with plasma in 5 dogs. They
found that when Hb concentration fell to half its normal values the RBC 2,3-DPG
showed approximately double its base line levels. RBC 2,3-DPG reached
approximately five times its base line levels at Hb concentration of 28 g/L. The
authors showed a figure of the relationship between RBC 2,3-DPG levels and Hb
concentrations and the relationship was a linear. Table (3.13) shows the observed
mean ± SD values ofRBC 2,3-DPG in different Hb concentrations.










The authors suggested that RBC 2,3-DPG increased as a compensatory mechanism
to anaemia, however, they hypothesised that the increase in RBC 2,3-DPG values
due to acute anaemia in dogs appear to be greater than in humans (Cropp, Gee 1972).
Holter et al. studied the relationship between P50 and RBC 2,3-DPG during the early
phase of the post-natal decrease in haemoglobin in rabbits. The authors mentioned
that in these species Hb levels tend to decrease dramatically during the first ten days
after birth. The authors found that there was a decline in Hb levels during the study
period, gradual increase in the P50 value from 2.3 kPa to 3.2 kPa, and RBC 2,3-DPG
increased markedly from 2.5 pmol/g to 17 pmol/g. They also showed a correlation
between the rise in P50 and RBC 2,3-DPG (r = 0.86, P<0.001). The authors reported
another negative correlation between P50 and Hb levels (r = 0.63, P<0.001). They
suggested that this negative correlation, together with the correlation between P50
and RBC 2,3-DPG reflect an anti-hypoxic mechanism that occurs in acute anaemia
(Holter, Halvorsen, Refsum 1982).
Fong et al. showed figures for RBC 2,3-DPG and the corresponding Hb levels in
acutely bled rabbits and normal controls in one of their studies. Mean ± SD RBC 2,3-
DPG was higher in the acutely bled group than the normal controls (31.1 ± 1.6 and
28.5 ± 0.9 pmol/gHb respectively) and the corresponding Hb levels were 92 ± 4 and
136 ± 4 g/L respectively (Fong, Ko, Streczyn, Westerman 1976).
Chronic anaemia
Few authors have investigated the relation between chronic anaemia and RBC 2,3-
DPG. Most of these studies were carried out in relation to various types of anaemia
such as anaemia associated with malignancy. Some were carried out in patients with
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other types of anaemia such as sickle cell anaemia, folate deficiency and iron
deficiency.
Fong et al. did an experimental study to investigate chronic anaemia, wound healing
(as an indictor of oxygen delivery to the tissues), and RBC 2,3-DPG in rabbits. The
authors included 42 rabbits with different types of anaemia; 13 iron deficiency, 10
water-induced anaemia, 10 phenylhydrazine anaemia, 9 iron deficient and received
iron supplement, and 18 normal rabbits served as a control group. All the groups
underwent a 5 inches skin incision, which was stitched in the same manner. Wound
healing was measured by special fonnulas (tensile strength and energy absorption)
that were derived from the wound characteristics. Table (3.14) summarises the result
of the study.
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The authors found that there was increased levels of RBC 2,3-DPG and wound
healing was normal in rabbits with iron deficiency and water induced anaemia. They
suggested that normal wound healing was associated with a decrease in oxygen
affinity due to high levels ofRBC 2,3-DPG. The Phenylhydrazine group showed
decreased levels ofRBC 2,3-DPG and nonnal wound healing. The authors suggested
that the change in RBC 2,3-DPG was due to the effect of phenylhydrazine on the
RBC 2,3-DPG metabolic pathway and that normal wound healing occurred due to
other compensatory mechanisms for keeping nonnal tissue oxygen delivery such as
increased cardiac output and vascularization (Fong, Ko, Streczyn, Westennan 1976).
Haidas et al did a study to show RBC 2,3-DPG levels in children with nutritional
iron deficiency (N = 7, age between 1.5 and 3 years), acute lymphoblastic leukaemia
(N = 35, age between 2.5 and 13 years), and nonnal children served as a control
group (N = 45, age between 1.5 and 14 years). The authors found a significant
difference between RBC 2,3-DPG levels in patients with iron deficiency compared to
controls. In the acute leukaemia group, 16 Children (no relapse) had normal levels of
RBC 2,3-DPG and 19 children (with one or more relapse) had higher levels
compared to controls. Table (3.15) summarises the findings of the study.
Table (3.15): RBC 2,3-DPG level in children with chronic anaemia (Haidas, Zannos-
Mariolea, Matsaniotis 1976)
Subjects Hb RBC 2,3-DPG
Control group 126.9 ± 16.0 14.90 ±0.68
Iron deficiency group 79.4 ± 12.0 20.87 ±3.11
Acute leukaemic group
No history of relapse 128.8 ± 13.5 14.11 ±0.88
With history of relapse 118.0 ± 12.0 22.05 ±2.75
Mean ± SD Hb (g/1), RBC 2,3-DPG (mol/gHb)
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The authors suggested that the increase in RBC 2,3-DPG in the iron deficient group
was a compensatory mechanism to low Hb levels, however, they did not give good
explanations for the findings in the leukaemic group. They assumed that treatment in
patients with no relapse might affect RBC 2,3-DPG levels. They recommended
further studies to investigate the activities of enzymes responsible for the production
and degeneration ofRBC 2,3-DPG in these group of patients (Haidas, Zannos-
Mariolea, Matsaniotis 1976).
Festa et al did a similar study. The authors studied the ODC (using an automatic
apparatus) in children with anaemia and malignant disease. They studied 68 children
with acute leukaemia and 27 with solid tumours. The authors included children who
were anaemic at the time of diagnosis or developed anaemia during the course of the
disease (Hb < 90 g/L). This group of children was compared to another 25 healthy
adults, suggesting that RBC 2,3-DPG levels in children to be 3-12% higher than
normal adults (normal adults 4.35 ± 0.33 pmol/ ml RBC). The authors found that
RBC 2,3-DPG and P50 were elevated in children at the time of diagnosis and before
starting treatment. They suggested that early before treatment, increased RBC 2,3-
DPG was a compensatory mechanism to anaemia. There were a decrease in RBC
2,3-DPG and P50 levels in patients who received red cell transfusion and
chemotherapy. The authors suggested that red cell transfusion decreased blood
oxygen affinity and chemotherapy prevented the production of new red blood cells
which have the ability to increase RBC 2,3-DPG levels (Festa, Asakura 1979).
Hjelm at al did similar study to measure RBC 2,3-DPG in 57 adult patients (age
range from 21 to 83 years) with myelomatosis and different types of leukaemia and
without cardiac, renal, or respiratory complications. The authors found that RBC 2,3-
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DPG correlated inversely with Hb in all groups except acute leukaemia (r and P
values are shown in table (3.16).
Table (3.16): The correlation between RBC 2,3-DPG and Hb in patients with
myelomatosis and different types of leukaemia (Hjelm, Uden, Engstedt 1976)
Diagnosis v1 P value
Myelomatosis -0.76 <0.001
Chronic myelocytic leukaemia -0.78 <0.05
Chronic lymphoblastic leukaemia -0.827 <0.001
Acute leukaemia -0.208 <0.01
They suggested that RBC 2,3-DPG increased due to anaemia (Hb range was 70-90
g/L), but not in acute leukaemia because of disease-related factors such as drugs or
red cell transfusion (Hjelm, Uden, Engstedt 1976).
Charche et al. investigated RBC 2,3-DPG in 32 patients with sickle cell anaemia and
compared the results to 34 healthy individuals. The mean ± SD ofRBC 2,3-DPG in
healthy subjects was 4.47 ± 0.53 pmol/ml packed RBCs and in patients was 6.25 ±
0.91 pmol/ml packed RBCs. There was no correlation between RBC 2,3-DPG and
either Hct (rs = 0.06) or reticulocyte count (rs = 0.14). The authors suggested that
hypoxia due to the nature of the disease led to respiratory alkalosis, which increased
RBC 2,3-DPG levels via increased pH (Charache, Grisolia, Fiedler, Hellegers 1970).
Opalinski et al studied RBC 2,3-DPG and creatine levels (as an indicator of red cell
age) in 17 patients with different types of anaemia and compared the results to 13
healthy individuals (controls). The study included 3 patients with aplastic anaemia, 8
patients with haemolytic anaemia, and 6 patients with different types of anaemia
such as iron, folate, or pot-haemorrrhagic anaemia.
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The authors found that creatine levels were low and RBC 2,3-DPG was significantly
increased in patients with aplastic anaemia compared to controls. In patients with
haemolytic anaemia and other types of anaemia, both RBC 2,3-DPG and creatine
were significantly increased. Table (3.17) summarises the results of the study.
Table (3.17): RBC 2,3-DPG and creatine levels in patients with different types of
chronic anaemia (Opalinski, Beutler 1971)
Subjects Hct Creatine RBC 2,3-DPG
Controls (13) 45.4 (40-49) 1.07 (0.83-1.35) 15.03 (13.64-16.21)
Aplastic anaemia (3) 16.8 (15-19) 0.19 (0.09-0.39) 16.45(15.57-17.73)
Haemolytic anaemia (8) 22.7 (13-29) 8.37 (3.7-15.12) 23.12 (17.43-29.73)
Other types of anaemia (6) 23.0(14-31) 3.08 (1.58-4.24) 22.28 (16.87-27.71)
Mean (range) Hct (%), creatine (pmol/gHb), RBC 2,3-DPG (pmol/gHb)
The authors found a significant correlation between RBC 2,3-DPG and creatine. The
authors suggested that younger red blood cells had higher levels ofRBC 2,3-DPG.
They concluded that anaemia was associated with increased RBC 2,3-DPG, but
suggested an additional mechanism for this was the presence of young red cells that
contained higher levels ofRBC 2,3-DPG (Opalinski, Beutler 1971).
Espinos D et al. showed the relationship between RBC 2,3-DPG, anaemia,
hypoxaemia and acid-base status in patients with liver cirrhosis. They compared 60
patients with hepatic cirrhosis, 33 patients with iron deficiency anaemia, and 86
healthy subjects. They found that RBC 2,3-DPG level was significantly higher in
cirrhotic patients compared to the healthy subjects and the 33 patients with iron
deficiency anaemia despite lower Hb concentration than observed in cirrhotic
patients. Table (3.18) summarises the results.
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Table (3.18): RBC 2,3-DPG level in cirrhotic and iron deficient patients (Espinos,
Alvarez-Sala, Villegas 1982)
Variables Cirrhotic Iron deficient Controls
Hb 7.31 ± 1.55 6.27 ± 0.98 9.02 ± 1.02
RBC 2,3-DPG 7.40 ± 1.23 5.86 ± 1.06 4.58 ±0.59
Mean ± SD Hb (mmol/L), RBC 2,3-DPG (mmol/gHb)
The authors suggested that RBC 2,3-DPG level was affected by the acid-base
disturbance accompanied liver cirrhosis more than the degree of anaemia, and they
showed that alkalosis increased RBC 2,3-DPG (r = 0.482, <0.001). The authors did
not mention pH levels for the other groups (Espinos, Alvarez-Sala, Villegas 1982).
In summary, although clinical and animal studies do not all have consistent
conclusions, the following factors have been associated with increase RBC 2,3-DPG
in vivo:
Low Hb level (acute and chronic) (Cropp, Gee 1972; Haidas, Zannos-
Mariolea, Matsaniotis 1976; Fong, Ko, Streczyn, Westerman 1976;
Hjelm, Uden, Engstedt 1976; Festa, Asakura 1979; Holter, Halvorsen,
Refsum 1982)
Alkalosis (Luque, Pinilla, Ventura, Santos-Ruiz 1972; Jelkmann,
Bauer 1978)
High altitude (Yoshino, Hayashi, Katsumata, Mori, Mitarai 1980;
Winslow, Samaja, West 1984; Mairbaurl, Schobersberger, Oelz,
Bartsch, Eckardt, Bauer 1990)
Exercise (Meen, Holter, Refsum 1981; Katz, Sharp, King, Costill,
Fink 1984; Ricci, Castaldi, Masotti, Lupi, Bonetti 1984)
Lower age (Pearson 1973; Purcell, Brozovic 1974)
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Part of confusion is data probably reflects the lack of consideration of all possible
factors in the studies.
ANAESTHESIA AND SURGERY
Very few studies have investigated factors that affect RBC 2,3-DPG during
anaesthesia and surgery. Schweizer et al. did a study in 50 patients undergoing major
surgery such as thoracic, abdominal, and neurological. Anaesthetic technique and
drugs used for all patients were similar. Blood transfusion was given as required.
Pre-operative and post-operative RBC 2,3-DPG, Hb, pH, oxygen saturation, and P02
were measured. Blood samples were withdrawn immediately pre and post
operatively. The authors found that 19 patients had no significant change between
pre and post-operative RBC 2,3-DPG and blood lactate level. 31 patients showed a
significant decrease ofRBC 2,3-DPG post-operatively and a significant increase in
blood lactate level. Table (3.19) summarises the findings.
Table (3.19): RBC 2,3-DPG before and after surgery (Schweizer, Howland 1973)
Patients with no significant Patients with significant change
change in RBC 2,3-DPG (19) in RBC 2,3-DPG (31)
Variables Preoperative Post-operative Preoperative Post-operative
RBC 2,3-DPG 15.14 ± 3.29 15.29 ±3.57 15.92 ±2.63 11.07 ±2.80
Hb 124.9 ± 16.6 111.3 ± 16.8 119.6 ± 16.0 116.4 ± 12.1
so2 83.08 ± 10.18 79.43 ± 8.55 73.15 ±24.76 78.85 ± 12.78
pH 7.36 ±0.02 7.36 ±0.05 7.36 ±0.02 7.37 ±0.05
Phosphate 1.64 ±0.36 1.53 ±0.44 1.71 ±0.22 1.67 ±0.20
Lactate 1.15 ± 0.45 1.78 ±0.82 1.07 ±0.22 2.17 ± 0.91
Blood 108 1844
transfused
Mean ± SD RBC 2,3-DPG (pmol/gHb), Hb (g/L), SO2 (%), inorganic phosphate
(meq/L), lactate (meq/L), blood (ml)
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The authors suggested that the low levels of RBC 2,3-DPG was <jue t0 blood
transfusion with RBC 2,3-DPG depleted blood. They hypothesized that the increased
level ofblood lactate was due to low concentration ofRBC 2,3-DPG which shifted
ODC to the left and induced an aerobic respiration with increased levels of lactate
(Schweizer, Howland 1973). The authors did not consider the high lactate
concentration of stored blood.
RBC 2,3-DPG IN STORED BLOOD
The decrease in the level ofRBC 2,3-DPG and other phospho-compounds in blood
stored for transfusion is well known. Depletion of DPG during the storage process
has been a major concern because of the belief that this adversely affects oxygen
unloading at the tissue level. The factors influencing RBC 2,3-DPG concentration
during storage has been a major focus in transfusion medicine. All currently used
systems for storage ofRBCs result in loss ofRBC 2,3-DPG and an associated
increase in affinity for oxygen (Luque, Pinilla, Ventura, Santos-Ruiz 1972; Kahn,
Zaroulis, Goetz, Howland 1986; Hogman, Knutson, Loof, Payrat 2002; Hess, Hill,
Oliver, Lippert, Greenwalt 2002). Some key papers relating to advances in red cell
storage are summarised in table (3.20). The authors of these studies have based their
explanations on the fact that pH has a role in maintaining RBC 2,3-DPG in stored
blood. The more alkalotic media used for preserving blood the more RBC 2,3-DPG
would be preserved through the effect on its synthesis and degeneration.
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Table(3.20):Advanc si redc llstorage. AuthorAimofthestudy
Settings
Resultsandconclusions
Hogmanet al.(Hogman, Knutson, Loof,Payrat 2002)
Theauthorsimed
toimprovehe qualityofstored bloodcollectedin ordinaryCPD.
AformulationofErythro-sol (Erythro-sol2),whichm re alkaline(pH8.8)wascompar d withErythro-sol(Erythro-s l1) (pH7.4).Invitromeasuresof ATPandRBC2,3-D Gduring 49daysofstorageinthe2 additiveswercompar d.
ThemaintenanceofRBCATP&2,3-D G wassignificantlybetterinErythro-sol2(more alkaline)thaninErythro-sol1(morecidic). Erythro-sol2wasanimproveddditives lu n forthestoragefRBCs.Tauthorssugg t d thatalk linepHt ectivityofhex kinased phosphofructokinaseinv lvedRBC2,3-DPG synthesishowedhig rconcentrationi alkaline pH.
Hesst al.(Hess, Hill,Oliver, Lippert, Greenwalt 2002)
Theaimoft studywasto investigatetherole ofalkalineCPDin preservationof RBC2,3-DPG.
12unitsofRBCwerecollect d anddividedinto4groups;each groupwaspreservedinCPD withdifferentpH(pH=5.7,6 5 7.5,or8.7). Another12unitswerecollect d
inalkalineCPD(pH=8.7).The unitsweredividedinto4 groups;anextradditiveof disodiumphosphatewasadded toeachgroup(0,918r27 mmol).











































































Few studies have investigated the benefits of transfusing blood rich with RBC 2, 3-
DPG and its impact on improving different organ functions.
Dennis et al. did a study to investigate myocardial performance after transfusing red
cells with high RBC 2, 3-DPG concentrations. 22 patients undergoing coronary
artery bypass surgery were included in the study. 11 patients received blood with a
mean age of 5.5 days and contained 70% of normal RBC 2, 3-DPG concentration,
this group served as a control group. 11 patients (the study group) received
previously frozen, washed, concentrated blood with 150% of normal RBC 2, 3-DPG.
There was a significant increase in cardiac index in patients who received blood
enriched with RBC 2, 3-DPG compared to controls (2.95 L/min. versus 2.18 L/min.
respectively). After transfusion and immediately off bypass, RBC 2, 3-DPG after
transfusion was significantly higher in the study group compared to the control group
(13.5 versus 10.6pmol/gHb respectively). Oxygen consumption was higher in the
study group compared to the controls (135 versus 106 ml/min./square meter
respectively). Hb level was similar in both groups. Patients in the study group were
slightly more acidotic than the controls at the time of terminating the bypass process
(pH = 7.26 versus 7.29 respetively). In vivo P50 (measured using a tonometer) was
also elevated in the study group compared with controls (31.6 versus 28.3 torr
respectively). After 24 hours, in vivo P50 and RBC 2, 3-DPG remained elevated in
the study group compared with controls. Patients in the study group received less
inotropes and showed a reduced frequency of use of intra-aortic balloon pumping.
The authors suggested that high level of RBC 2, 3-DPG shifted the ODC to the right
and improved tissue oxygenation. As a result of that, myocardial tissue oxygenation
was improved with increase in myocardial work. The authors suggested that acidosis
182
in the study group was the reason ofhigh level of in vivo P50 (Dennis, Vito, Weisel,
Valeri, Berger, Hechtman 1975).
Proctor et al. described a case report of the effect of transfusing red blood cells rich
with RBC 2, 3-DPG to a multiple traumatized unconscious 10 years old girl with
severe hypoxia. Inosin, sodium pyruvate, and Na2HP04 were added to the blood to
increase its RBC 2, 3-DPG. A total of five units with high RBC 2, 3-DPG were
transfused. The patients became fully alert after receiving the second unit and fully
responded to simple commands. 92 hours later the patient died and brain autopsy
revealed cerebral oedema and cortical petechiae. The authors suggested that high
level of RBC 2, 3-DPG shifted the ODC to the right and improved tissue oxygen
delivery including the brain tissues (Proctor, Parker, Fry, Johnson, Jr. 1973).
OXYGEN AFFINITY AND RBC 2,3-DPG IN CRITICALLY ILL PATIENTS
There have been a number of investigations into whether haemoglobin-oxygen
affinity is increased, normal or decreased during critical illness, but the published
data are inconclusive and conflicting.
Bevington et al investigated phosphate metabolism in erythrocytes of critically ill
patients. The authors studied 46 critically ill patients within 24 hours of ICU
admission. Red cell orthophosphate (Pj), adenosine 5-diphosphate (ADP), adenosine
5-triphosphate (ATP), and RBC 2,3-DPG were measured. The authors found that Pj
varied widely in critically ill patients compared to a reference range (0.1 to 4.2 and
0.6 to 1.5 mmol/1 respectively). The relationship between cellular organic phosphate
and Pj was weak with marked depletion ofATP and this occurred only at very low
levels of Pj. RBC 2,3-DPG did not show dependence on Pj levels. ATP/ADP ratio
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was not significantly affected by Pi concentration (Bevington, Asbury, Preston,
Russell 1985).
Myburgh JA et al studied P50 in critically ill patients with a mean age of 58 years.
They compared standard P50 on venous blood in 20 critically ill patients and 20
normal individuals. The formula used in the calculation did not include RBC 2,3-
DPG measurement. Arterial blood gas, lactate, haemoglobin, and phosphate levels
were also measured. The authors found that P50 was significantly lower in critically
ill patients compared with normal subjects. There was a strong positive correlation
between P50 and arterial pH (r = 0.79) and base excess (r = 0.69). There were poor
correlations between P50 and other variables measured in the study. They concluded
that standard P50 is reduced in many critically ill patients, and correlats with arterial
acid base status (Myburgh, Webb, Worthley 1991). However, the authors did not
consider mathematical linkage as a confounder or the unknown true RBC 2,3-DPG.
Morgan et al did another study in the critical care setting. The authors investigated
RBC 2,3-DPG and P50 in 20 critically ill male patients with APACHE II score > 20
and compared the RBC 2,3-DPG values to 20 healthy non-smoking males (controls).
Venous blood samples were taken from patients and controls to measure RBC 2,3-
DPG. Arterial blood samples were collected from patients only to calculate the in
vivo P50 using the oxygen status algorithm of the Siggaard-Anderson formula. This
formula of calculating P50 include arterial pH, arterial P02, arterial carboxy-
haemoglobin, Hb, mean core temperature, and venous RBC 2,3-DPG. The authors
found that the mean RBC 2,3-DPG concentration was lower in patients than that in
controls (4.2 ± 1.3 and 4.9 ± 0.5 respectively). The mean in vivo P50 for patients was
28.0 ± 1.3 mmHg. Using multiple regression analysis, there was only a positive
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significant correlation between RBC 2,3-DPG and pH. There was a weak positive
correlation between RBC 2,3-DPG and Hb concentration. There was no correlation
between RBC 2,3-DPG and calculated in vivo P50 (Morgan, Koch, Morris, Clague,
Purdie 2001). A review of some clinical studies in other relevant sittings is shown in
table (3.21)
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Table(3.21):Publish dc inicalstudiesthatinvestigateddiffer ntf ctorsthaff cRBC2,3-DPGdiffer nts ttingsfp e s AuthorAimofthe study UmimotoeTo al.(Umimoto,investigate Hirai,theeff ctof Hayashi,biofiltration Tanaka2000)(BF)on RBC2,3- DPGand redcell-pH. PiccionietInvestigate al.(Piccioni,RBC2,3- Cestari,DPGinlow Strunz,Aulercardiac 2003)output patientsand itsnfluence onInvivo P50.Settings
Resultsandconclusions
5malepatients(agr nge52- 60years)werestudied. 2weekscrossoverstudya conductedwithbicarbonate hemodialysis(BcHD)and biofiltration(me hodn whichbicarbonatesnotused fordialysis).Allpatientsw re diabeticandidnotrece ve celltransfusionfor6months beforethestudy.DPGandre cell-pHweremeasur d.
RBC-pHsignificantlyincreasedduringbothtyp sf treatmentsf othbaseline.H w ver,t dfth typesofreatments,herwasnosignificantdiffer nce(7.19 ±0.02forBcHDand7.20f F).Therewasno significantdifferencebetweeRBC-2,3DPGvalu sh beginningofBcHDa dF(16.4±.202 pmol/gHbrespectively).RBC-2,3DPGduringBcHD remaineduncha gedw ilitshowsign ficantincre se after120minndttheofBFsessions.Theauthors suggestedthatBFcorr ctedmetabolicacidos snb hr effectcausedbynincreasenRBC-pHduringialy iss compensatedf rbyaincreasenRBC-2,3DPG.
TheauthorsmeasuredRBC 2,3-DPGandcalculatedthei vivoP50for18patientsw th end-diastolicpressure>20 mmHg,ejectionfractio< 40%,orvalvep thology undergoingelectivecardiac surgeryandcomparethe resultsto20n rmalheal hy volunteers.






KeittAS al.(Keitt, Hinkes,Block 1974)
Tocompare factorsregulating RBC2,3-DPGin acutehypoxia.
12chronichypoxaemip tients, arterialoxygenwasincreas db chronicadministrationof oxygenbnasalcannulaf r4t 12months,7ofthembeca e acutehypoxicbysudden withdrawalofthenasalcannula.
Beforeoxygenadministration,RBC2,3-DPGwas correlatedsignificantlywithart r alPo2butnot arterialpH,how ver,duringthfirst24ursfter stoppinggivinoxygebthenasalc nnula, acutechangeinRBC2,3-DPGw shighlycorrela ed withachangeinrterialpH.Theresoco relat on betweenRBC2,3-DPGandHbl v l.Thuthors suggestedthatch ngeinpHwmoimportant factorthataffectedRBC2,3-DPGlev lincu hypoxia.Otherfactorssuchasoxygensat rationd P02controlRBC2,3-DPGinhronicstablehyp xia.
Oskiet al.(Oski, Gottlieb, Delivoria- Papadopoulos, Miller1969)
InvestigateRBC 2,3-DPGin subjectswith chronic hypoxaemia.
20normaln-smoking subjects,10hypoxaemic patients,5cyanotiche rtdise se patients,and5chroniche rt diseasepatientswerincluded thestudy.RBC2,3-DPG,pH, P02andSweremeasured.






Kahnet al.(Kahn, Zaroulis, Goetz, Howland 1986)
Toevaluate oxygentransport andRBC2,3- DPGlevelsin patientsw thacute respiratoryfailure afterredc ll transfusion.
15patientsw threspiratory failure(P02<70to r)andHct 35%wereincludednthstudy. 7-ml/kgredblooc lswere transfusedover2hour .All measurementswerc r iedo t beforetransfusionand301 houraftertransf sion.
Therewasasignificantincr seHblevelfter transfusion(109±8beforeand125 g/Laftertransfusion).RBC2,3-DPGdecreased significantlyaftertrans usion(14.5±1 1before transfusionand13.1±.5pmol/gHb).Therewaso significantdifferenceinP50valubeforea dfter transfusion(29.9±2.2ver us8.89o r respectively).Theauthorsexclud dt atch ngeinpH couldbethea sefRBC2,3-DPGlev s;how v r, theydidnotsuggestanreasonforeirsult .T referredthinsignificantchangeofP50 inRBC2,3-DPG.
Edwardset al.(Edwards, Canon1972)
Toinvestigate RBC2,3-DPG levelsins ver hvpoxaemiaf chroniclung disease.
50bloodsampleswertak n from5patientsw thsev re arterialhypoxa mia(meanP02 38,Pco2=54torrandpH 7.34).Theauthorsmeasured RBC2,3-DPGandcalculated standardP50(ivitro50).





LyonsetTdet rminethe13chro ichypoxaemp ti ts al.(Lyons,effectofchronicwereincludedtstudy. Tabak1972)hypoxianthe oxygenaffinity andtoinvestigate therelation betweenthacid basestatusandth affinityofHbf r oxygen.
Therewasnorelationshipbet eeP50ands excessvalues.Therwastrongpositivecorrelatio betweenP50andthsumofrel oc llNaK. Theauthorsexplainedthisrelat nbyc ngin intracellularpH.Th rewasositivecorre ation betweenP50andRBC2,3-DPG.Therreno relationshipsbetweenpl smaH,RBC2,3-DPG, oxygentension,rhaematocritv lues.Thauthors suggestedthatacidbasdisturb ncinpatien sw th chronichypoxiaaddiffere tff conRBC2,3- DPGcomparedtothersubjects.
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MATERIAL AND METHODS
RED CELL 2,3-DIPHOSPHOGLYCEREATE [RBC 2,3-DPG] AND P50




To measure red cell RBC 2,3-DPG concentration and P50 during critical illness.
SECONDARYAIM
To investigate factors that are associated with red cell RBC 2,3-DPG concentration and P50
during critical illness.
PATIENTS STUDIED
All patients who were admitted to ICU between 22/01/2002 and 14/07/2002 were
considered for the study.
• INCLUSION CRITERIA
Critically ill patients within 24 hours of ICU admission.
Patients who were expected to survive more than 24 hours
after admission.
Informed assent was obtained from patient's relatives on the
first day of admission.
■ EXCLUSION CRITERIA
Pregnant females.
Patients who were not expected to survive more than 24 hours
after admission.
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Patients who received red cell transfusion within 24 hours of
sampling.
Patients who were expected to receive red cell transfusion
within 24 hours of admission.




LREC reference number: LREC/2002/1/2.
No interventions were carried out and patient management was not altered in any
way on the basis of the data collected and the extra blood tests that had been
perfonned. Guidelines from the data protection act were followed and data were
anonymised after completing the study. Patients' identifiers were deleted and ICU
key number was used as a primary key in analyzing the data.
RECRUITMENT
All ICU admissions were screened daily during the study period for eligibility within
24 hours of ICU admission.
ORGANIZATION
During the study patients' demographic data were collected and some laboratory
investigations were carried out.
PA TIENTS' DEMOGRAPHICS
Demographic data were collected from the ICU database (Scottish Intensive Care
Society (SICS) Audit Group database). Table (3.22) shows the data that were
extracted from SICS database.
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LABORA TORYINVESTIGA TIONS
All blood samples were taken from an indwelling arterial catheter (each blood
sample = 2mL). During processing, blood samples were kept at ambient temperature.
Table (3.23) shows the different investigations and calculated values that were done.







Date of ICU admission
Date of ICU discharge
APACHE II score
ICU length of stay
ICU outcome
Table (3.23): Laboratory investigations, calculated, and recorded values.
Arterial Biochemical Electrolytes Haematological Calculated Recorded
blood gas values values
Hydrogen Urea** Calcium* Haemoglobin** Calculated FI02
ions* P50









*Values measured using the blood gas machine. ** Values measured in the hospital
laboratory. The methodology ofmeasuring RBC 2,3-DPG will be discussed later.
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EQUIPMENT
All blood samples for the study and control group, and reproducibility tests were
treated in the same manner. Blood samples were collected in to a blood gas
monovette (Sarstedt 05.1147.020 monovette 2ml LH).
The blood gas machine used in analysing the blood samples was a Bayer (Chiron)
865 analyser.
TIMING
Patient's demographic data were collected at the time of ICU admission.
Laboratory investigations: a total of up to 5 blood samples were taken from patients
during the study:
■ Baseline sample
Immediately after ICU admission and obtaining assent from the patient's
relatives, a 2 ml arterial blood sample was taken. The sample was analysed in
the blood gas machine. The remaining volume of blood was taken to measure
red cell RBC 2,3-DPG.
■ Daily samples
The remaining blood from the routine morning arterial blood gas samples was
kept in ice after analysis. Samples were collected to measure RBC 2,3-DPG
concentrations. Daily samples were collected up to 4 days after the first
baseline blood sample.





Patient's relative wanted to withdraw the patient from the study.
2,3-DIPHOSPHOGLYCERATE (RBC 2,3-DPG) ASSAY
KIT: Sigma Diagnostics RBC 2,3-DPG reagents, quantitative enzymatic
determination of 2,3-diphosphoglyceric acid in blood at 340 nm (procedure No. 35-
UV).
PRINCIPLE:
Three enzymatic reactions involved in the procedure are as follows:
1 - RBC 2,3-DPG is hydrolysed to 3-PGA and inorganic phosphorus (Pi). The
enzyme that catalyses this reaction is present in purified preparations ofPGM
and is termed 2,3-DPG phosphatase. 2-Phosphoglycolic acid is needed as a
stimulator for this reaction.
2,3-DPG 2,3-DPG phosphatase (PGM) 3-PGA + Pi
►
2-Phosphoglycolic Acid
2- 3-PGA reacts with ATP in the presence ofPGK to form
1, 3-diphosphoglycerate (1, 3-DPG) and ADP.
3-PGA + ATP PGK 1, 3-DPG + ADP
3- 1,3-DPG oxidized NADH to NAD in the presence ofGAPD and is reduced to
G-3-P
1,3-DPG + NADH GAPD ^ G-3-P +NAD
Measuring the decrease in absorbance at 340 nm caused by the oxidation ofNADH




Add 5mL Triethanolamine buffer to the ATP (This can be stored frozen).
Add 5mL PLO to the phosphoglycolic acid (Store frozen).
Add 8.0 mL triethanolamine buffer to NADH vial. Cap and invert several times to
NADH. (One vial will do 3 tests and can be stored in the fridge for up to 1 week.)
2-Preparation of supernatant (deproteinisation).
Add 3.0 mL ice-cold 8% TCA + 1.0 mL blood.
Shake vigorously for 10 seconds and keep cold for 5 min.
Centrifuge 3000 rpm for 10 mm at 4°C.
This supernatant is stable for at least 1month when stored frozen.
3-From frozen.
a) To a cuvette add:
2.5 mL solution from vial
0.1 mL ATP solution
0.25 mL supernatant
Then mix by inversion.




Any delay beyond 5 min will cause an underestimation ofDPG content.
c) Then read against H2O at 340nm = Initial.
d) Then add 0.1 mL phosphoglyceric acid.
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Mix by inversion.
Leave 30 min at room temperature (or 15 min at 37°C) to allow the reaction to go to
completion.
Read against H20 at 340 nm = Final
4-Calculate
[(Initial - Final) - 0.03] x 7.7 2,3-DPG pmol/mL
Multiply by 100 to give pmol/dL.
Divide by Hb g/dL to give RBC 2,3-DPG pmol/gHb.
Samples were kept frozen after step (2) and were analysed in batches within one
month of preparation.
CALCULATION OF IN VIVO P50
The in vitro method used by commercial blood gas analysers uses the Hill equation
to calculate P50 from the Pa02 and venous haemoglobin oxygen saturation alone,
and does not include actual values for RBC 2,3-DPG, PaC02, pH, or temperature. It
is therefore subject to assumptions that are not met by many sick patients. Direct in
vivo assessment ofP50 uses tonometry was not feasible. We used the only published
method derived specifically to estimate in vivo P50 from directly measured values
for pH, RBC 2,3-DPG, PC02, and body temperature. We considered this the best
method of estimating the true position of the haemoglobin oxygen dissociation curve.
P50 values for arterial blood were calculated from the equation described in the study
by Samaja M et al. (Equations and nomogram for the relationship ofhuman blood
P50 to 2,3-Diphosphoglycerate, C02, and H+) (Samaja, Mosca, Luzzana, Rossi-
Bernardi, Winslow 1981).
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The input variables for this calculation are arterial pH, PC02, body temperature,
RBC 2,3-DPG levels, and carboxy haemoglobin level. Microsoft excel program was
used to calculate P50 values. The detail of this calculation was described previously.
REFERENCE GROUP
We aimed to construct a control group that matched the study group in number, age,
and sex. All subjects were healthy volunteers who worked for the Scottish National
Blood Transfusion Service. 2mL blood was taken from each volunteer for measuring
RBC 2,3-DPG. Hb concentration was measured for every volunteer as a part of
measuring RBC 2,3-DPG.
REPRODUCIBILITY
Number of patients: 10 critically ill patients.
3 mL blood sample was taken from each patient. Each sample was analysed for
measuring 2,3-DPG concentration three times. Hb concentration was measured in
each sample as part ofmeasuring 2,3-DPG. Reproducibility was explored by
calculating the within patient standard deviation using analysis of variance
(ANOVA) from the analysed samples. This calculation allowed us measurement
error between the measured RBC 2,3-DPG and the actual RBC 2,3-DPG in the blood




Data were collected in an excel file. After completing the study, patients' identifiers
(surname, forename, and date of birth) were deleted. ICU key numbers were used to
identify the patients. Table (3.24) shows the fields of the final dataset that was used
for analysis.
DATA ANALYSIS
Data were analysed in two steps:
FIRSTSTEP
Examination of all patients' data on day one of the study was carried out.
Regression analysis for day 1 DPG data
We further explored the relationship between the measured physiological variables
on day one in the ICU and the red cell RBC 2,3-DPG concentration using regression
analysis. We included variables that had correlations with RBC 2,3-DPG on
univariate analysis using correlation coefficients, namely pH, creatinine, K+,
calcium, and chloride. We did not include derived acid-base variables. We also
entered Hb and Pco2 in to the model as this can influence RBC 2,3-DPG
concentrations in other settings.
SECOND STEP
Examination of various factors that affected RBC 2,3-DPG and P50 for patients who
completed > 3 days in the study. For this group of patients, all available values for
days 1, 2, 3, 4, and 5 were averaged. The relationships between the average RBC 2,3-
DPG and other measured and derived variables were explored. These relationships
allowed us to examine the relationships over a longer period of critical illness.
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The intensive care unit was screened daily from 22/01/2002 until 14/07/2002. A total
of 313 critically ill patients were admitted to ICU during the study period, of these
111 matched the inclusion criteria and were included in the study.
64 (58%) patients were males and 47 (42%) were females. Patients' demographic
data are shown in table (3.25).
Table (3.25): Patients' demographic data
Variable Mean SD Median Range Qi Q3
Age (years) 52.3 17.1 53 14-86 41 65
APACHE II 17.5 8.7 17 0-37 12.5 23
ICU stay (days) 6.3 9.4 3.3 0.2-52.4 1.4 7.1
Days in Hospital
after ICU (days)
11.8 17.6 5 0-101 0 16
REFERENCE GROUP
There was a technical problem in the company producing the commercial kit for
RBC 2,3-DPG measurement (Sigma No. 35-UV), which occurred midway through
the study. It was not possible to obtain enough kits to construct the aimed reference
group to match the study group in age, sex, and number, because the company
stopped manufacture.
We were able to include 34 patients in the reference group. 18 (53%) were males and
16 (47%) were females. The mean ± SD of their age was 48 ± 14 years. It was not
feasible to calculate the in vivo P50 from the reference group because arterial blood
samples were not collected from this group.
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REPRODUCIBILITY
A total of 10 blood samples were collected from 10 critically ill patients. Each blood
sample was analysed 3 times for RBC 2,3-DPG concentration. Table (3.26) shows
the results of this analysis.
Table (3.26): Absolute values for RBC 2,3-DPG (pmol/gHb) in blood samples used
for measuring reproducibility.
Sample First analysis Second analysis Third analysis
1 12.94 13.84 15.51
2 9.82 11.74 10.59
3 13.26 12.92 12.75
4 5.82 5.82 5.82
5 17.27 17.59 17.59
6 10.09 9.74 9.03
7 10.53 10.61 10.46
8 14.63 12.80 13.96
9 11.83 11.37 11.37
10 5.94 5.50 5.72
Reproducibility: within patient standard deviation was 0.63 pmol/gHb.
FIRST DAY ANALYSIS:
Mean ± SD, median, inter-quartile range, minimum, and maximum values for all the
investigations that were carried out are shown in table (3.27).
RBC 2,3-DPG RESULTS
The mean ± SD of 2,3-DPG for male patients was 14.9 ± 6.2 pmol/g Hb and 13.0 ±
6.4 pmol/g Hb for females (mean difference = 1.97, 95%CI of the mean difference =
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4.39 to - 0.44%, t = 1.63, and p = 0.11). Table (3.28) shows the mean 2,3-DPG
values for the study group and reference group. Figures (3.3 & 3.4) show the
distribution ofRBC 2,3-DPG levels for females and males in the study and reference
groups.
Table (3.28): Mean ± SD of RBC 2,3-DPG for the study and reference group (pmol/g
Hb).
Males Females
Study group (N = 111) 14.9 ±6.2 13.0 ±6.4
Reference group (N = 34) 15.3 ±3.6 17.8 ±3.5
All patients (males and females) in the study group: 14.1 ± 6.3 pmol/gHb
All subjects (males and females) in the reference group: 16.7 ± 3.7 pmol/gHb.
A comparison between first day RBC 2,3-DPG for the study group and the reference
group, males, females and all patients [mean difference, 95% CI, t test, and p values],
are shown in table (3.29). Figure (3.5) shows the distribution of first day RBC 2,3-
DPG values for all patients in the study group and RBC 2,3-DPG values for the
reference group.
Table (3.29): Comparison between RBC 2,3-DPG in the study group and the
reference group [first day RBC 2,3-DPG values (pmol/g Hb)].
Category Mean 95% CI of the mean t test p value
difference difference
Males 0.68 2.94 to-1.58 0.60 0.55
Females 4.87 7.50 to 2.24 3.72 0.001
All patients 2.56 4.29 to 0.83 2.94 0.004
There was no significant difference between mean RBC 2,3-DPG in males in the
study group and the reference group. The mean RBC 2,3-DPG level in females in the
study group was lower compared to females in the reference group. For all patients
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(males and females), the mean RBC 2,3-DPG level was significantly lower in the
study group compared to the reference group.
Correlations
Correlations between RBC 2,3-DPG and primary and derived measures were
explored.
Primary measures
Highly significant correlation was found between RBC2,3-DPG and arterial pH (r
=0.47, p<0.0001), but not with Paco2 (r2=-0.07, p=0.45). Weaker correlations were
found with creatinine (r2=-0.35, p<0.0001), potassium (r2=-0.20, p=0.032),
phosphate (r2=-0.20, p=0.046), chloride (r2=-0.19, p=0.044), glucose (r2=0.19,
p=0.044) and urea (r2=-0.18, p=0.073). There were no significant correlations
between 2,3-DPG and haemoglobin concentration, blood lactate, oxygenation
indices, other blood electrolyte concentrations, age or temperature.
Derived measures
Highly significant correlations were found between RBC 2,3-DPG and standard
bicarbonate (r2=0.46, p<0.0001), base excess (r2=0.44, p<0.0001), and P50 (r2
=0.80, p<0.0001). There was a weak correlation between RBC 2,3-DPG and anion
gap (r2=-0.29, p=0.002).
Table (3.30) shows r2 and P values [uncorrected for multiple tests] for all recorded
variables in relation to first day RBC 2,3-DPG. Figures (3.6, 3.7, 3.8, 3.9, 3.10) show
the relationships between 2,3-DPG and some of these variables.
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Regression analysis
Using regression analysis, our final model included only pH and CI concentration.
The B coefficients were not significant for creatinine, calcium, Hb, phosphate, or K+
after adding pH to the model. The final B coefficients were:
PH: B 32.15 (95% CI 19.07 to 46.22), P < 0.001
CI: B-0.196 (95% CI: -0.39 to-0.01), P = 0.044
R2 for the model was 0.293
These data suggest that pH had the strongest relationship with red cell DPG with a
weak association with plasma CL. The model explained about 29% of the variation
in RBC 2.3-DPG concentration observed.
FIRSTDA Y CALCULA TED IN VIVO P50 RESULTS
The mean ± SD (range) of first day calculated in vivo P50 for all patients who were
included in the study was 28.6 ± 4.5 (15.2 - 41.8) mmHg. The mean ± SD first day
P50 for males was 29.2 ± 4.6 mmHg and for females was 27.9 ± 4.3 mmHg. There
was no significant difference in mean calculated in vivo p50 between males and
females. Table (3.31) shows the mean difference between males and females,
95%CI of the mean difference, t test, and p values.
Table (3.31): Comparison between P50 values in males (N = 64) and females (N =
47y
Mean difference 95% CI of the mean difference t test p value
1.26 2.97 to-0.45 1.46 0.15
First day P50 values (mmHg)
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Figure (3.11) shows the distribution of first day calculated in vivo P50 values for
males and females in the study group. Figure (3.12) shows the distribution of
calculated in vivo P50 values for all patients in the study.
Correlations between measured variables and in vivo p50
The correlation coefficients between p50 and factors known to influence it were
calculated, namely pFI, Pco2, temperature, and RBC 2,3-DPG. Table (3.32) shows r
and p values for these correlations.
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Figure (3.3) the distribution of first day RBC 2,3DPG for females

























Figure (3.4) the distribution of first day RBC 2,3DPG for males in




























Figure (3.5) the distribution of first day RBC 2,3DPG
for all patients in the study and reference groups.
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Females N = 47
Mean ± SD 27.9 ±4.3
Males N = 64
Mean ± SD 29.2 ± 4.6
Figure (3.11): The distribution of calculated in vivo P50 values for both
male and female patients.
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O
All patients N = 111
Mean ± SD 28.6 ± 4.5
Figure (3.12): The distribution of calculated in vivo P50 values for
all patients included in the study.
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Table (3.32): Correlations coefficient for the different measurements of first day
that are known to affect P50 (number ofpatients = 111).




RBC 2,3-DPG 0.80 <0.0001
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PATIENTS WHO STAYED > 3 DAYS
55 patients completed 3 days or more in the study. 33 (60%) were males and 22
(40%) were females. Patients' characteristics and demographic data are shown in
table (3.33).
Table: (3.33) Patients' demographic data (N = 55)
Variable Mean SD Median Range Ql Q3
Age (years) 51.6 17.6 52 14-86 39 65
APACHE II 16.8 8.5 18 0-33 12.5 22
ICU stay (days) 10.5 11.7 6.7 3.0-52.4 4.5 11.5
Days in Hospital
after ICU (days)
13 21 4 0-101 0 16
RBC 2,3-DPGANALYSES
RBC 2,3-DPG levels for patients who completed > 3 days were averaged. The mean
± SD of the average RBC 2,3-DPG for males and females was 16.7 ± 6.0 and 14.6 ±
5.8 pmol/gHb respectively and for all patients was 15.8 ± 6.0 pmol/gHb. There was
no significant difference between the mean RBC 2,3-DPG level in male and female
patients in the study group [the mean difference was 2.09 pmol/gHb, 95% CI of the
mean difference = 1.2 to - 5.4, t test = 1.29, and p value = 0.205], There was no
significant difference between the mean RBC 2,3-DPG in both the reference and the
study groups [the mean difference was 0.84 pmol/gHb, 95% CI of the mean
difference = 2.9 to - 1.2, t test = .83, and p value = 0.41],
Correlations
Correlations between RBC 2,3-DPG and primary and derived measures were
explored for patients who completed > 3 days (N = 55).
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Primary measures
Highly significant correlation was found between RBC2,3-DPG and arterial pH (r2
=0.43, p = 0.001). Weaker correlations were found with creatinine (r2= -0.25, p =
0.075), calcium (r2=-0.26, p=0.055), and Paco2 (r2 = -0.23, p=0.093). There were no
significant correlations between 2,3-DPG and haemoglobin concentration, blood
lactate, oxygenation indices, other blood electrolyte concentrations, or temperature.
Derivedmeasures
Highly significant correlations were found between RBC 2,3-DPG and P50 (r2=0.67,
p<0.0001). There were weaker correlations between RBC 2,3-DPG and standard
bicarbonate (r2=0.23, p = 0.099), and base excess (r2=0.24, p = 0.074).
Table (3.34) shows r2 and P values [uncorrected for multiple tests] for all recorded
variables in relation to first day RBC 2,3-DPG. Figures (3.13, 3.14, 3.15, 3.16, and
3.17) show the relationships between 2,3-DPG and some of these variables.
CALCULA TED IN VIVO P50 RESULTS
The mean ± SD of calculated in vivo P50 for all patients who completed > 3 days
was 29.2 ± 3.8 mmHg. The mean ± SD for males was 29.6 ± 3.8 mmHg and for
females was 28.7 ± 3.9 mmHg. There was no significant difference in mean
calculated in vivo p50 between males and females.
Correlations between measured variables and in vivo p50
The correlation coefficients between calculated in vivo p50 and factors known to
influence it were calculated, namely pH, Pcoa, temperature, and RBC 2,3-DPG.
Table (3.35) shows r2 and p values for these correlations.
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Table (3.35) Correlations coefficients for mean measurements that are known to
affect P50 in relation to mean P50 values for patients who completed > 3 days (N
= 55).




RBC 2,3-DPG 0.67 <0.0001
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Figure (3.13): The correlation between mean RBC 2,3-
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Figure (3.14): The correlation between mean RBC 2,3-
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Figure (3.15): The correlation between mean RBC 2,3-
DPG and mean haemoglobin for patients completed >

















rs = -0.25 P=0.075
0 100 200 300 400 500
Creatinine [umol/L]
Figure (3.16): The correlation between mean RBC 2,3-
DPG and mean creatinine for patients completed > 3
days in the study
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Figure (3.17): The correlation between mean RBC 2,3-




SUMMARY OF THE RESULTS
111 critically ill patients were included in the study. 58% were males and 42% were
females. Mean age was 52 ± 17 years and mean APACHE II score was 17.5 ± 8.7.
Mean first day RBC 2,3-DPG value as 14.9 ± 6.2 pmol/gHb for males and 13.0 ± 6.4
pmol/gHb for females. There was no statistically significant difference between the
mean first day RBC 2,3-DPG in male patients compared to males in the reference
group. Females in the study group had a significantly lower first day RBC 2,3-DPG
level than females in the reference group. There was a much wider variation in RBC
2,3-DPG values in critically ill patients compared with reference healthy subjects,
which was present in males and females.
Highly significant correlations were found between first day RBC 2,3-DPG and
arterial pH. Strong correlations were, not surprisingly, also found with derived acid
base variables, but not with Paco2. Weaker correlations were found with creatinine,
potassium, phosphate, chloride, glucose, and urea. There were no significant
correlations between 2,3-DPG and Hb, blood lactate, oxygenation indices, other
blood electrolyte concentrations, age or temperature.
The mean ± SD first day calculated in vivo P50 for all patients was 28.6 ± 4.5
mmHg. There was no significant difference between mean first day calculated in
vivo P50 values between male and female patients. P50 correlated strongly with
RBC 2,3-DPG, but not Pco2, pH or temperature.
55 critically ill patients completed 3 days or more in the study. The mean age for this
group of patients was 51 ± 17 years and the mean APACHE II score was 16.8 ± 8.5.
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The mean ± SD of the 3-5 day average RBC 2,3-DPG for males was 16.7 ± 6.0 and
14.6 ± 5.8 pmol/gHb for females. There was no significant difference in mean RBC
2,3-DPG between male and female patients.
There were a highly significant correlation between RBC2,3-DPG and arterial pH,
and P50. Weaker correlations were found with creatinine, calcium, standard
bicarbonate, base excess, and Paco2. There were no significant correlations between
2,3-DPG and haemoglobin concentration, blood lactate, oxygenation indices, other
blood electrolyte concentrations, or temperature.
The mean ± SD of the 3-5 day average calculated in vivo P50 for males was 29.6 ±
3.8 and 28.7 ± 3.9 mmHg for females. There was no significant difference between
males and females.
Using multiple regression analysis, our data suggest that pH had the strongest
relationship with red cell RBC 2,3-DPG with a weak association with plasma CL.
The model explained about 29% of the variation in DPG concentration observed.
WEAKNESSESAND STRENGTHS IN THE STUDY
The study took place in a large medical-surgical teaching hospital ICU. The study
group included a wide case mix, with typical ICU illness severity, and included
males and females, so selection bias was unlikely.
Transfused patients were excluded from the study, so the effect of red cell
transfusion on RBC 2,3-DPG did not affect the results. A wide range of
physiological variables were included in the study to allow us to explore the effect of
these factors on RBC 2,3-DPG. It is possible that a different relationship would have
been found if concentrations within red cells were measured. However, we believed
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that, for factors such as pH and plasma abnormalities probably reflected acid-base
disturbances within red cells. Specific measurements of red cell abnormalities would
be needed to confinn this assumption, but were not feasible in this study. Patients
were followed up for five days during the study period, if they remained in the ICU.
We were therefore able to examine data both from the day of ICU admission and
averaged over 3 to 5 days of critical illness.
We constructed a reference group comprising a number of healthy volunteers in
whom RBC 2,3-DPG was measured, so results were compared to subjects who
represented the healthy population in Scotland. We aimed to construct a reference
group with sex and age match with the study group. The company producing the
commercial kits for measuring RBC 2,3-DPG stopped producing them during the
study, so we were unable to study as many reference subjects as intended. However,
the age distribution of the volunteers examined was similar to the patient sample.
We established the reproducibility for RBC 2,3-DPG assays. Within sample standard
variation ofRBC 2,3-DPG in the measured samples was small, demonstrating low
measurement errors. Differences between patients were therefore likely to indicate
true physiological variations.
It was unclear the best way to estimate P50 in the critically ill patients. The blood gas
machine [Bayer (Chiron) 865 analyser] can provide P50 values from a venous blood
sample by calculating it from p02 and oxygen saturation using an equation based on
Hill's equation (discussed in detail on page 148). This method of estimating the in
vitro P50 does not include the actual values of RBC 2,3-DPG, pH, and temperature
of the patient [all of these values are standardised by the machine].
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Siggaard-Andersen et al used an equation to calculate the in vivo P50 that includes
all the variables that can affect in vivo P50 (pco2, pH, RBC 2,3-DPG, and body
temperature). However, they used a calculated value for RBC 2,3-DPG not the actual
measured RBC 2,3-DPG value in the patient's blood (Siggaard-Andersen, Siggaard-
Andersen 1990). We used the only available method of estimating in vivo P50 from
directly measured values for pH, RBC 2,3-DPG, PCO2, and body temperature.
The equation by Samaja et al. used in the study (Samaja, Mosca, Luzzana, Rossi-
Bernardi, Winslow 1981) is based on a calculation that includes physiological factors
(pC02, pH, RBC 2,3-DPG, and body temperature) that are known to affect the in vivo
P50 value. These factors can vary widely during the course of critical illness.
However, it is likely that the correlation between 2,3 DPG and the calculated P50 are
due to mathematical linkage as both appear in the Samaja equation. Mathematical
linkage can cause artificial relationships in medical research. Because of this
uncertainty, the significance of the strong correlation between RBC 2,3-DPG and
P50, but lack of correlations between pH, PCO2, temperature, and P50 is unclear.
Samaja et al validated their formula and found that calculated in vivo P50 is more
accurate than the standard in vitro P50 when comparing both to the measured in vivo
P50 using tonometry (Samaja, Mosca, Luzzana, Rossi-Bemardi, Winslow 1981).
It was not possible to directly measure P50 in the blood of critically ill patients. Our
method therefore represented the best available technique for measuring oxygen-
binding characteristics of Hb in a large sample of critically ill patients.
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COMPARISONWITH OTHER STUDIES
We have shown that the mean RBC 2,3-DPG level in the 111 critically ill patients
[males and females] was on average slightly lower and had larger variability than its
level in the normal reference group. Morgan et al showed similar results, in a small
study of 20 male critically ill patients (Morgan, Koch, Morris, Clague, Purdie 2001).
In our 64 male patients, there was no significant difference between the mean RBC
2,3-DPG compared to the nonnal reference group. Our literature review found no
other studies that measured RBC 2,3-DPG specifically in critically ill ICU patients.
We found a strong correlation between RBC 2,3-DPG and blood pH in the critically
ill. Acidosis was associated with lower levels ofRBC 2,3-DPG and alkalosis was
associated with higher RBC 2,3-DPG levels. Morgan et al showed similar results
(Morgan, Koch, Morris, Clague, Purdie 2001).
There is some evidence suggesting that pH has a strong effect on RBC 2,3-DPG
level. Rose et al., Luque et al, and Jelkman et al. showed that pH can affect the rate
ofRBC 2,3-DPG production as pH affects the activity ofmutase and phosphatase
enzymes responsible for the synthesis and the destruction ofRBC 2,3-DPG (Rose,
Liebowitz 1970; Luque, Pinilla, Ventura, Santos-Ruiz 1972; Jelkmann, Bauer 1978).
There is strong evidence that pH affects RBC 2,3-DPG level in vitro. Most of these
studies were carried out to show the effect of pH in maintaining RBC 2,3-DPG in
stored blood. Hogman et al. and Hess et al. showed that alkaline media maintained
RBC 2,3-DPG level in stored blood (Hogman, Knutson, Loof, Payrat 2002; Hess,
Hill, Oliver, Lippert, Greenwalt 2002).
We found no correlations between RBC 2,3-DPG and Pco2 and P02. Some studies
have found correlation between hypoxia, hypercapnia and increased RBC 2,3-DPG
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level. Most of these studies were carried out in hypoxic non-critically ill patients
with abnormally high Pco2 and low P02 levels (Oski, Gottlieb, Delivoria-
Papadopoulos, Miller 1969; Keitt, Hinkes, Block 1974). We suggest that this
correlation was not present in our patients as none of them were left hypoxic in the
ICU and all patients were well oxygenated [the mean PCO2 was 5.7 ± 1.4 kPa and
Pao2 was 16.8 ± 6.6 kPa]. Hypercapnia was present early in a few patients.
In the present study there was no correlation between RBC 2,3-DPG and the acute
anaemia that characterises early critical illness (Hb level). In the 20 critically ill
patients studied by Morgan et al, there was a negative correlation between Hb level
and RBC 2,3-DPG (Morgan, Koch, Morris, Clague, Purdie 2001). However, Hb
level was lower in our study, compared to the Morgan et al. study [median (range)
Hb g/L = 100 (62 to 167) g/L and 113 (89 to 154) g/L respectively] as we used more
evidence based transfusion triggers in our ICU.
Most studies that showed a correlation between acute anaemia and increased RBC
2,3-DPG were carried out in animal models (Cropp, Gee 1972; Fong, Ko, Streczyn,
Westerman 1976; Holter, Halvorsen, Refsum 1982). It is unclear if red cell
physiology in these animals is similar to human red cells.
Other studies have shown a negative correlation between Hb level and RBC 2,3-DPG
in patients with chronic anaemia. Most of these studies were carried out in anaemia
associated with malignancy (Haidas, Zannos-Mariolea, Matsaniotis 1976; Hjelm,
Uden, Engstedt 1976; Festa, Asakura 1979). In these settings it has been argued that
increasing RBC 2,3-DPG concentration in RBCs is a compensatory mechanism that
increases oxygen unloading when oxygen content is decreased, therby improving
tissue oxygen delivery (Opalinski, Beutler 1971; Hjelm, Uden, Engstedt 1976).
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Our data indicate that during early critical illness, and over the first 3 to 5 days,
anaemia is not associated with compensatory high or supernormal RBC 2,3-DPG
concentrations within red cells. In fact, in these patients with strongest evidence of
tissue hypoxia, namely systemic acidosis, RBC 2,3-DPG concentration is decreased.
It is unclear from our data whether this is of clinical relevance to tissue oxygen
delivery.
The mean calculated in vivo P50 in our study using the Samaja et al equation was
28.6 ± 4.5 mmHg. In a similar study by Morgan et al, the mean calculated in vivo
P50 using the modified Siggaard-Andersen equation [the original fonnula contains a
calculated value for RBC 2,3-DPG, but a modification included the actual measured
venous value for RBC 2,3-DPG], was similar to our result [28.0 ± 1.3 mmHg]
(Morgan, Koch, Morris, Clague, Purdie 2001).
In the present study and Morgan et al study, P50 values of the study group were not
compared to normal subjects. However, Myburgh et al showed that the mean
calculated in vitro P50, in 20 critically ill patients, was 24.5 ± 2.9 mmHg and this
value was significantly lower than 20 normal subjects [26.2 ± 2.2 mmHg] (Myburgh,
Webb, Worthley 1991). Our results did not show similarity to the data ofMyburgh et
al results. This variation in the results may be due to: a) Myburgh et al calculated the
vitro P50 and we calculated the in vivo P50 (a different method), b) differences in
the characteristics of the patients and illness severity. Our data suggest that overall
P50 values are similar to quoted normal values in critically ill patients. However, as
with RBC 2,3-DPG, we observed a wide range of values.
We found a strong positive correlation between RBC 2,3-DPG and calculated in vivo
P50. This was not found in the study by Morgan et al for calculated in vitro P50. This
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may be due to the difference in the formulae used to calculate the in vivo P50 and the
position ofRBC 2,3-DPG jn these formulae. However, in addition the correlation in
our study should be considered with caution, as it is possible that it results, at least in
part, from mathematical linkage. Walsh et al showed that if a relationship is
investigated between a derived variable and another variable that is either a
component of the derived variable or shares a component with it, the relation might
be affected by mathematical coupling. As a result, part or all the relation may be
spurious (Walsh, Lee 1998). Mathematical coupling might be the case in the relation
between RBC 2,3-DPG, Pco2, pH, temperature, and P50, as P50 is a derived variable
from a formula that included all of these variables. Our data suggest that RBC 2,3-
DPG has the strongest correlation with in vivo P50, but we can not adjust for
mathematical linkage in our conclusion.
IMPLICA TIONS OF OUR FINDINGS
The clinical importance ofRBC 2,3-DPG levels in critically ill patients is unclear,
but it is widely believed that low RBC 2,3-DPG values could have adverse effects,
particularly in relation to stored blood. A few studies showed that high RBC 2,3-
DPG was associated with improved clinical condition and outcome. Dennis et al.
showed that there was a significant increase in cardiac index after transfusing red
cells with high RBC 2, 3-DPG concentrations for patients undergoing coronary
artery bypass surgery (Dennis, Vito, Weisel, Valeri, Berger, Hechtman 1975). In
another experimental study, Bakker et al. perfused isolated rat livers with fresh and
RBC 2,3-DPG-depleted human erythrocytes at different levels ofhypoxia and found
that perfusion with fresh erythrocytes showed higher venous P02 values. By using
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bile flow rate as an indirect measure for the rate of oxygen consumption, a
favourable effect of perfusion with fresh erythrocytes was found (Bakker 1977).
These studies supported the fact that higher levels ofRBC 2,3-DPG could improve
tissue oxygen delivery. If these studies are translatable to critical illness, our finding
of lower RBC 2,3-DPG concentrations in sicker patients could be clinically relevant.
Old stored blood has lower RBC 2,3-DPG concentration than fresh blood. With the
current leucodepleted product RBC 2,3-DPG is absent after 10 days (Walsh et al.
2004). If acidosis decreases RBC 2,3-DPG regeneration, which is usually thought to
take 4 to 24 hours, then this process could delay regeneration of older stored blood in
acidotic patients. In theory, this could mean older transfused blood takes longer to
recover in acidotic patients, who would paradoxically benefit most from augmented
oxygen delivery. The hypothesis that older stored blood is ineffective or even
harmful in the critically ill was supported by a study using gastric tonometry as an
oxygenation endpoint(Marik, Sibbald 1993; Marik 1993), although a more recent
double blind randomised study found no differences between RBCs aged < 5 and
>20 days in changing oxygenation indices (Walsh et al. 2004).
In conclusion, RBC 2,3-DPG concentration was slightly lower in critically ill
patients. Female critically ill patients had lower values than males. Lower RBC 2,3-
DPG values were most likely secondary to acid-base disturbance, possibly through
enzymatic effect on RBC 2,3-DPG metabolism. Calculated in vivo P50 values were
normal overall, but there was wide variation that correlated most closely with RBC
2,3-DPG.
Further studies need to establish whether these observations translate in to clinically
importance effects on oxygen transport.
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CHAPTER FOUR
ANAEMIA, BLOOD LOSS, AND TRANSFUSION IN ELECTIVE
ORTHOPAEDIC SURGERY
INTRODUCTION
Most patients attending for elective orthopaedic surgery (EOS) are elderly and a
proportion have a haemoglobin concentration (Hb) below the normal reference
range. Preoperative anaemia increases the risk of peri-operative transfusion. If it
could be shown that pre-operative anaemia could be corrected by simple, safe and
inexpensive treatment, this might be an effective way of reducing transfusion needs
and so could be included among the interventions that could be recommended to
reduce the needs for transfusion. This chapter reviews the relevant evidence from
clinical studies, concentrating on the two commonest major elective orthopaedic
procedures, Total Hip Replacement (THR) and Total Knee Replacement (TKR). In
some tables these procedures are grouped together and referred to as Major Joint
Surgery (MJS).
RATIONALE FOR THE STUDY
Lower pre-operative Hb or haematocrit levels (Hct) appear to be strongly associated
with peri-operative blood transfusion [Scottish Intercollegiate Guidelines Network
(SIGN): Preoperative Blood Transfusion for Elective Surgery] (Feagan, Wong,
Kirkley et al. 2000; 2004b, SIGN guideline, page 363). Although it may seem self -
evident that an anaemic patient is more likely to be transfused, the nature of the
relationship between pre-operative Hb and the probability ofblood transfusion is not
entirely clear. An obvious explanation is that if a patient is already anaemic, surgical
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blood loss will more rapidly cause a critically low Hb level, but other factors are
probably also at work, for example:
■ Lower Hb is associated with prolongation of the bleeding time (Baskurt,
Meiselman 2003).
■ Many surgical units routinely order blood if the pre-operative haemoglobin
concentration is below a predefined level: the immediate availability of blood
may lower the clinician's threshold for administering blood transfusion.
A number of authors and guidelines recommend that pre or peri-operative
haematinics be given to anaemic surgical patients to improve their Hb concentrations
and so decrease the incidence of red cell transfusion [Scottish Intercollegiate
Guidelines Network (SIGN): Pre-operative Blood Transfusion for Elective Surgery]
(Taylor, Mallen, Lind 1982; Zauber, Zauber, Gordon et al. 1992; Andrews, Lane,
Bradley 1997; Weisbach, Skoda, Rippel et al. 1999; 2004b, SIGN guideline, page
363). Nevertheless, there is little published evidence that this measure is effective in
treating pre-operative anaemia or reducing red cell transfusion.
At the surgical pre-admission clinic, determination ofHb level can identify anaemic
patients and give the opportunity to investigate and correct this anaemia before
surgery (Andrews, Lane, Bradley 1997). However, treating anaemia during pre¬
operative assessment without going further to investigate its cause may mean a lost
opportunity to diagnose and treat a major underlying cause.
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PRE OPERATIVE HAEMOGLOBIN OR HAEMATOCRIT LEVELS IN EOS
PATIENTS
A few studies were identified on the prevalence and type of anaemia in patients
attending for Elective Orthopaedic Surgery (EOS). Most commonly, the laboratory
findings are those typical of "anaemia of chronic disease" which is characterized by
normocytic normochromic red cell indices.(Beutler, Lichtman, Coller, Kipps, editors
1995; Andrews, Lane, Bradley 1997; Towheed, Shea, Wells, Hochberg 2002)
Goodnough et al. reported that of 385 patients undergoing EOS in the USA, 25%
were anaemic (defined as a Hct below 39%) (Goodnough, Vizmeg, Marcus 1993). In
a similar study of 281 EOS patients 26% were anaemic (Goodnough, Vizmeg,
Sobecks, Schwarz, Soegiarso 1992b).
Andrews et al. in the UK showed that 18% of 100 EOS patients were anaemic (Hb
below 120 g/L) (Andrews, Lane, Bradley 1997). Some studies report pre-operative
Hb or Hct levels for patients undergoing EOS as a baseline values before a study
intervention. Table (4.1) shows the mean ± (SD) values for pre-operative Hb or Hct
recorded in these studies.
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Table (4.1): Reported pre-operative Hb and Hct values for patients undergoing EOS.



























































CAUSES OF PRE OPERATIVE ANAEMIA IN EOS POPULATION
Causes of anaemia can be broadly categorised as: (a) Decreased red cell production,
and (b) Increased erythrocyte destruction or loss (chapter 1) (Beutler, Lichtman,
Coller, Kipps, editors 1995; Cuervo, Mahomed 2002). While anaemia is extremely
common worldwide, the causes of anaemia that are more likely to affect EOS
patients in a developed country are: i) medications, ii) nutritional insufficiency, and
iii) other associated medical conditions that are more common in older patients such
as renal insufficiency and malignancy.
In 30 anaemic EOS patients reported in the study cited above, Goodnough et al.
found that 30% of them had evidence of iron deficiency anaemia and 53% had
unclassified anaemia of chronic disease (Goodnough, Vizmeg, Sobecks, Schwarz,
Soegiarso 1992a). In another study of elderly surgical patients, Kiyama et al. studied
32 patients with mean age > 68 years who underwent open-heart surgery. They found
that 18 (56.25%) of these patients had iron deficiency anaemia, 2 (6.25%)had
anaemia of chronic renal failure, and 12 (37.5%) had unexplained anaemia (Kiyama,
Ohshima, Imazeki, Yamada 1999).
Increasing age in the absence of disease is not a cause of anaemia: it has little effect
on the circulating red blood cell mass, white blood cell count, the number or function
of platelets, or coagulation. Red blood cell fragility increases by age but it does not
affect erythrocyte life span in vivo. Therefore, clinically significant anaemia or
disorders of haemopoiesis in the elderly as in younger individuals should always be
considered first as due to disease and not attributed to age (Millar, editor 2000).
The use of drugs may be a cause of anaemia in EOS patients. Many patients have
chronic joint pain and been taking aspirin-containing and/or non-steroidal anti-
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inflammatory drugs for many years. These are known to cause increased
gastrointestinal blood loss often leading to iron deficiency (Beutler, Lichtman,
Coller, Kipps, editors 1995; Andrews, Lane, Bradley 1997; Towheed 2002).
Dietary insufficiency of vitamins and essential minerals is common in elderly
patients who represent the majority of EOS population (Zauber et al. 1992; Avenell
2002). Moreover, malabsorption is not uncommon in this group of patients (Beutler,
Lichtman, Coller, Kipps, editors 1995). There is some evidence that in elderly
people; significant non-symptomatic low serum vitamin B12 levels may be found in
individuals who do not have clinical findings of vitamin B12 deficiency. Low levels
of B12 may be due to mal-absorption of protein-bound vitamin B12, but not due to
mal-absorption of free vitamin B12 (Beutler, Lichtman, Coller, Kipps, editors 1995).
A few studies, summarised in table (4.2), report ferritin levels as an indication of iron
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BLOOD LOSS INEOS
Peri-operative blood loss in patients undergoing EOS, especially during major joint
surgery can be substantial and much of the blood loss is into the tissues. Bleeding is
significantly greater during revision surgery (Bierbaum, Callaghan, Galante, Rubash,
Tooms, Welch 1999; Grosvenor, Goyal, Goodman 2000; Millar, editor 2000; Parker,
Rajan 2002).
There are many ways to estimate intra-operative blood loss during surgery, however,
none of them has been proven to be an accurate or "gold standard" method and none
can measure blood loss into tissues surrounding the operative site. Intra-operative
blood loss may be estimated by: (a) visual assessment of the amount of blood coming
out from the operative field (qualitative estimation), (b) the volume of the blood in
the operating suction, (c) swab-weighing, as 1 ml of blood weights approximately 1
g, (d) such values may be recorded in real time or retrospectively recorded from
anaesthetics charts, and (e) calculating red cell mass pre and post-operatively (Rawle,
Seeley 1987).
A widely used method of estimating post-operative blood loss is to measure the
amount of blood in the operative drains. However, this does not give an accurate
measurement of red cell loss as the haematocrit (Hct) in the drained blood falls with
time after surgery. Majkowski et al. compared the mean post-operative Hct level in
venous blood and drained blood for patients following TKR. The authors found that
Hct was 37% in the venous blood versus 31% in the drained blood (Majkowski,
Currie, Newman 1991).
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Another approach is to estimate the blood loss from the fall in Hct and an estimate of
blood volume, taking account of any blood that been transfused and ofhaemodilution
(Toy, Kaplan, McVay, Lee, Strauss, Stehling 1992).
Table (4.3) summarizes published data on surgical blood loss during major joint
surgery, estimated by, use of one or other of these methods.
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BennanAT et al.(Bennan, Geissele, Bosacco 1988)
Retrospectivestudy investigatethedegr eof bloodlossass ciated withTKR.*
140
Proceduresthatdinor q ireblo d transfusion(=70). Proceduresthatrequi dblood transfusion(=70).
1.8 units*/procedure. Notmentioned. Themeanblood




Aretrospectivestudyt assessthran fusion needsforhipank e arthroplasty.*
103
THR(n-44) TKA(n=59)
758(range:200- 2250)ml Therewasnointra¬ operativebl odloss (tourniquetwas used).
Notmentioned Notmentioned










































































Knight JL(Knight, Sherer,Guo 1998)
Non-ra domised prospectivestudyt suggestalternative strategiestominimize autologousblo d wastage,theri kof homologousbl d transfusion,ndcost associatedwithblo d productusageafter TKA.++
177(155UnilateralTKAanddidnotpre- patients)donateanddmissioHctw s< 40%(n=19/155patients). UnilateralTKAanddidnotpre- donateanddmissionHctw s> 40%(n=28patients). UnilateralTKAandpre-donated oneu it(=47patients). Unilateralandpre-donated2units (n=20patients). Bilateralndpre-donated2units (n=21patients). Revisionsurgeryandpre-donation wasoptional(n=14patients).
957ml 1013ml 833ml 820ml
1936ml( 8mlper TKA) 973ml
12.3% 8.5% 7.9% 6% 7.7% 10.2%
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AuthorS udydesign&aimsrgicalinte ventionMea±Di t a-du tion proceduresoperativebl odlossHbtfr m
topost-operative
Prospectivecon roltrial80imaryTHR(=47)1356±415N tm tion d
toinvestigateheefficacy ofacuteiso-volaemicRevisionh preplacement(n=33)2174±1655mlNotenti n d haemodilutioncombined withintra-operativer d salvagendrec ll salvagealone.+++
Methodsusedtestimatehvolumfblolo s: •*Casenotreview(n tspecified) •**Casenotreview(anaesth ticscords)ndcal ulatev l mefblolo s. •***CalculatedfromHctlevelst t lamountfr dltransfus . •++Measuredbloodlo s(thuthorsdidn tmentione hod) •+++Measuredusingutotransfusiond vic .Shulman (Shulman, Grecula, Hadjipavlou 2002)
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BLOOD TRANSFUSION IN EOS
The blood components most often administered during or after orthopaedic surgery
are red blood cells or whole blood (Lemos, Healy 1996; Knight, Sherer, Guo 1998).
The volume and red cell content of these components vary, but typical values are
shown in table (4.4) (2004a, guidelines for the blood transfusion services in the UK).
Table (4.4): Volume and red cell content of a red cell and a whole blood unit (2004a,
guidelines for the blood transfusion services in the UK )
Red cells Whole blood
(with additive solution)
Volume (ml) 220-420 513 ± 45
Haemoglobin (g/pack) 40-66 40-66
Haematocrit (%) 50-75 46-66
Studies on transfusion report either the volume of blood (ml) or number blood pack
units -transfused during different EOS procedures.
Studies of the effectiveness of the different strategies to reduce the need for blood
transfusion report blood also report their data several different ways such as: a)
percentage of operated patients who get transfused, b) units ofblood per patient who
is transfused, and c) units ofblood per patient operated. This leads to difficulty in
comparing the results of studies.
QUANTITY OF BLOOD TRANSFUSED
Several studies show that the frequency and amount ofblood transfusion to patients
having similar orthopaedic procedures (e.g. primary unilateral hip arthroplasty) vary
widely (Sirchia, Giovanetti, McClelland, Fracchia, editors 1994). Table (4.5)
summarises published studies that reported amount of blood loss during EOS.
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In summary, it is likely that the variation in blood use that is observed among
surgical teams is due to the combined effect of 3 broad categories of influence:
(1) Differences in thepatientpopulation: age profile, socio-economic status,
proportion ofmales and females, proportion of anaemic patients, and level of co¬
morbidity
(2) Types ofsurgicalprocedure performed e.g. primary or revision, hip or knee
replacement, and associated technical details of procedure.
(3) Differences in patient management these may include: a) use of blood ordering
schedules and transfusion protocols or thresholds, b) variants of surgical technique,
c) variants of anaesthetic technique, d) use of specific blood conserving measures
such as pre-operative autologous blood donation intra or post operative blood salvage
or anti fibrinolytic agents (EACA or aprotininin).
In large observational studies, analysis of the variables associated with blood use
show that the two strongest predictors of transfusion are low preoperative Hct
(confounded with female gender) and an effect linked to the hospital or surgical team
performing the procedures (Sirchia, Giovanetti, McClelland, Fracchia, editors 1994).
These factors are explored in more detail in the next section.
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Toyet al.(Toy, Kaplan, McVay,Lee, Strauss, Stehling 1992)
Retrospectivestudyt estimatebloodlo san numberofredc llunits transfusedi patients undergoingTHR.
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PrimaryTHR[madeautologousdon ti n] (n=189). PrimaryTHR[didnotmakeautologousdonati n] (n=60). RevisionsTHR[madeautologousdon ti n] (n=51).
2.1±1 2 1.7±2.9 3.3±2.3 2±2.2
[Mean±SDoft t l
RevisionTHR[d dnotmakeautol gousdonati ]numberfu ittra sf se (n=24).(bothhomologousa d autologous)pertransfused
patient]
Bennant al.(Berman, Geissele, Bosacco 1988)







Helmt al.(Helm, Karski, Parsons, Sampath, Bale2003)
Prospectivetudyto estimatetheamount bloodlossan transfusioni patients undergoingMJS.
161
79patientsbeforeintroducingclinical/laboratory protocolforreducingblood-transfusion requirements 82patientsaft rintroducingtransfusionprotoc l.
1.3(0-6) 0.6(0-4)
[Mean(range)ofnumber ofunitstransfusedper operatedpatient].
Goodnough et al.(Goodnou gh,Vizmeg, Marcus 1993)
Casenotreviewt determinetheamount ofredc lllossan transfusioni pre- donatedandonpre- donatedp tientswho undergoingMJS.
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Autologousdonor ,56primaryTHR Non-autologousd n r ,27primaryTHR Autologousdonor ,23revisi nTHR Non-autologousd n r ,21revisionTHR Autologousdonor ,73TKA Non-autologousd ors,28TKA
3±1.3
2.3±1 5 4.1±1 8 4± 2.5±1 6 1.2±5








































































STRATEGIES USED TO REDUCE THE NEED FOR BLOOD
TRANSFUSION
Many authors and guidelines recommended particular techniques to reduce the
need for red blood transfusion during EOS. The evidence for clinical
effectiveness of these specialised methods is limited although there is evidence
that attention to general aspects ofmanagement, and the use of transfusion
protocols may be effective in reducing transfusion needs. Table (4.6) summarizes
some of the techniques that may be used with intention to decreasing red cell
transfusion requirements for patients undergoing EOS.
Table (4.6): Summary of approaches to reducing the need for blood transfusion in
EOS
Pre-operative management. Manage pre-operative anaemia.
Blood ordering schedule
Intra-operative management. Anaesthetic techniques.
Surgical techniques.
Transfusion protocol
Specific transfusion sparing strategies. Pre-operative autologous donation.
Acute isovolaemic haemodilution.
Red blood cell salvage.
Antifibrinolytic agents.




General aspects of management
Transfusion practices have significantly changed in the surgical setting in recent
times. A Hb level below lOOg/L was accepted as an indication for peri-operative
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blood transfusion for many years but many recent guidelines recommended
transfusion at a Hb range between 60g/L and lOOg/L, depending on the patient's
physiological reserves and the degree of anaemia. Transfusion at these lower Hb
levels in the surgical setting reduces the use of red cell transfusion (Goodnough,
Marcus 1998; Faris, Spence, Larholt, Sampson, Frei 1999; Hill et al. 2002).
Hill SR et al. performed a Cochrane systematic review on the effect of
transfusion thresholds and protocols on the use of red blood cell and on patients'
clinical outcomes. This review did not only include studies of patients
undergoing EOS. The authors included randomised controlled trials from 1966 to
2000 in which defined levels ofHb or haematocrit were used as trigger for red
cell transfusion and blood was transfused below these levels. Ten trials
comprising 1780 patients (838 critically ill patients from one trial) matched the
inclusion criteria. The review authors found that restrictive transfusion strategies
reduced the probability of red cell transfusion by 42%. Post-operatively,
haematocrit or Hb levels were 5.6% lower in the restrictive strategy than that in
the liberal. The authors showed that reduction in the use of allogeneic blood was
not associated with increase in morbidity ormortality. Mortality was one fifth
lower in patients who received less allogeneic blood compared to that among
patients transfused liberally. It must be noted that this conclusion was obtained
mainly from the study ofHebert et al.(Hebert et al. 1999), which contributed
83% of the weight in the meta-analysis. The authors reported that the relative risk
ofgetting exposed to blood transfusion is 0.58 and 95% CI (0.47 to 0.71)(\\i\\ et
al. 2002).
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Helm et al. have subsequently reported a study to evaluate post-operative transfusion
practice before and after introducing a clinical and laboratory protocol for reducing
blood transfusion in patients undergoing EOS. Before establishing the protocol,
patients were transfused when their 24 hours post-operative Hb was < 90g/L. The
protocol depended on calculating the maximum allowable blood loss (MABL) for
each patient using the formula:
MABL = estimated blood volume x Hct levelpre-operatively - minimum Hct /pre¬
operative Hct.
This formula was combined with replacing intra and post-operative blood loss with
crystalloids until the MABL has been reached. Following introduction of the
protocol the percentage of patients transfused decreased from 66% to 24% (Helm,




Body iron stores can be restored by oral iron therapy. This is simple, safe, and
inexpensive but compliance may be poor. Ferrous sulphate is the most commonly
used preparation. 200 mg contains 60 mg iron. Other preparations contain different
amounts ofmetallic iron e.g. 300 mg ferrous gluconate, which provides 36 mg iron
(Hoffbrand, Lewis, Tuddenham, editors 1999).
The few studies that were identified on the effect of oral iron alone on pre-operative
Hb in patients awaiting EOS are summarised in table (4.7). More data are available
about the effects of iron with erythropoietin: also shown in the table.
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Table(4.7):Pre-operativei nl velnsurgicalpatients(orthop edicath ri lproc dur ). AuthorAimNumberofsubjectsStudyintervention
Results
AndrewsC et al.(Andrews, Lane, Bradley 1997)
Randomised controlledstu yt investigatetherole ofir npre-loadn optimisingHblevels andirostorespre- operativelyin patientsund rgoing MJS.
100
Patientsdividedinto3 groupsaccordingtheir pre-operativeHblevel:
Hb<120g/L+4week courseforalferr us sulphate(N=18). Hb>120g/L+4weeks courseforalferr us sulphategroup(N=35).
BeforetreatmentAfter MeanHb=108g/L MeanHb=138g/L
19g/L



















































































Randomised,double blind,multi-centre trialoinvestigate theefficacyofEPO withirontherapyn reducingdcell transfusionfor patientsund rgoing THR.
201
4weeksbeforesurgeryall patientsreceivedoralir andweredivideinto3 groups:
Beforetreatment
HighEPOdose(N=44).Meanb114g/L









OlijhoekG et al.(Olijhoek etal.2001)
Arandomised, doubleblind,multi¬ centre,placebo- controlledtrial investigatetherole ofralversusintra¬ venousiron erythropoietic responsetoEPO therapyinpatients undergoingEOS.
110
14daysbeforesurg ry, patientsweredivid dinto4 groups: EPO+oralir n(N=29). EPO+intravenousro(N =29).
Beforetreatment MeanHb=123g/L. MeanHct=37% MeanR t.%=1.3 MeanHb=120g/L. MeanHct=35.7% MeanR t.%=1.6
Placebo+oralir n(N=MeanHb125g/L. 27).MeanHct=37.5% MeanR t.%=1.5 MeanHb=126g/L. Placebo+intr venousroMeanH t=37.5% (N=25).MeanR t.%1.6





Rohlinget al.(Rohling, Zimmermann, Breymann 2000)
Randomisedtrial assesstheff ctof differentpre¬ operativeir n treatmentmodalities toincrease erythropoiesis.
12patients undergoingelective surgery.
3weeksbeforesurgeryall thepati ntsreceivedEPO 200U/kgandweredivide into2groups. Ironsucrosegr up(iv) (N=6).
Beforetreatment MeanHb=128g/L MeanHct=39.6% MeanR t.%=8.6% Meanferriti=27.3 pmol/L
Aftertreatmentnd beforesu gery 154g/L 48.4% 35% 266.8pmol/L
MeanHb=128g/L49

















































ofir ntherapyas adjuvantto autologousblo d donationi elective surgery(EOSand cardiacsurgery).
90
Patientswhopre-donated blood3timesweredivid d into3groups5daysbef re surgery: Oralirongroup(n=23).




MeanHb=141g/L MeanR t.%=1.1 Meanferriti=217 pg/L
127g/L %=2.3 224pg/L
Noiron[controlgr up](: 17).




Regional anaesthesia such as spinal or epidural is a common type of anaesthesia used
for patients undergoing THR and TKR. There is a widely held view that there are
certain advantages of regional over general anaesthesia for these patients including a
reduction in the incidence of thrombotic episodes and a reduced operative blood loss.
However, the published evidence does not fully support this opinion and why this
should occur is unclear. These effects may be a consequence of an increased
peripheral limb blood flow in combination with reduced venous tone. Alternatively
they may arise from an alteration of blood viscosity and coagulability, as a result of
changes in the metabolic and neurohumoral responses to surgery (Aitkenhead, Smith,
editors 1996; Millar, editor 2000; Parker, Handoll, Griffiths 2002).
Some studies of the effect of different anaesthetic techniques on peri-operative blood
loss during major joint surgery are reviewed below.
Niemi et al. compared spinal with hypotensive epidural anaesthesia on blood loss and
coagulation in a randomised controlled trial for patients undergoing THR. They
studied 30 patients, 15 patients in each group. All patients received low molecular
weight heparin once before anaesthesia. Epidural blockade was done up to reach T1 -
T4 and spinal blockade at least to T10. The mean arterial blood pressure was 62
mmHg in hypotensive epidural group and 84 mmHg in the spinal anaesthesia group.
In contrast to Parker et al, the authors found a significant difference in the amount of
blood loss and the number of red cell units transfused in the two groups. Table (4.8)
shows the amount ofblood loss and numbers of red cell units transfused in both
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groups. The authors did not find significant difference in the coagulation profile in
both groups (Niemi, Pitkanen, Syrjala, Rosenberg 2000).
Table (4.8): Blood loss and transfusion in THR with spinal and epidural anaesthesia
(Niemi, Pitkanen, Syrjala, Rosenberg 2000)
Blood loss (ml) Blood transfusion (units) per
patient transfused.
Epidural group Spinal group Epidural Spinal group
(n = 15) (n= 15) group
(N = 15) (N = 15)
End of surgery 400 (163-575) 900 (663-1100) 0 1.1 (0-2)
3 h post¬ 600 (300-775) 1100 (763-1338) 0.5 (0-3) 1.7 (0-3)
operatively
Next morning 850(500-1350) 1500 (1025-1838) 1.7(0-5) 2.9(1-6)
Total 1850 3500 2.2 5.7
Estimated median cumulative blood loos (IQR). Median cumulative number of
transfused red cells (range)
Juelsgaard P et al. measured the amount of blood loss and red cell transfusion in 43
patients underwent hip surgery under general and spinal anaesthesia. The patients
were divided into 3 groups: the first group received incremental spinal anaesthesia,
the second received single-dose spinal anaesthesia, and the third received general
anaesthesia. The authors did not compare the mean arterial blood pressure levels of
the three groups. There was no significant difference in the amount ofblood loss or
the number of red cell units transfused intra or post-operatively [table (4.9)]
(Juelsgaard, Sand, Felsby et al. 1998).
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Table (4.9): Blood loss and transfusion in THR with incremental spinal, single dose
spinal, or general anaesthesia (Juelsgaard et al. 1998).
Blood loss (ml) Blood transfusion (ml) per patient
transfused.
(N = 43) (N = 43)
Type of Increment Single General Increment Single General
anaesthesi -al spinal dose -al spinal dose
a spinal spinal
(N= 14) (N = 15) (N = 14) (N= 14) (N = 15) (N = 14)
Intra¬ 300 (100- 463 (100- 396(40- 107 (0- 117(0- 71 (0-
operative 1000) 1700) 2000) 500) 600) 700)
Post¬ 124 (40- 170 (25- 129 (0- 107 (0- 120 (0- 186 (0-
operative 370) 550) 340) 450) 300) 600)
Total 424 633 525 214 237 257
Values are mean (range)
Dauphin et al. compared the use of combined general with epidural anaesthesia to
general anaesthesia alone in the amount ofblood loss during hip arthroplasty in a
randomised control trial. The authors studied 37 patients underwent THR. Patients
were divided into 2 groups, 17 patients received general anaesthesia alone (group A)
and 20 patients received combined general with epidural anaesthesia (group B). The
mean intra-operative blood loss was significantly less in group B compared to group
A patients. There was no statistically significant difference in the mean amount of
post-operative blood loss in the two groups. The total mean blood loss was
statistically significant between both groups. Table (4.10) shows the amount of peri¬
operative blood loss in each group. The authors suggested that combined general
with epidural anaesthesia decreased intra-operative blood loss (Dauphin, Raymer,
Stanton, Fuller 1997).
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Table (4.10) Blood loss in THR with combined general with epidural anaesthesia to
general anaesthesia (Dauphin, Raymer, Stanton, Fuller 1997)
General anaesthesia. Epidural + general
anaesthesia.
Mean ± SD intra-operative 1259.2 ±366 663.8 ±299
blood loss (ml).
Mean ± SD post-operative 600.8 ± 390.8 444 ±300.8
blood loss (ml).
Total mean ± SI) blood 1860 ±616.6 1107.8 ±387.6
loss (ml).
Borghi B et al. showed in a prospective, randomised, multi-centre study the amount
ofperi-operative blood loss and red cell transfusion in 210 patients underwent THR
under different anaesthetic techniques. The patients were randomised to receive
either general anaesthesia alone, epidural anaesthesia alone, or combined general and
epidural anaesthesia, 70 patients were in each group. In each group, patients were
similar in their demographic data, history of hypertension, and the duration of
surgery. There were no significant differences in the amount ofperi-operative blood
loss and red cell transfusion in the three groups [table (4.11)]. However, clinically
relevant hypotension (systolic blood pressure decreased > 30% from baseline) and
bradycardia (heart rate < 45 beats/ minute) occurred in patients who received
combined general and epidural anaesthesia at the time of inducing general
anaesthesia (Borghi, Casati, Iuorio et al. 2002).
266
Table (4.11): Blood loss in THR with general anaesthesia, epidural anaesthesia, and
combined general anaesthesia with epidural (mean values ± SD) (Borghi et al. 2002)





479±107 547 ± 99 465±102





Patients 22% 13% 18%
transfused
Urwin et al. did a meta-analysis for randomised trials to compare general versus
regional anaesthesia in patients undergoing hip surgery. The analysis included 2162
patients. They clarified that regional anaesthesia had some advantages over general
anaesthesia in reducing early post-operative mortality and the incidence of deep vein
thrombosis. Intra-operative blood pressure was statistically significant lower in the
regional anaesthesia group compared to the general anaesthesia group. However,
there was a significant lower amount of blood loss in the general anaesthesia group.
Table (4.12) shows summary of the study results (Urwin, Parker, Griffiths 2000).
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Table (4.12) Mortality rate, blood loss and transfusion, and operative complications
in THR with regional and general anaesthesia (Urwin, Parker, Griffiths 2000)
Regional anaesthesia. General anaesthesia.
Mortality-1 month. 6.4% 9.4%
Mortality-3 months. 12.1% 12.8%
Mortality-6 months 16.8% 16.1%
Mortality-12 months. 22.5% 21%
Patients received 58.3% 56.7%
transfusion per operated
patients.
Blood loss per operated 152 6
patient (ml).
Transfusion per operated 103 100
patient (ml).
Deep vein thrombosis. 30.2% 46.9%
Operative hypotension. 34.3% 26%
Operative time (min). 189 187
Other technique of anaesthesia for hip surgery is the local nerve block. This may be
supplemented with sedatives or analgesics. A lumber plexus block can be used in hip
surgery (Millar, editor 2000). Only the plexus on the side of the fracture needs to be
blocked, which may reduce the incidence of anaesthetics complications such as
hypotension. This technique may markedly increase the incidence of other
complications such as peripheral nerve injury. There are no studies compared the use
of local anaesthetics techniques with other techniques in measuring the amount of
peri-operative blood loss and transfusion in patients undergoing joint surgery.
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The choice of the anaesthetic technique whether regional, general, or local should be
determined by the patient's medical status (Aitkenhead, Smith, editors 1996; Millar,
editor 2000).
Surgical techniques
It is widely stated / believed that blood loss and transfusion requirements during EOS
can be influenced by many different techniques that can be applied during surgery
such as: a) application of a limb tourniquet, b) aggressive wanning, c) temporary
balloon occlusion of the main arterial supply, d) the use of diathenny, e) experienced
surgical team, and f) operative position. However, the published evidences did not
fully support these beliefes. The techniques are reviewed below.
Application ofa limb tourniquet
Bloodless operative field during EOS can be done in certain operations where a limb
tourniquet can be used e.g. knee surgery. The limb should first elevated and squeezed
using a bandage before inflation. The inflation pressure of the tourniquet should be
approximately 100 mmHg above the systolic blood pressure of the patient for lower
limb surgery and 50 mmHg for upper limb surgery. Towards the end of the
procedure, the tourniquet should be deflated temporarily to check proper haemostasis
within the operative field (Emmanuel, McClelland, Page, editors 1997).
Jarolem KL et al. did a retrospective study to compare blood loss and transfusion
requirements in 106 patients who underwent total knee arthroplasty with and without
the use of arterial tourniquet. During the procedure, 56 had a lower limb arterial
tourniquet and 50 did not. The authors found that the mean intra-operative blood loss
was significantly higher in patients without tourniquet compared with patients with
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tourniquet (445 ml versus 300ml respectively). One hour post-operatively, there was
a significant difference in the mean change of Hb level (pre-operative and post¬
operative) between the two groups. There was no significant difference between the
numbers of patients who received blood transfusion. From these results, the authors
clarified that the only clear benefit from using a tourniquet during TKA is the
bloodless field, however, it might not decrease the need for blood transfusion. Table
(4.13) summarises blood loss and transfusion in TKA with and without arterial
torniquate (Jarolem, Scott, Jaffe, Stein, Jaffe, Atik 1995).
Table (4.13): Blood loss and transfusion requirements in TKA with and without the
use of arterial tourniquet (Jarolem, Scott, Jaffe, Stein, Jaffe, Atik 1995)
With tourniquet (n = 56) Without tourniquet (n=
50)
Mean intra-operative 300 ml. 445 ml.
blood loss.
Mean decrease in early 14.4 g/L 20.4 g/L
post-operative Hb.




Hypothermia is a common complication during surgery. In anaesthetized patients,
heat loss exceeds production as a result of an alteration in hypothalamic functions
due to the effect of the anaesthetics agents, wound exposure, and inappropriate
intravenous fluids' temperature. The risk of hypothermia is greater in patients with
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limited metabolic rate such as elderly patients (Aitkenhead, Smith, editors 1996;
Millar, editor 2000).
Hypothermia leads to serious complications such as alteration in the clotting system
due to inhibition ofplatelets functions and coagulopathy. This can lead to increase
the incidence ofblood loss during and after surgery (Aitkenhead, Smith, editors
1996; Millar, editor 2000; Winkler, Akca, Birkenberg et al. 2000).
Watts et al. investigated the effect of different degree ofhypothermia on platelets
functions and fibrinolytic activity. They studied 112 severely traumatized patients,
40 were normothermic (temperature = 37 C) and 72 patients were hypothermic
o o
(temperature < 37 C). The authors found when used multivariate analysis that 34 C
was the critical point at which enzyme activity slowed significantly, and at which
significant alteration in platelet activity was occurred. Fibrinolysis was not
significantly affected at any temperature (Watts, Trask, Soeken, Perdue, Dols,
Kauffnann 1998).
Winkler M and colleagues investigated the effect of aggressive warming and
maintenance of normothermia on the amount ofblood loss and the need of red cell
transfusion during hip arthroplasty. The authors studied 150 patients undergoing hip
arthroplasty procedures under spinal anaesthesia. Patients were randomly divided
into two groups, 75 patients each, aggressive wanning group (tympanic membrane
temperature was maintained at 36.5 C) or conventional wanning group (tympanic
membrane temperature was maintained near 36.0 C). The authors found that intra¬
operative blood loss was significantly higher in the conventional wanning group
compared to the aggressive wanning group. However, there was no significant
difference in post-operative blood loss in both groups. The total median amount of
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blood loss during surgery and 2 days pos-operatively showed statistically significant
difference in the 2 groups. Table (4.14) summarises the study results. The authors
suggested that aggressive wanning to maintain nonnothennia during hip surgery
reduced the amount ofblood loss (Winkler et al. 2000).
Table (4.14): Effect of aggressive warming and maintenance of normothermia on the
amount ofblood loss and the need of red cell transfusion during hip arthroplasty
(Winkler et al. 2000)
Aggressive wanning Conventional warming
(N = 75). Z II -j en
Median (IQR) intra¬ 488 (368-721) 618 (480-864)
operative blood loss (ml).
Median (IQR) early post¬ No significant difference.
operative blood loss (ml).
Total median (IQR) blood
600 (400 - 820)
1531(1055- 1746)
600 (480 - 864)
1678 (1366- 1965)
loss 2 days post¬
operatively (ml).
Widman et al. investigated the effect ofwanning using amino acid infusion for
patients underwent hip arthroplasty. They studied 46 patients, 22 received amino acid
infusion one hour before and during spinal anaesthesia, 24 patients received Ringer's
lactate and served as a control group. The authors calculated the mean change in the
core body temperature before and after anaesthesia and the amount ofblood loss
prei-operatively. They found that the mean pre-anaesthetic core temperature
increased in the amino acid group and it did not change in the control group. Post¬
operatively, the mean core temperature decreased in both groups by different level.
The authors found that the mean intra-operative blood loss was significantly higher
in the control group compared to the amino acid group. However, there was no
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significant difference in the amount of post-operative blood loss in both groups.
Table (4.15) summarises the study results (Widman, Hammarqvist, Sellden 2002).
Table (4.15): Effect ofwanning using amino acid infusion on blood loss in hip
arthroplasty (Widman, Hammarqvist, Sellden 2002)
Amino acid group Ringer's lactate group
(N = 22). (N = 24).
The change in mean pre¬ + 0.4°C No change.
anesthetic core
temperature
The change in mean post- -0.4°C -0.9°C
anaesthetic core
temperature
Mean ± SD peri-operative 516 ±271 ml 702 ± 344 ml
blood loss.
Mean ± SD post-operative No significant difference.
blood loss.
Schmied et al. studied 60 patients undergoing primary THR. The authors investigated
blood loss and blood transfusion in 30 normothermic patients (core temperature 36.6
± 0.4°C) and 30 hypothermic patients (core temperature 35.0 ± 0.5°C). They found
that the mean peri-operative blood loss was significantly greater in the hypothermic
patients compared to normothermic patients (2.2 ± 0.5 L vs 1.7 ± 0.3 L respectively).
Seven hypothennic patients required 8 units of allogenic blood and one
normothermic patient required a unit (Schmied, Kurz, Sessler, Kozek, Reiter 1996).
Temporary balloon occlusion of the main arterial supply
Temporary arterial balloon occlusion has been used in controlling intra-operative
bleeding in many major abdominal procedures. Ullmark G et al. studied the
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effectiveness of the temporary balloon occlusion of the iliac or femoral in reducing
blood loss in major joint surgery. 15 hip and knee (mixture of primary and revision)
procedures in 13 patients were included in the study. The authors found that the use
ofballoon occlusion during surgery reduced the peri-operative bleeding when they
compared the amount of blood loss to a matched retrospective group of 12 patients
(control group). The mean peri-operative blood loss was 0.5 L for the balloon group
and 1 L for the matched control group. However, two complications in patients with
balloon occured, one patient had bleeding due to catheter dislocation and another
patient developed postoperative necrosis of the tip of a toe. (Ullmark, Hovelius,
Strindberg, Wallner 2000).
Diathermy
Electrocautery is commonly used in many surgical procedures. Scarring and poor
wound healing are frequent complications. Kearns SR et al. did a randomised clinical
study to compare the use of electrosurgical incision with the traditional scalpel
incision. They studied 100 patients underwent elective laparotomy. The patients were
randomised to either scalpel or diathermy incision. There was a significant difference
between both groups in the mean wound related blood loss (105.5 ± 8.7 ml in the
scalpel group versus 64.4 ± 6.7 ml in the diathermy group). There was no significant
difference in the mean total peri-operative blood loss in the two groups (915 ± 88 ml
in the scalpel group versus 927 ± 110 ml in diathermy group). The authors also found
that the diathermy group showed significant lower pain scores than the scalpel group
and there was no difference between both groups in wound complications (Kearns,
Connolly, McNally, McNamara, Deasy 2001).
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Widman et al. investigated the efficacy of the diathenny knife in reducing the
amount of intra-operative blood loss in patients undergoing primary THR. They
studied 67 patients prospectively. Patients were divided into two groups, group A
where the diathermy knife was used in all dissections and group B where the scalpel
was used. Bleeding points were coagulated with diathenny in both groups. The
authors found that there was no significant difference in the mean intra-operative
blood loss in the two groups (Widman, Isacson 1999).
The use of diathermy might reduce intra-operative blood loss and keep a clear
operative field, which facilitates the operative procedure.
Operativeposition
Few studies have investigated the role of operative position on the amount ofblood
loss during THR. Widman et al. studied 74 patients underwent THR. They compared
the amount of peri-operative blood loss when the surgery was carried out in the
lateral position with that in the supine position. There was a significant less blood
loss peri-operatively in the lateral group, on average 201 ml (Widman, Isacson
2001).
Schneeberger et al. compared the amount of blood loss in primary THR in lateral
position with preservation of the joint capsule (20 patients) with that in supine
position without preservation of the capsule (20 patients). There was a significant
less intra-operative blood loss in the lateral group than that in the supine group. The
mean volume of intra-operative blood loss was 830 ml in the lateral group and 1165
ml in the supine group. The authors concluded that the intra-operative blood loss in
patients undergoing primary THR can be reduced significantly in the lateral position
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and combined that with preservation of the joint capsule (Schneeberger, Schulz,
Ganz 1998).
Experienced surgical team and operative technique
The training, experience and care of the surgeon performing the procedure are the
most crucial factor in reducing blood loss. Surgical technique and careful pre¬
operative planning, meticulous attention to bleeding points and careful haemostasis,
and appropriate use of different intra-operative haemostatic techniques such as
collagen pads, thrombin powder, and fibrin glue can reduce intra-operative blood
loss (Lemos, Healy 1996; Emmanuel, McClelland, Page, editors 1997).
Surgical approach may decrease bleeding during EOS (Keating 1998). Parker et al.
reported the percentage of patients who underwent hip surgery and received red cell
transfusion under different surgical techniques. The authors mentioned that 79% of
the patients who had hip arthroplasty required blood transfusion of at least 400ml.
On the other hand, 57% of patients who had extra-capsular procedures required
blood transfusion (Parker, Handoll 2000).
SPECIFIC TRANSFUSION SPARING INTERVENTIONS
There are transfusion sparing interventions have been mentioned in the literatures to
reduce the need of red cell transfusion in patients undergoing EOS [table (4.16)].
Table (4.16): transfusion-sparing interventions for patients undergoing EOS.




Drugs to reduce the need ofblood transfusion.
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PRE-OPERA TIVE A UTOLOGOUS DONA TION
Pre-operative blood donation is used for patients undergoing elective surgery and
likely to have significant peri-operative blood loss which needs blood transfusion.
This process involves donation of a number of red cell units by the patient few weeks
before surgery and keep the units within the blood bank to be used by the same
patient when needed (Thomas 1996; Henry, Carless, Moxey, O'Connell 2002).
Patients can donate 10.5ml/kg blood once a week until 72 hours before surgery. In
some cases patients may donate twice a week. Iron supplements and/or EPO in many
settings can be given to decrease the incidence of phlebotomy-induced anaemia
(Biesma, Kraaijenhagen, Poortman, Marx, van de 1992; Baudoux 1996; Desmond,
Thomas, Gillon, Fox 1996).
Henry et al. did a Cochrane review to evaluate the effectiveness of autologous blood
donation in decreasing the need of allogeneic blood in surgical patients. The authors
reviewed 19 randomised control trials, however, only nine of these studies matched
the selection criteria. Other studies were rejected because of weakness in their
methods, particularly inadequate randomisation techniques, un-blinded observations,
and the subjective nature of the outcome variables. Accepted studies reported blood
transfusion data but other clinical outcome data could be analysed.
Of the nine accepted studies, four were carried out in the EOS setting. A total of
1119 patients were studied, of whom 566 were randomised to pre-operative
autologous blood donation. The authors found that the overall risk of allogeneic
blood transfusion was decreased by 63% in patients who underwent pre-operative
autologous blood donation. Most ofpatients (80%) who donated autologous blood
pre-operatively received peri-operative blood transfusion (i.e. autologous and/or
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allogeneic). Although pre-operative autologous blood donation decreased the use of
allogeneic blood, the risk of receiving any blood transfusion (i.e. allogeneic and/or
autologous) was increased in patients whom donated blood pre-operatively. The
authors did not achieve a definite conclusion about the actual benefits of pre¬
operative blood donation. The authors reported that the relative risk ofgetting
exposed to allogeneic blood is 0.37 and 95% CI (0.26 to 0.54) (Henry, Carless,
Moxey, O'Connell 2002).
Table (4.17) summarises other published studies that investigated the role of
autologous pre-operative blood donation in reducing the need of allogeneic blood
transfusion.
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Table(4.17)pu lishedstudi sthatinve igatero fa to ogousre- p rativeblo ddonati nreducingt llogeneicblo transfusion. AuthorAimofthestudyNumberof subjectsStudyintervention
Results
SculcoetAr trospectivestudyt al.(Sculcoshowtheeffectivenessof ,Gallinapre-operativeaut logous 1999)blooddonationprograms bloodmanagementt li patientsund rgoingEOS.
1405
Allpatientsreceivedd y oralir nsupplementation severalwe kspr -oper tively andweredivideinto2 groups: Pre-donatedblo dgroup(n= 1162).
Percentagesofpatientwhoertransfusedith autologousnd/orallogeneicbl(t all transfusion)wereexpress dfromhnumbersf operatedpatients. 84%ofTHRweretransfused. 80%ofTKAweretransfused. Thene dofallogeneicbl dwasrangingfr m4%t 17%(correlatedinv rselywithp e-donationHb).
Nonpre-donatedgr up(n=52%ofTHRw retransfused. 243).48%ofTKAweretransfused. Thene dofallogeneicbl dwasrangingfr m31% to83%(correlatedinv rselywithpre-operativeHb).
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Hatzidaki set al.(Hatzid akis, Mendlick, McKillip, Reddy, Garvin 2000)
Aretrospectiveanalysist identifytheriskfactorso allogenicblo dtransfusion andtodefi eheindications forpreoperativeaut logous blooddonationi p tients undergoingMJS.
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al.(Church ill, McGurk, Chapman etal. 1998)
Amulti-centreretrosp ctive studytoc mpare transfusionpract cei patientsund rgoingEOS.
2655





Meanunits/ transfused patients. 2.91±2.29 2.13±1 2 2.30±1 46
Non-pre-donatedTKA(=611)31.75±0 99
Meanlengthof hospitalt y (days). 9.7±6.3 7.3±2.5 8.3±4.0 7.6±3.2 282
Few studies have shown any evidence that autologous blood offers other benefits
to the patient over allogeneic blood. Avail et al did a controlled randomised trial
to investigated post-operative inflammatory response after autologous blood
transfusion in 31 patients underwent THR. Patients either received allogeneic red
blood cells (n = 15) or predeposited autologous whole blood transfusion (n = 16).
Plasma concentrations of some inflammatory mediators were measured before,
during, and after surgery. The authors found that there was significant increase in
plasma concentrations of IL-6 and IL-8 in both groups, with a significantly
greater increase in the autologous blood group. The authors suggested that the
lower response in the allogeneic group might result from transfusion-induced
suppression of cellular immunity (Avail, Hyllner, Bengtson, Carlsson, Bengtsson
1997).
Difficulties for autologous blood transfusion
Pre-operative autologous blood donation can be logistically difficult due to: a) low
degree of public interest to donate blood before major surgery (Thomas 1996).
Goodnough et al mentioned that up to 25% of hip and 35% of knee replacement
patients do not pre-donate autologous blood even in aggressively promoted
programs(Goodnough, Vizmeg, Sobecks, Schwarz, Soegiarso 1992a), b) patient's
medical condition such as pre-operative anaemia, pregnancy, cardiac patients, active
bacterial infection, and coagulation disorders(Thomas 1996; Desmond, Thomas,
Gillon, Fox 1996; Hartmann, Winkler, Preis, Germann, Donner, Muller 1997), c)
time consuming and expensive(Bierbaum, Callaghan, Galante, Rubash, Tooms,
Welch 1999), d) transfusion reactions are likely to occur(Hatzidakis, Mendlick,
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McKillip, Reddy, Garvin 2000), and e) errors in labelling and storage (Desmond,
Thomas, Gillon, Fox 1996).
ACUTE ISO-VOLAEMICHAEMODILUTION
Acute iso-volaemic haemodilution is a form of autologous blood donation that can be
defined as removal of one or four units of blood from a patient immediately before
operation, either before or shortly after induction of anaesthesia, and maintain the
circulating volume by crystalloid and/or colloid fluids. This process leads to 20% to
30% decrease in patient's baseline haematocrit level (Lemos, Healy 1996; Napier,
Bruce, Chapman et al. 1997; Callaghan 2000).
It is hard to find studies that investigated the role of acute isovolaemic haemodilution
in reducing the incidence of allogeneic blood transfusion in EOS setting. Schmied H
et al. evaluated the effect of red scavenging, haemodilution and active wanning in
reducing allogeneic blood transfusion. The authors retrospectively studied 821
patients underwent THR (601 patients) and TKR (220 patients). During the studied
period, the authors' institute launched three different transfusion-sparing programs;
red cell scavenging, haemodilution, and active wanning. As an overall view, the
authors found that the presence of such programs decreased the requirement of
allogeneic blood significantly. They also found that acute iso-volaemic
haemodilution by its own showed a statistically significant effect on reducing the
amount of allogeneic blood transfusion. They also found that there was a significant
positive relation between the mean pre-operative Hb and the use of iso-volaemic
haemodilution technique. Table (4.18) shows the amount of allogeneic blood used
before and after these transfusion-sparing programs (Schmied, Kurz, Sessler, Kozek,
Reiter 1996).
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Tabic (4.18) The mean (SD) number of allogeneic red cell units per transfused
patients (Schmied, Kurz, Sessler, Kozek, Reiter 1996)
Mean ± SD blood
requirement before the
program.
Mean ± SD blood
requirement after the
program.




Haemodilution only. 1.1 ± 0.9 units 0.4 ± 0.9 units
Some authors suggested that the use of these techniques is impractical in many
orthopaedic procedures as most of them are for short duration. During these short
blood-loosing procedures, there is great concern of sudden decrease in the patient's
Hb level (Napier et al. 1997; Keating 1998). However, Sculco et al mentioned that
blood collected by this technique is fresh; its oxygen carrying capacity and
coagulation functions are well preserved (Sculco 1995).
Goodnough et al. did two randomised trials to compare acute isovolaemic
haemodilution with pre-operative autologous donation in reducing the need for
allogeneic red cell transfusion. One of these trials involved patients undergoing TKA
and the other trial involved patients who underwent THR. Table (4.19) summarises
these studies.
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48patients undergoing THR.(Goodnough, Despotis,Merkel Monk2000)
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INTRA-OPERA TIVE BLOOD SAL VAGE
Intra-operative blood cell salvage can be used in procedures with acute blood loss of
more than 1000 ml (Sculco 1995; Thomas 1996). This process involves collection of
autologous blood from the operative site that can be re-infused with or without
washing with saline (Mertes, Booke, Van Aken 1997). In a short time 250 ml of
autologous blood with haematocrit between 40% and 60% can be re-infused intra-
operatively (Lisander, Ivarsson, Jacobsson 1998; Catling, Williams, Fielding 1999).
Carless et al explored in a Cochrane review the effectiveness of red cell salvage as a
tool of autologous blood transfusion. They reviewed 30 trials comprised 2125
patients. 1073 patients were included in randomised controlled trials. 12 trials
involved EOS procedures. The authors concluded that the methodology and the
quality of the trials were poor. For example methods of randomisations were
inadequate in every study. The authors found that over all the studies the use of red
cell salvage reduced the rate of exposure to allogeneic blood by 42%. However,
when the relative risk ratio of allogeneic blood transfusion was compared between
cardiac surgery (N = 12 trials) and EOS, there was a significantly larger effect of
blood salvage when used in EOS procedures (relative risk of allgeneic transfusion
was 0.35% in EOS versus 0.82% in cardiac surgery. The authors reported that the
relative risk ofgetting exposed to allogeneic blood is 0.75 and 95% CI (0.41 to 1.37)
(Carless, Henry, Moxey, O'Connell, Fergusson 2003).
Other studies investigated the effectiveness of this method in reducing the need of
allogeneic blood transfusion are summarised below.
Lisander et al. did a prospective observational study to investigate the role of intra¬
operative red cell salvage in reducing the incidence of allogeneic blood transfusion in
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patients undergoing THR. 96 patients were included in the study and intra-operative
red cell salvage device was used for all patients. Table (4.20) shows the volume of
salvaged red blood cell, number of salvaged red cell units, number of allogeneic
blood units transfused, number of patients who did not receive allogeneic blood
transfusion, and the baseline and last Hct before hospital discharge for all the study
groups.
Table (4.20): Prospective observational study to investigate the role of intra-operative
red cell salvage in reducing the incidence of allogeneic blood transfusion in patients
undergoing TRH (Lisander, Ivarsson, Jacobsson 1998)
Primary Primary non- Revision hip
cemented cemented surgery
( N = 49) (N = 11) GcnII£
Volume of salvaged red cells (mL). 159 (104-23) 166(119-319) 299(191-417)
Number of salvaged units (units). 1.1 (0.7-1.6) 1.1 (0.8-2.1) 2(1.3-2.8)
Number of allogeneic units 0(0-1) 0 (0-2) 2 (0.5-3)
transfused (units).
Percentage of patients not 69 55 9
receiving allogeneic blood (%).
Baseline Hct (%). 40 39 40
Hospital discharge Hct (%). 34 (31-37) 35 (32-36) 32 (29-33)
Values are the median (IQR). All red cell unit (i.e. salvaged and allogeniec) = 150 ml.
The authors suggested from this study that blood salvage has limited effectiveness in
avoiding allogeneic blood transfusion (Lisander, Ivarsson, Jacobsson 1998).
Shulman et al compared the use of both acute iso-volaemic haemodilution and intra¬
operative blood salvage in 40 patients underwent THR with another 40 patients who
had intra-operative blood salvage alone (control group). Table (4.21) summarises the
main findings in the study (Shulman, Grecula, Hadjipavlou 2002).
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Table (4.21): Acute isovolaemic haemodilution with intra-operative blood salvage
versus intra-operative blood salvage alone in THR (Shulman, Grecula, Hadjipavlou
2002)
Blood salvage + Blood salvage alone.
haemodiultion. (N = 40) (N = 40)
Total red cell units 183 146
transfused.
Mean number of total red 4.6 ± 2.5 units 3.9 ± 3.7 units
cell units transfused per
transfused patients.
Per patient autologous red 4 ± 1.4 units 1.9 ± 1.8 units
cell units (mean)
Percentage of patients who 58% 42%
received at least one
autologous unit (330ml).
Salvage blood
Haematocrit level 36% ± 4.4 %
2,3-diphospholycerate 2.1 ± 0.2 pmol/dL
Adenosine tri-phosphate 51.8 ± 3.5 pmol/dL
Mean hospital stay. 6.2 ± 1.2 days 8.4 ± 4.6 days
Abildgaard et al investigated the effectiveness of intra-operative red cell salvage
in patients undergoing major EOS. They studies retrospectively 43 patients. 58 %
of intra-operative blood loss and 24 % of the total peri-operative blood loss were
salvaged, however, 36 of the patients needed allogeneic blood transfusion. The
authors suggested that the efficiency of the intra-operative autotransfusion in
reducing allogeneic blood transfusion was relatively low mainly because the
postoperative blood loss is substantial in patients undergoing major EOS
(Abildgaard, Aaro, Lisander 2001).
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POST-OPERA TIVE BLOOD SAL VAGE
Postoperative blood loss can be significant after major joint surgery, particularly
after knee arthroplasty where a tourniquet is usually used throughout the procedure
(Majkowski, Currie, Newman 1991; Sculco 1995; Millar, editor 2000). In such cases
the average post-operative blood loss may exceed 1000 mL (Kurdy 1996; Lotke,
Barth, Garino, Cook 1999). In post-operative blood salvage procdure, post-operative
blood loss can be drained from the wounds by special drainage system, washed with
saline or unwashed, and re-infused to the to the patient (Lemos, Healy 1996;
Callaghan 2000).
There are few studies of the efficacy ofpost-operative red cell salvage alone and its
role in reducing the need of allogeneic blood transfusion in patients undergoing EOS.
Most of the studies investigated the role of this method combined with pre-operative
autologous donation. Table (4.22) summarises some of these studies.
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Hazards of red cell salvage
Some authors showed some adverse effects of re-infusing the salvaged blood to the
patients during or after surgery. These adverse effects are: a) Anaemia due to
infusion of diluted blood, b) thrombocytopenia and coagulopathy due to loss of
platelets during salvage, c) sepsis bacterial contamination is likely to occur with such
devices, and d) microemboli due to the ineffective filtering system (Desmond,
Thomas, Gillon, Fox 1996; Huet, Salmi, Fergusson, Koopman-van Gemert, Rubens,
Laupacis 1999).
DRUGS USED TO DECREASE THE NEED FOR ALLOGENIC BLOOD
Henry et al did a Cochrane review to investigate the role of anti-fibrinolytic drugs
such as aprotinin, tranexamic acid, and epsilon aminocaproic acid, on peri-operative
blood transfusion. The authors reviewed 61 trials of aprotinin compromised 7027
patients. They found that aprotinin reduced the rate ofblood transfusion by 30% and
decrease post-operative bleeding. The authors also reviewed 18 trials of tranexamic
acid comprising 1342 patients. They found that tranexamic acid decreased the rate of
blood transfusion by 34%. However, the authors reviewed four trials of epsilon
aminocaproic acid comprising 208 patients and they found that the use of epsilon
aminocaproic acid had non-significant reduction in blood transfusion. The authors
concluded that aprotinin could reduce the need for blood transfusion and decrease
post-operative bleeding without side effects. The authors mentioned that there were
similar trends for the other two drugs (Henry, Moxey, Carless, O'Connell 2002a).
Henry et al did another Cochrane review to investigate the role of desmopressin in
minimising peri-operative allogeneic blood transfusion in patients who do not have
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congenital bleeding disorders. The authors reviewed 14 randomised controlled
parallel group trials comprised 1034 patients. The authors found that there was no
evidence that desmopressin can decrease peri-operative allogeneic blood transfusion
in patients who do not have congenital bleeding disorders (Henry, Moxey, Carless,
O'Connell 2002b).
Some other studies investigated the use of Tranexamic acid and Aprotinin.
Hiippala et al. did a randomised control study to investigate the use of short-term
anti-fibrinolytic (Tranexamic acid) therapy in reducing post-operative blood loss in
patients undergoing TKA. The authors hypothesised that application of a limb
tourniquet enhances local fibrinolysis and the use of such treatment may reduce
blood loss through the inhibition of the fibrinolytics. They studied 77 patients, 39
patients received the treatment intra-operatively and 38 received normal saline and
served as a control group. Peri-operative blood loss was measured and the number of
red cell units transfused was recorded. The authors found that the amount of peri¬
operative blood loss in the control group was a significantly greater compared with
the study group. They also found that the number of red cell units transfused was
significantly higher in the control group than that in the study group. The authors
suggested that the use of such treatment had a significant effect on reducing the need
of red cell transfusion. Table (4.23) summarises the results of the study (Hiippala,
Strid, Wennerstrand et al. 1997).
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Table (4.23): The effect of the use of short-term anti-fibrinolytic (Tranexamic acid)
therapy in reducing post-operative blood loss in patients undergoing TKA (Hiippala
etal. 1997)
Treatment group (N = 39). Control group (N = 38).
Mean Peri-operative 689 ± 289 ml 1509 ±643 ml
blood loss.
Mean number of red cell
units transfused/patients 1 ± 1.2 3.1 ± 1.6
transfused.
Veien et al also studied Tranexamic acid in 30 patients underwent TKR in a
randomised control trial. The patients were divided into two groups, 15 patients each.
One group received Tranexamic acid and the other did not and served as a control
group. The number of patients who were transfused with allogeneic blood was higher
in the control group. There was a significant reduction in mean total blood loss in the
study group compared with the control group. Table (4.24) summarises the results of
the study (Veien, Sorensen, Madsen, Juelsgaard 2002).
Table (4.24): The effect of the use ofTranexamic acid in reducing total blood loss in
patients undergoing TKR(Veien, Sorensen, Madsen, Juelsgaard 2002)
Treatment group (n = 15) Control group (n = 15)
% Of patients who 0% 13%
received allogeneic blood.
Mean total blood loss. 409.7 ± 174.9ml 716.7 ±313.1 ml
Aprotinin has also been studied to investigate its role in reducing blood loss and
transfusion in patients undergoing major EOS. Aprotinin is a proteinase inhibitor
derived from bovine lung that has anti-fibrinolytic properties. Aprotinin acts as an
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inhibitor of human trypsin, plasmin, plasma-kallikrein and tissue kallikrein, thus
inhibiting fibrinolysis. It also inhibits the contact phase activation of coagulation that
both initiates coagulation and promotes fibrinolysis.
Murkin et al. studied 53 patients underwent bilateral or revision THR. They divided
the patients into two groups. Treatment group received Aprotinin and a placebo
group who served as a control group. The authors found that the mean peri-operative
blood loss was significantly lower in the study group compared with the control
group [table (4.25)] (Murkin, Shannon, Bourne, Rorabeck, Cruickshank, Wyile
1995).
Table (4.25): The role ofAprotinin in reducing blood loss for patients undergoing
THR (Murkin, Shannon, Bourne, Rorabeck, Cruickshank, Wyile 1995)
Mean peri-operative
blood loss.
% Of patients transfused.
Mean number of units
transfused/patients
transfused
Treatment group (n = 29).
1498 ± 110 ml
62.1%
2 ±0.2
Control group (n = 24).
2069 ± 223 ml
70.8%
2.9 ± 0.4
Capdevila V et al studied the role ofAprotinin in reducing the need of allogeneic
blood transfusion in patients undergoing major EOS. The authors studied 23 patients,
12 patients received Aprotinin and 11 patients did not and used as a control group.
Total blood loss was lower in the study group by 65% than in the control group. The
study group had 67% lower intra-operative blood transfusion requirements than the
control group [table (4.26)]. There were no adverse effects of the drug such as deep
vein thrombosis. The authors suggested that Aprotinin reduced bleeding and
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allogeneic blood transfusion dramatically in patients undergoing major EOS without
adverse effects (Capdevila, Calvet, Biboulet, Biron, Rubenovitch, d'Athis 1998).
Table (4.26): The role of Aprotinin in decreasing blood loss in patients undergoing
major EOS (Capdevila, Calvet, Biboulet, Biron, Rubenovitch, d'Athis 1998)
Treatment group (N = 12). Control group (N = 11).
Median (range) total 5305 (3000-9770) ml 1783 (1140-4955) ml
blood loss.
Median (range) number of
red cell units transfused/ 7 (4-16) 3 (2-5)
patients transfused.
POST-OPERATIVE CARE FOR PATIENTS UNDERGOING EOS.
There are many issues which should be considered during post-operative period in
patients undergoing EOS that can minimize the need for red cell transfusion.
TEMPERATURE CONTROL
As mentioned before hypothermia may aggravate bleeding by impairing platelet
function and directly reducing clotting factor enzyme function. Optimising patients'
body temperature may decrease post-opeative bleeding and the need for blood
transfusion (Rohrer, Natale 1992; Schmied, Kurz, Sessler, Kozek, Reiter 1996).
POST-OPERA TIVEANAEMIA
Anaemia after surgery could be explained by blood loss during and after operation.
Elowever, some authors referred it as a manifestation of post-operative acute phase
inflammatory response. Others mentioned that the mechanism of postoperative
anaemia remains unknown (Biesma, van de, Beguin, Kraaijenhagen, Marx 1995; van
Iperen, Kraaijenhagen, Biesma, Beguin, Marx, van de 1998).
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Patients undergoing EOS especially major joint replacement are often malnourished
at the time of surgery. Post-operative period, the actual amount of iron absorption
from food may be limited by poor dietary intake and impaired intestinal function and
could further contribute to iron deficiency anaemia (Zauber et al. 1992; Rock, Jr.,
Meeks 2001).
Avenell et al. did a Cochrane review to assess the effects of nutritional interventions
in elderly people recovering from hip fracture. The authors reviewed 15 randomised
trials comprising 1054 participants. Overall the quality of trials was poor;
specifically in terms of allocation concealment, assessor blinding and intention to
treat analysis. Some of the studies suggested that high protein diet might decrease the
period of stay in rehabilitation hospitals. On the other hand, few trials investigated
the role of vitamin B1 and vitamin D supplements on the rate of recovery. The
authors found no evidence ofbenefit for either vitamin supplement. They concluded
that there is very weak evidence that high protein diet might affect the rate of
recovery in elderly patients recovering from hip fracture (Avenell 2002).
Little information was found on the causes ofpost-operative anaemia and its
pathophysiology. Biesma et al investigated the pathophysiology ofpost-operative
anaemia in 48 patients who underwent THR and had normal levels of folic acid,
vitamin B12, and iron indices. Patients had no signs ofpost-operative fever or
inflammation were only included in the study. During the study they measured
different variables of erythropoiesis, iron metabolism, and markers of inflammation
during recovery from surgery for the patients who received blood transfusion and
who did not. Most of patients were females (43 patients) with a mean age of 71.6
years. The authors found that C-reactive protein (CRP) increased significantly on day
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4 post-operatively from a mean of 4 mg/L to 82 mg/L (the maximum level during the
follow up period). CRP fell after day 4 post-operatively, was high until day 14, but
returned to its baseline level on day 42.
IL-6 was undetected pre-operatively, however, peaked on first day post-operatively
and was undetected again by day 7.
Hb, iron, transferrin, and ferritin concentrations were not influenced by iron therapy
during the postoperative period. There were no differences of erythropoietic and iron
variables between transfused and non-transfused patients. The authors suggested that
post-operative anaemia is a form of "anaemia of chronic disease" due to the presence
of post-operative inflammatory mediators. They hypothesized that there is decreased
response of erythropoietin. This leads to a doubt about the effectiveness of using
either erythropoietin and/or iron therapy in treating this type of anaemia. Table (4.27)
summarizes laboratory findings for patients included in the study (Biesma, van de,
Beguin, Kraaijenhagen, Marx 1995).
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Management of post-operative anaemia.
Very few studies have investigated different managements ofpost-operative anaemia
in patients undergoing EOS. Zauber et al. did a randomised controlled trial to assess
the role of oral iron in treating post-operative anaemia following hip surgery. All
patients had normal iron stores and normoblastic erythropoiesis (revealed from the
surgically removed femoral head). Patients were randomised to receive either oral
ferrous sulphate during their hospital stay (N = 37) or placebo (N = 42). The authors
did not find statistically significant differences in the rate of Hb or reticulocyte
recovery. They suggested that administration of oral iron postoperatively to elderly
orthopaedic patients with adequate tissue iron stores did not hasten the recovery of
haemoglobin levels. Table (4.28) summarises laboratory findings during the follow
up period (Zauber et al. 1992).
Table (4.28): The role of oral iron in treating post-operative anaemia in patients
undergoing hip surgery (Zauber et al. 1992)
Females Males Reticulocyte count
Iron group Control Iron group Control Iron group Control
group group group
Baseline 133 ± 14 135 ±9 144 ± 15 144 ± 15 17 ± 7 13 ± 6
Week 1 109 ±9 110± 11 113± 17 107 ±7 21 ±9 21 ±9
Week 2 109 ± 10 111 ± 10 114 ± 10 112 ± 8 27 ± 10 34± 17
Week 3 111 ± 14 112 ± 8 107 ±3 108 ±8 27 ±19 34 ± 17
Mean Hb (g/L), reticulocyte count (x 10" )
In another surgical setting, Crosby et al. evaluated the role of iron in treating acute
blood loss anaemia in elderly patients undergoing coronary artery bypass surgery.
121 elderly patients were included in the study. Patients were randomised to one of
four groups: control group, placebo group, low iron dose group, and usual iron dose
303
group. Treatment started post-operatively and for 8 weeks. The authors found that
both Hb and Hct decreased 6 days post-operatively for all patients to a mean of 95 ±
12 g/L and 28% ±2.3%. Mean Hb and Hct levels returned to near normal values, 136
± 9.7 g/L & 40.6% ± 3% at the end of the study. Iron stores remained within normal
ranges for most subjects regardless of randomisation. The authors suggested that the
use of iron in treating acute blood loss anaemia did not help in Hb recovery or
change iron stores post-operatively (Crosby, Palarski, Cottington, Cmolik 1994).
304
DEFINITIONS
Patients administration system (PAS): A database maintained by the
hospital's records department that covers all of hospital admissions and
contains patients' identifiers, hospital admission date, hospital discharge date,
and the surgical procedure.
Patient's identifiers & fields of linkage: Patient's forename, surname, gender,
date ofbirth, and hospital number.
Hospital Laboratory database: A database that contains haematological
results, samples request date, and a code that indicates the source of the blood
sample (hospital and ward) all are linked to patients' identifiers.
Preoperative /Pre-admission Hb: Hb value that had been requested within
one month before admission and including the day of admission. If there were
more than one Hb value within that month, the pre-admission Hb is defined
as the Hb value with a sample request date closer to the date of admission.
Pre-operative /Pre-admission haematology results: Haemoglobin [Hb],
mean red cell volume [MCV], and mean red cell corpuscular haemoglobin
[MCH] values that had been requested within one month before admission. If
there were more than one result within that month, the pre-admission
haematology results is defined as the result with a sample request date closer
to the date of admission.
Anaemia: Haemoglobin concentration <130 g/L for males and <115 for
females.
SNBTS Blood Bank Patient Database: A database, for the study hospital, that
contains patients' identifiers, records ofblood samples received for group and
305
save procedure, and number of blood products assigned for identified patient,
issued to and returned unused by that patient.
Blood Bank Patient record: any records of an event in which a patient's
blood sample is received for group and save, or one or more red cell units are
assigned.
Group and save [G&S]: An event in which a blood sample is received by the
blood bank for blood grouping and detection of red cell antibodies and is
saved for 3 days maximum in the blood bank (no red cell units assigned).
Red cell units assigned: An event in which one or more individually
identified red cell units are assigned to an identified patient: (often referred to
as "Issue" or "Cross match").
Transfusion episode: Any admission record with a number of (red cell units
issued) - (number of red cell returned) > 0.
Transfusedpatient: A patient who appeared in the blood bank database with
one or more admissions in which the number of red cell units issued is more
than the number returned.
Princess Margaret Rose Hospital [PMR]: The main teaching orthopaedic
Hospital (Edinburgh).
EOS: Elective orthopaedic surgery.
THR: Total hip arthroplasty or replacement.
TKA - TKR: Total knee arthroplasty or replacement.
MJS: Major joint surgery (THR + TKA).





To determine the prevalence and type ofpre-operative anaemia in patients
undergoing elective orthopaedic surgery.
SECONDARYAIM
To determine the prevalence ofperi-operative red cell transfusion
To detennine the association between the rate of red cell transfusion and pre¬
operative Hb level.
PATIENTS STUDIED
A large cohort of patients from a specialized orthopaedic hospital perfonning only
elective surgical procedures [PMR] was used for this study, for which
haematological and transfusion data were retrospectively extracted from existing
databases.
STUDY PERIOD
All inpatients admitted to PMR from 1/8/2000 to 31/7/2001.
STUDY DESIGN
The study was designed to use only data that had been recorded during routine
patient management and was available in the hospital's computerized information
systems.
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Three datasets were accessed:
Patient dataset [from PAS database].
Haematology dataset [from the Hospital Laboratory database].
Transfusion dataset [from the Blood Bank Patient database].
ETHICS AND CONFIDENTIALITY
A senior consultant anaesthetist in the clinical unit sponsored the study. It was
carried out in the form of a retrospective audit. No interventions were carried out and
patient management was not altered in any way on the basis of the data collected. We
obtained guidance from the Local Regional Ethics Committee that ethical review was
not required. Guidelines from the data protection act were followed and anonymous
data after linkage were done. Patients' identifiers were deleted and each linked
record was assigned a key number that was used as a primary key in analyzing the
data.
DATASET FORMAT
Each dataset was obtained in Excel files.
DATA MANAGEMENT
Datasets were imported to Microsoft Access for linking.
PASDATASET
From the orthopaedic hospital PAS database, patients' identifiers were obtained. The
extracted fields for each patient are shown in table (4.29).
Addition of haematology laboratory data to PAS data
This process involved the linking of the each patient record to an extract from the
haematological laboratory database, using the patient identifier.
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The extract from the laboratory database contained all the specified haematological
results (Hb values and red cell indices) on patients' samples submitted from PMR
between 1/7/2000 and 31/7/2001 (1 month before study period).
The process of linkage is described in detail in appendix (1). The extracted fields are
shown in table (4.30)
Addition of Transfusion data to PAS data
This process involved linking of each patient record, using the patient identifiers to
make an extract from the blood bank patients database.
From the blood bank database we obtained all transfusion records for all patients
who had any request forms originating from PMR between 1/7/2000 and 31/8/2001.
The extract from the blood transfusion database for each patient is shown in table is
shown in table (4.31)
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Figures (4.1, 4.2, and 4.3) illustrate the linkage procss of different datasets to obtain
the final database for analysis.
STUDYDATABASE
From the linked PAS dataset, the laboratory dataset, and the hospital blood bank
dataset, a study database was prepared consisting of, for each admission, the PAS
data with any linked haematology and transfusion data. Patients' identifiers were
deleted and a unique key number was assigned for each admission for further
analysis. Table (4.32) shows the fields that were included in study dataset.
After the linkage process was completed, some patients had more than one
haematological record. For the purpose of the study, the pre-admission
haematological record was defined as a haematological result, with sample request
date within one month before the hospital admission date [if there was more than one
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result, the one closest to admission date was used in the analysis]. The rest of the
haematological records were ignored (deleted).
After linking the blood transfusion dataset, some patients had more than one
transfusion record. For the group and screen records, the events related to the study
were defined as (1) the records ofG&S requests submitted within one month before
admission and during hospital stay (the period between hospital admission and
discharge dates). (2) Red Cell Units Assigned (RCUA) and (3) Red Cell Units
"Transfused" (RCU "T") were defined as the records created by the Blood Bank
within one week before hospital admission and during the hospital stay.
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Number of red cell units returned
Number of red blood cell units
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Total accepted links = 1749 records
Figure (4.1): Flow chart to illustrate the linkage




extract from Blood Bank





admissions for PMR from
PAS between 01/08/2000 and
31/07/2001
(N = 3417 records)
Linkage ofboth datasets


















Total accepted links = 2458 records
Figure (4.2): Flow chart to illustrate the linkage between
PAS dataset and the patients blood bank dataset
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A file of the linked patients'
dataset with the transfusion
dataset.
A file of the linked patients'
dataset with the haematology
dataset.
Final spreadsheet for analysis contained
3417 admission records:
Admissions with records from patients'
dataset + haematology dataset + transfusion
dataset
(N = 830 records).
Admissions with records from patients'
dataset + haematology dataset
(N= 1668 records)
Admissions with records from patients'
dataset + transfusion dataset
(N = 844 records).
Admissions with records from patients'
dataset alone
(N = 1749 records).
Figure (4.3): Flow chart to illustrate the final spread
sheet used for analysis
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RESULTS
PATIENTS' CHARACTERISTICS: THE PATIENTS' DATASET.
3417 admissions were recorded in PAS that comprised 3257 patients between
01/08/2000 and 31/07/2001. Numbers of patients who were admitted more than once
are shown in table (4.33). 1696(49.6%) of admissions were males and 1721(50.4%)
were females. The mean (SD) and median [IQR, (range)] age (years) for all
admissions during the study were 54.6 (18.4) and 57 [40 to 70, (12 to 93). There
were no admissions in age band 21 to 30 years old; table (4.34) shows the number of
admissions in different age bands.
1322 (38.6%) admissions underwent major joint surgery (MJS). 2095 (61.4%)
underwent other different orthopaedic procedures. Table (4.35) shows the number
(%) of admissions in different EOS procedures. Table (4.36) shows the general
characteristics of admissions undergoing different procedures. Table (4.34) shows
the characteristics of admissions in which MJS was perfonned.
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Table(4.33):otalnumb rfpa ientswhoh ddiffer tb radm ssi nsu i gths udyeriod. HipNumberofpatientstti ntsertie whohadonet ohrefour admissionissionsi i ns 58020
1
admissions 0

















Table(4.34):Numb r%)ofldmissionsindifferentgband . AgeBands(years) 10-20 21-30 31-40 41-50 51-60 61-70 71-80 81-90 >90
Males(n=1696) N(%) 67/1696(4) 0/1696 491/1696(2 ) 249/1696(15) 270/1696(16) 321/1696(19) 246/1696(14) 51/1696(3) 1/1696(<1)
Females(n=1721) N(%) 50/1721(3) 0/1721 265/1721(15) 199/1721(1 ) 312/1721( 9) 392/1721( 3) 388/1721(22) 110/1721(6) 5/1721(<1)
Totaladmissions(n=3417) N(%) 117/3417( ) 0/3417 756/3417(22) 448/3417(13) 582/3417(17) 713/3417(21) 634/3417(19) 161/3417(5) 6/3417(< )
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Table(4.35):Numb r%)ofadmissionsinwhichdifferentEOSproc duresrcarr dut. Procedures THR TKR Revisionh p Revisionknee Revisionother Other: Softtissue Spine Construction Otherjoints Endoscopy MiscellaneousMales(n=1696) N(%) 249/1696(15) 245/1696(14) 46/1696(3) 19/1696( ) 3/1696(<1) 1134/1696(67) 132 79 168 195 512 48
Females(n=1721) N(%) 374/1721(23) 310/1721( 8) 59/1721(3) 20/1721( ) 2/1721(<1) 956/1721( 5) 145 113 230 236 218 14















































































































































































































Linkage results [haematology data]
Of the linked haematology records, 1631 were complete matches and 118 were
partial matches but were accepted as true matches on visual inspection.
Ten patients had two haematological results one month before hospital admission
date. The result with the nearest request date to hospital admission date was used in
the analysis. 12 anaemic female patients (Hb <115 g/L) had no MCY or MCH
records in the haematology database. The linkage process and the numbers of linked
records are described previously in figure (4.3).
HAEMATOLOGICAL RESULTS
1749 (51.2%) admissions had pre-admission haematological results. Of these 1142
(63.7%) admissions were for MJS. Table (4.38) shows the number and percentage of
admissions with and without pre-admission haematological results that underwent
different procedures.
The mean (SD) and median [IQR, range] pre-admission haemoglobin (g/L) for all
admissions with haematology records were [132 (14.38) and 133 [124 to 142, (76 -
184)]. Table (4.39) and figure (4.5) show the numbers ofmales and females in
different Hb bands. Figure (4.6) shows the number of all admissions in different Hb
bands. Figure (4.7) shows mean pre-admission Hb levels in different procedures.
Figure (4.8) shows mean pre-admission Hb levels for different age bands.
299 (17%) admissions were anaemic [Hb < hospital laboratory reference range:
males <130g/L and females <115g/L]. Of these 154 (51.5%) were males and 145
(48.5%) were females. Table (4.40) shows number (%) of anaemic admissions in
different procedures.
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For all anaemic admissions that had Hb results, 64% had normocytic normochromic
anaemia before hospital admission. The prevalence of different types of anaemia for
all admitted anaemic males and females is shown in table (4.41). Figure (4.9) shows
the percentage of all anaemic admissions with different types of anaemia.
MCV and MCH results were available for 211 anaemic admissions that underwent
MJS. Table (4.42) shows the number (%) ofmales and females admissions with
different types of anaemia that underwent MJS. Figure (4.10) shows the percentage
of all MJS admissions with different types of anaemia.
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Table(4.38):Numb r%ofthetalnumberadmissionsieachprocedure)w tnithoutv ilablepre- dmission haematologicalresultsindiff rentEOSprocedure . Procedures THR(N-623)Withpre-admissionhaematologicalr sults (N =1749). N(%) 544/623(87)Withoutpre-admissionhaematol gicalresults
(N=1668). N(%) 79/623(13)
TKR(N=555) Revisionh p(N=105) Revisionknee(N=39)
490/555(88) 77/105( 3) 31/39(80)
65/555(12) 28/105(27) 8/39(20)
Other(N=2090) Softtissue Spine Construction Otherjoints Endoscopy Miscellaneous Revisionother(N=5)
603/2090(2 ) 96 54 119 207 112 15




























































































Figure(4.5):Numb rofaleandfe aldmissionsidifferentpr -admissionHb d
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Figure (4.8): Mean pre-admission Fib levels in different age bands
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Table(4.40):Numb r%)ofanaemicadmissionsth tund rwentdifferentEOSprocedure . Operation THR TKR Revisionh p Revisionknee Other RevisionotherMales(n=154) N(%) 51/154(33) 50/154(32.5) 8/154(5) 4/154(2.5) 39/154(25.5) 2/154(1.5)
Females(n=145) N(%) 47/145(32. ) 35/145(2 ) 9/145(6) 7/145(5) 47/145(32. ) 0
Total(n=299) N(%) 98/299(3 .5) 85/299(28) 17/299(6) 11/299(4) 86/299(2 ) 2/299(0.5)
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Table (4.41): Prevalence of different types of anaemia for all anaemic admissions.





Prevalence of anaemia (Hb < 130 for males
and < 115 for females).
154/744 (20.7) 133/1005 (13.2)







Normocytic + hyperchromic 10/154 (6.5) 5/133 (3.8)
Microcytic + hypochromic 5/154 (3.3) 9/133 (6.7)
Macrocytic + hyperchromic 4/154 (2.5) 9/133 (6.7)
Macrocytic + normochromic 0 1/133 (0.8)
Figure (4.9): Prevalence of different types of anaemia for all anaemic




















Table (4.42): Prevalence of different types of anaemia for all anaemic admissions
that underwent MJS.
Male (n = 491)
N (%)
Female (n = 651)
N (%)
Prevalence of anaemia (Hb < 130 for males
and < 115 for females).
113/491 (27.1) 98/651 (15)
Normocytic (MCV 76-100fl) +
normochromic (MCHC 27-32pg) 77/113(68.1) 79/98(80.6)
Normocytic + hypochromic 20/113 (17.7) 4/98 (4.1)
Normocytic + hyperchromic 9/113 (8) 4/98 (4.1)
Microcytic + hypochromic 3/113 (2.7) 4/98 (4.1)
Macrocytic + hyperchromic 4/113 (3.5) 6/98 (6.1)
Macrocytic + normochromic 0 1/98 (1)
Figure (4.10): Prevalence of different types of anaemia for anaemic




















3400 records were received from the blood bank patient database. These had been
selected as all request records originating from the PMR and covering the period
between 01/07/2000 and 31/08/2001. The linkage process and the numbers of the
linked records are described previously in figures (4.2 & 4.3).
3095 (86.5%) BTS records fully matched with the entire fields of linkage and 460
(13.5%) ofBTS records were not linked. Of the linked records, 2458 were related to
the study period as a decision was made to include only G&S records that had been
requested one month before hospital admission date and cross-match records one
week before that date. 1049 records in which red cell units were assigned related to
923 admissions and 1409 records of group and save only related to 1368 admissions
(the reasons for obtaining a period of 14 months data and accepting the full matches
only are discussed in detail in the discussion section). Table (4.43) shows number
(%) of admissions in G&S group. Table (4.44) shows number (%) of admissions with
different numbers of instances on which one or more red cell units were assigned
during the same hospital stay.
305 admissions had one or more transfusion episode comprising a total of 367
episodes. Of these episodes 128 (35%) were for males and 239 (65%) were for
females. General characteristics of admissions that had transfusion episodes are
shown in table (4.45). Table (4.46) shows number of transfused admissions in
different numbers of transfusion episodes.
838 red cell units were used for all the admissions in the cohort during the study
period. Table (4.47) shows number of admissions in different procedures that were
transfused with different numbers of red cell units.
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83% of total units of red cell units during the study period were used for admissions
undergoing MJS and 17% were used for admissions undergoing other EOS
procedures. Table (4.48) shows numbers of red cell units transfused for different
procedures. Table (4.49) shows the mean (SD), median (IQR) and range of the
number of red cell units transfused per transfused admission in each procedure.
59% of admissions that were transfused were in the age range between 61 to 80
years. Table (4.50) shows number of admissions transfused in different age bands in
different procedures. Figure (4.11) shows the number of all transfused admissions in
different age bands.
BLOOD BANKREQUESTAND TRANSFUSIONINRELA TION TO
HAEMATOLOGICAL RESULTS
Pre-operative red cell transfusion in relation to availability of Hb results
271(73.8%) of the transfusion episodes occurred during admissions for which a pre¬
admission Hb records had been linked and 96 (26.2%) episodes occurred during
admissions for which no pre-admission Hb records could be linked. Table (4.51)
shows number of transfusion episodes in different procedures with and without
available pre-admission Hb records.
631 red cell units were transfused for episodes in which there was a linked pre¬
admission Hb records and 207 units transfused for admissions with no linked pre¬
admission Hb records.
Of the transfusion episodes for admissions with a linked Hb results, 73 % occurred in
cases with pre-admission Hb value between 100 g/L and 135 g/L. For these episodes,
72% of the transfused red cell units were used. Table (4.52) shows the number of
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transfusion episodes and red cell units used in different Hb bands. 31 % of the
transfusion episodes occurred with pre-admission Hb level < 124 g/L. Figure (4.12)
and table (4.53) show the total number of transfusion episode in different Hb bands.
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Revisionother0 (N =5) Total809/3417(24%)1 5/3417(37/ 7(<1%)923/34177 (N =3417)
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Table(4.45):Generalcharacteristicsofadmissionst atin ludedlr nsfu onepi odes. VariableMeanSDM dianQ13R nge Age(years)6617.7710813-90 Pre-admissionHb1225.43101328 -162 (g/L) Lengthof119.721-86 hospitalt y (days) Numberofred20.831-6 cellunits transfused
Table(4.46):Numb r%)ofadmissionswithdifferentnumbersftr nsfusionpi ode(pad i n). ProcedureOneepisode N(%)Twoepisodes N(%)Threeepisodes N(%)
Fourepisodes N(%)
Fiveepisodes N(%)































































































































































































































































































































Table (4.50): Number (%)of admissions transfused in different age bands in different








n other (N = 305)
N (%)
10-20 0 0 0 0 14 0 14/305 (5)
21-40 3 1 0 0 2 0 6/305 (2)
41-50 10 2 2 0 1 0 15/305 (5)
51-60 20 3 7 0 7 0 37/305 (12)
61-70 46 6 15 2 6 0 75/305 (25)
71-80 50 21 21 3 9 0 104/305 (34)
81-90 33 8 8 3 2 0 54/305 (18)












<21 21-40 41-50 51-60 61-70
Age band (years)
71-80 81-90 >90
Figure (4.11): Number of admissions transfused in different age bands
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Table(4.51):Numb r%)oftransfusionepisodeshatccurr dwithithoutvailablepre- dmissioHr or sidiff renp oc du
(%ofalldmissionsineachgroup). Procedure THR
Transfusionepisodewithknownr iunkn wotalnumbersepisode pre-admissionHb(N=271)i i n96)367 N(%) 162/271(59.8)N(%) 25/96(26)
N(%) 187/367(51)
TKR Revisionh p Revisionknee Other
38/271(14) 50/271(18.5) 8/271(2.9) 13/271(4.8)
4/96(4.1) 15/96(15. ) 5/96(5.2) 47/96(4 )












































































"S60 v> a a)
.250 V)a c 240 0 L_4>130 3
20 10
0
Table (4.53): Number (%) of transfusion episodes in Hb bands (% per total number
of admissions in each Hb band).
Hb bands (g/L) Number (%) of transfusion episodes.
(N = number of admissions).
80-90(10) 6(60%)
91 - 100(27) 12(44%)
101 - 110(81) 45 (55%)
111 - 120(170) 46(27%)
121 - 130(394) 78 (20)
131 - 140(534) 52 (10%)




SUMMARY OF THE RESULTS
3417 EOS admissions [3257 patients] were admitted to the main teaching
orthopaedic hospital [PMR] during the study period and were included in the study.
For 51.2% of these admissions a full blood count result within one month before
hospital admission was available. The prevalence of anaemia before hospital
admission in those admissions that had a full blood count result was 17%. Of these
anaemic patients 64% had normocytic nonnochromic blood indices.
1322 (38.6%) admissions underwent major joint surgery (THR & TKA). Of these
1142 (86.4%) patients had pre-admission full blood count results, 211 (18.5%) were
anaemic. 74% of these anaemic admissions had pre-admission normocytic
nonnochromic blood indices.
305 admissions received red cell transfusion during the study period ofwhich 59%
were elderly patients between 61 and 80 years. A total of 838 red cell units were
transfused to these patients. The mean ± SD [median, (IQR), and range] of pre¬
admission Hb (g/L) for admissions that were transfused was 121.5 ± 15.4 [13,
(110,132), and (82 - 162)] respectively.
31% of the transfused admissions had pre-admission Hb level < 124g/L and these
anaemia patients used 72% of all the transfused red cell units. 83.5% of all




The study was carried out in a large elective orthopaedic teaching centre, the case
mix comprising all admissions to the hospital for a complete year.
Patients' demographic data were obtained from the Patient Administration System
[PAS] database, which covers all ofhospital admissions. This is the most complete
and accurate source of demographic and procedure infonnation that should be
routinely available for any hospital in the UK. It was unlikely to miss any admission
during the study period.
The haematology dataset was obtained for a period of 13 months to include an extra-
month before the study period. This was to capture the haematological results for
patients who had their pre-admission visit one month before the start of the study
period. Therefore, it was unlikely to miss any available pre-admission
haematological results. However, we showed that only 51.2% of the admissions had
pre-admission haematological values. Possible explanations for this are: a) the
haematological tests were not requested before and or the day ofhospital admission
(possible flaw in the pre-admission clinic protocol), b) there were no records in the
hospital laboratory database (possible flaw in data entry in labs), c) record in the
database but with wrong identifiers, so not liked to PAS dataset, d) result date could
be after admission date (possible flaw in the study protocol), e) Hb was requested the
next day after the day of hospital admission, f) error in the linkage process, this was
unlikely to occur as the process was carried out in steps and manual checks were
carried out for the fuzzy matches. Therefore, it was unlikely to miss any data because
of a faulty in entering of one or two characters of one or more linkage fields in any of
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the linked datasets (see pages 314, 315, 316 and appendix I). The methodology of the
linkage and the manual checks that followed provided the study with a high quality
dataset for further analysis.
The transfusion dataset contained extra two months period was obtained [one month
before and one month after the study period] to capture transfusion records for
admissions that had their pre-admission visit one month before the start of the study
period and to capture records until the time of hospital discharge [last admission was
discharged one month after the study period]. Therefore, it was unlikely to miss any
transfusion records for all admissions in the study.
86.5% the transfusion records were fully linked with PAS dataset, possible
explanations: a) dates' format in the blood bank dataset was different than that in
PAS dataset and full matches only were accepted for analysis after reformatting the
dates, b) records were in the dataset but with wrong identifiers, so not linked, c) for
some admissions, some G&S and assigned records were not related to the study
period (> one month before of hospital admission date or after the hospital discharge
date). These records were linked automatically to PAS dataset as a part of the linkage
process. These events were identified from their dates and were excluded from the
analysis.
All transfusion records related to the study period were linked to PAS and used in the
analysis, however, only the pre-admission haematology results was linked and used
in the analysis. This explains the higher proportion of records that had been linked
from the transfusion dataset to PAS dataset comparing it to the proportion of the
haematology records that had been linked.
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The linkage process of the patients' dataset was carried out under the supervision of
an expert in that field in a specialized unit with secure computers and procedures that
comply with data protection guidelines.
The study population contained a large number of patients who underwent major
joint surgery; this allowed us to construct a subgroup of patients typical of those who
are more likely to be older, anaemic, and thus more at risk of red cell transfusion.
The transfusion dataset was extracted from the Scottish National Blood Transfusion
Service [SNBTS] patient database. This database accounts for all patient blood bank
requests that occur in the PMR and its parent Trust. This dataset provides the same
patients' identifiers and transfusion data that can be linked to PAS dataset. Therefore,
it was unlikely to miss transfusion events in our study group.
WEAKNESSES
With the experience gained from this study, some aspects of the design could be
improved.
The PAS database does not record the exact date of the pre-admission clinic visit.
We therefore had to assume that hospital guidelines were complied with, i.e. that
patients preadmission clinic [PAC] attendances took place within the month
preceding their admission date. It would be preferable to have the PAC attendance
date recorded in the PAS dataset.
Some patients had more than one haematological result within one month before
hospital admission date. The result dated closest to the hospital admission date was
used in the analysis. It might be considered that a case note review should have been
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done to validate a sample of these dates, but this was not in the study design and was
not feasible with resources available.
During the linkage process of the patients' dataset with the haematology dataset any
haematological results during the period of admissions were excluded as the purpose
of the study was specifically to study the relationship between PAC Hb value and
blood use. It may have been better to include in the analysis the haematological
results for the whole period of the patients' admission. Obtaining these values would
decrease the numbers of patients without Hb values in the study and would help in
estimating the clinical thresholds for transfusion during the hospital admission.
The numbers of red cell units transfused was calculated from the numbers of red cell
units that the blood transfusion service assigned to individual patients and the
numbers of these units of red cells that were returned to BTS. The assumption had to
be made that these units were transfused to the patient, as there is no database that
records the actual administration of the blood units. Case note review to confirm the
numbers of red cell units transfused was not part of the protocol and could not be
undertaken with the available resource. Furthermore, previous work in the same
hospital has indicated that the case notes do not provide a reliable complete record of
all units transfused. [Palmer J (EUB, SNBTS) personal communication]
CRITIQUE OF THE STUDIES (included in literature review)
PRE-OPERATIVE ANAEMIA INPATIENTS UNDERGOING EOS
The present study is the first large-scale survey of pre-operative anaemia in a
representative large population of patients admitted for elective orthopaedic surgery.
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Some studies reported baseline Hb and/or Hct values for these patients as a part of
the recorded data; however, most of these studies did not report the nonnal reference
ranges (Biesma, Kraaijenhagen, Poortman, Marx, van de 1992; Laupacis, Feagan,
Wong 1993; Faris, Ritter, Abels 1996; Weisbach et al. 1999; Olijhoek et al. 2001).
MEASURMENTAND REPORTING BLOOD LOSS DURING EOS
There is no gold standard method in estimating the amount ofblood loss in surgical
patients. In most studies, intra-operative blood loss was mainly recorded from
anaesthetic charts and/or the volume of fluid in the suction device. Post-operative
blood loss was mainly recorded from the wound drains or calculated by different
equations (Berman, Geissele, Bosacco 1988; Toy, Kaplan, McVay, Lee, Strauss,
Stehling 1992; Kurdy 1996). None of the studies have mentioned tissue or unseen
blood loss.
The reported blood loss volumes for the same procedures were vary widely in
different studies. Table (4.54) shows the range ofmethods used in estimating
operative blood loss in published studies.
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Some authors reported the volume ofblood loss in ml; however, some others
expressed as the equivalent number of red cell units. Not all the authors mentioned
the volume or Hct of these units (Berman, Geissele, Bosacco 1988).
BLOOD TRANSFUSION INEOS
The amount ofblood transfusion varied widely in different studies that were similar
in their operative technique and surgical procedures (Sirchia, Giovanetti,
McClelland, Fracchia, editors 1994).
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Most of the studies reported the numbers of red cell units transfused without
clarifying the volume of the units transfused. Some of these studies did not clarify
whether the transfusion was with whole blood or red blood cells only (Berman,
Geissele, Bosacco 1988; Toy, Kaplan, McVay, Lee, Strauss, Stehling 1992).
The amount of red cell transfused was variously expressed as units per operated
patient, per transfused patient, or per procedure. A further inconsistency in reporting
is that some studies that investigated the amount of allogeneic and autologous red
cell transfusion have recorded the total amount of red cell transfusion without
reporting the amount of each type of red cell used separately.
Table (4.55) shows the inconsistency in methods of reporting the amount of blood
transfused.
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Table (4.55): Different ways of expressing the amount ofblood transfused in
published studies.
Per transfused Per transfused Per operated Per group of





































STUDIES ON TRANSFUSION SPARING OR BLOOD CONSERVATION
TECHNIQUES
The methodological quality ofmost of the trials that investigated different
transfusion sparing techniques was poor and the majority of these trials were un-
blinded. Most of these studies lacked randomisation and the number of subjects
included in the study were too small.
Pre-operative iron therapy
Very few studies have investigated the role of pre-operative iron therapy in treating
pre-operative anaemia and reducing the need for red cell transfusion. Most of these
were commercially supported studies that investigated the role of EPO and included
a group of patients who received iron therapy alone whether given by oral or
parenteral route as a control group. These studies have shown that iron alone appears
to be rather ineffective in erythropoiesis pre-operatively (Kasper, Lazansky, Stark,
Klimek, Laubinger, Borner 1998; Feagan et al. 2000; Olijhoek et al. 2001).
Pre-operative autologous donation
Some authors have studied the role ofpre-operative autologous blood donation in
reducing the need for allogeneic blood transfusion; many have shown the
impracticality of this technique. Pre-operative autologous blood donation can be
logistically difficult due to: a) low degree of public interest to donate blood before
major surgery (Thomas 1996). Goodnough et al mentioned that up to 25% ofhip and
35% of knee replacement patients do not pre-donate autologous blood even in
aggressively promoted programs (Goodnough, Vizmeg, Sobecks, Schwarz,
Soegiarso 1992a), b) patient's medical condition such as pre-operative anaemia,
pregnancy, cardiac patients, active bacterial infection, and coagulation disorders
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(Thomas 1996; Desmond, Thomas, Gillon, Fox 1996; Hartmann, Winkler, Preis,
Germann, Donner, Muller 1997), c) time consuming and expensive(Bierbaum,
Callaghan, Galante, Rubash, Tooms, Welch 1999), d) transfusion reactions are likely
to occur(Hatzidakis, Mendlick, McKillip, Reddy, Garvin 2000), and e) errors in
labelling and storage (Desmond, Thomas, Gillon, Fox 1996). f) substantial wastage
of the pre-donated blood units.
Moreover, most of the studies showed that patients who pre-donate autologous blood
are likely to be anaemic by the time of operation and receive higher volumes of red
cell transfusion (when both allogeneic and autologous units counted) than patients
who do not.
Red cell salvage
Some studies report a reduction in allogeneic red cell transfusion but a recent
systematic review concludes that there is little convincing evidence for the
effectiveness of the technique in reducing red cell use (Carless, Henry, Moxey,
O'Connell, Fergusson 2003). Furthermore there are reports of adverse effects of re-
infusing the salvaged blood to the patients during or after surgery. These adverse
effects are: a) Anaemia due to infusion of diluted blood, b) thrombocytopenia and
coagulopathy due to loss of platelets during salvage, c) sepsis due to bacterial
contamination, d) microemboli due to the ineffective filtering system (Desmond,
Thomas, Gillon, Fox 1996; Huet, Salmi, Fergusson, Koopman-van Gemert, Rubens,
Laupacis 1999).
Management of post-operative anaemia
There are not enough data showing the prevalence of post-operative anaemia in
patients undergoing EOS or the impact ofusing different transfusion sparing
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strategies on patients' Hb levels. Biesma et al. are the only authors who have
reported studies on post-operative anaemia in patients undergoing EOS (Biesma, van
de, Beguin, Kraaijenhagen, Marx 1995).
There is a need for a randomised controlled trial to show the effectiveness of peri¬
operative anaemia management to reduce the need for allogeneic blood transfusion
and on patients' clinical outcome.
Anaesthetic and surgical techniques that may reduce blood loss
Some studies have investigated different anaesthetic and surgical techniques that
may reduce operative blood loss and the need of red cell transfusion. Results are very
inconsistent. Juelsgaard et al and Borghi et al showed that there was no significant
difference in the amount ofblood loss in patients undergoing EOS under different
anaesthetic techniques namely general, spinal, epidural, and combination of epidural
and general anaesthesia (Juelsgaard et al. 1998; Borghi et al. 2002). However, Niemi
et al and Dauphin et al showed that epidural anaesthesia reduced the amount of
operative blood loss significantly (Dauphin, Raymer, Stanton, Fuller 1997; Niemi,
Pitkanen, Syrjala, Rosenberg 2000).
Blood loss measurement methods varied in the studies, as there is no gold standard
technique to estimate the amount ofperi-operative blood loss.
Blood losses were extremely variable between these studies, for example Niemi et al
reported that the total amount ofblood loss [peri-operative] in patients who
underwent EOS under spinal anaesthesia was 3500 ml and in a similar study by
Juelsgaard et al the amount ofblood loss was 633 ml (Juelsgaard et al. 1998; Niemi,
Pitkanen, Syrjala, Rosenberg 2000).
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Very few studies have investigated the role of different surgical techniques as the use
of tourniquet, operative position, and aggressive wanning in reducing operative
blood loss in EOS. Surprisingly, there was no significant difference in the amount of
intra-operative blood loss and transfusion in patients who underwent TKR with and
without tourniquet, there was a little reduction ofblood loss in patients underwent
THR in lateral position (Jarolem, Scott, Jaffe, Stein, Jaffe, Atik 1995; Schneeberger,
Schulz, Ganz 1998).
None of these studies have shown consistent evidence that any of these techniques
(anaesthetics or surgical) are effective in reducing blood loss and transfusion.
The literature reviewed suggested that not all of the "blood sparing" interventions
that are widely used are highly effective in reducing the need of red cell transfusion.
IMPLICATIONS OF THE RESULTS
The main study question was to investigate the extent to which correction of pre¬
operative anaemia might be expected to reduce the need for red cell transfusion in
view of the published evidence that pre-operative anaemia is associated with an
increased risk of peri-operative red cell transfusion. The study confirms this
relationship. Furthermore it shows that the 31 % of transfused admissions that had
pre-admission Hb level < 124g/L used 72% of all the transfused red cell units.
In this patients population we found that 83.5% of all transfusion episodes were
associated with total hip or knee replacement.
However, it is less clear to what extent a simple preoperative intervention to give
haematinics would impact on red cell transfusion needs, for the following reasons.
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(a) The majority of anaemic patients had normocytic normochromic anaemia and
may fail to respond to haematinic therapy. Only 25% (in total 75) of anaemic patients
have hypochromic red cell indices, (b) The timing of the preadmission clinic, i.e. less
than a month before admission, leaves inadequate time for an optimum response to
haematenics. (c) Review of the literature does not provide much support for the view
that preoperative iron (oral or parenteral) is effective in raising Hb prior to surgery in
this type ofpatient populations concerned unless used in conjunction with
erythropoietin.
It is possible that there is a population of non-anaemic patients with marginal iron
stores who could benefit from preoperative iron therapy, but the routine clinical data
available for analysis did not include the parameters needed to assess this possibility.
The present study raises doubts about the potential for reducing peri-operative red
cell transfusion by correction of pre-operative anaemia through early intervention




Anaemia is commonly found in critically ill patients. Compensatory physiological
effects of anaemia are governed by the extent and the rate of development of the
anaemia as well as by chronic or acute disease that limits physiological reserves.
Peri-operative blood loss and transfusion in elective orthopaedic patients is common.
It has been shown that the rate of red cell transfusion is associated with pre-operative
haemoglobin level. Audits and systematic reviews of the use ofblood transfusion
have been shown that peri-operative patients and critically ill patients in intensive
care units (ICUs) receive a significant number of units of red cells as these patients
are more likely to develop anaemia during hospital stay. The themes of this thesis
were to investigate the prevalence of anaemia and red cell transfusion in critically ill
and elective orthopaedic patients.
In chapter [2], prevalence of anaemia among survivors of critical illness managed
with conservative transfusion triggers, I established that anaemia is prevalent after
critical illness in a group of patients managed with conservative transfusion triggers.
This anaemia has blood indices similar to anaemia of chronic disease. The exact
nature, causes and duration of this anaemia are still unclear. The prevalence and
effects of long-term post-ICU anaemia on different body organs and quality of life
(QOL) are also unclear. There is clear evidence for an association between anaemia
and quality of life in other settings such as chronic renal failure, cancer, and chronic
heart failure. Treating anaemia in these setting improves QOL and patients' outcome.
It is unclear if active intervention in treating post-ICU anaemia with drugs such as
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iron, folate, and EPO could improve rates of recovery. The optimum time to start a
drug intervention and the doses are also unclear. Further studies are needed to: a)
further understand the prevalence of long tenn post-ICU anaemia, b) fully
understand the factors preventing normal recovery of erythropoiesis, c) investigate
the association of this type of anaemia with QOL and physical function, and d)
intervention studies to investigate different methods of treatment.
The studies that should follow my work should include:
1) A cohort study to understand the pathophysiology of anaemia during and at the
recovery from the critical illness. Nutritional status, inflammatory markers,
erythropoietin level, and functional iron status should be investigated.
Measuring vitamin B12, folate, and serum iron can assess nutrition status. CRP and
IL-6 can assess the extended of the inflammatory process. Serum transferrin, ferritin
level, and serum iron can be measured to revile functional iron deficiency.
These measures can be carried out at fixed times during the course of the critical
illness and for a respectable time during the recovery phase.
2) A study to establish the prevalence of anaemia at fixed time after ICU and hospital
discharge. Unlike our observational studies, where we were unable to follow up
patients at fixed times after ICU and hospital discharge, there was no source of data
after hospital discharge.
Patients should be recruited after ICU discharge and followed up weekly during the
first month, every 2 weeks during the second month, once during the third month,
and once at 6th month period.
During the study blood samples should be taken every time (mentioned above) to
assess the following functions:
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(b) Assess bone marrow stimulation by measuring
Erythropoietin level
(c) Assess bone marrow suppression by measuring.
Interleukin-6 (IL-6)
C-reactive protein (CRP)
(d) Assess the type of anaemia by measuring
Reticulocyte haemoglobin concentration (CHR)
Folate &B12
- MCH (FBC)
Haemoglobin level can be measured every time during the follow up period. QOL
assessment can be recorded during the period of the study by using different
questionnaires.
4) Randomised controlled trials to examine rates of recovery of Hb post-ICU with
EPO/iron treatment for a target population e.g. patients with Hb levels < 100 g/L at
the time of ICU discharge.
In chapter [3], we have been shown that there are changes occurred to patients'
RBCs as indicated by RBC 2,3-DPG during critical illness. It has been shown that
the anaemia of critical illness is not associated with abnormal RBC 2,3-DPG levels,
overall. In particular, increases in RBC 2,3-DPG, which could augment oxygen
unloading in tissues, do not occur. It is unclear from the present study if this lack of
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compensation affects oxygen unloading to the tissues. We have shown that acidosis
is associated with low RBC 2,3-DPG level. This paradoxical finding raises
interesting questions about the clinical importance ofRBC 2,3-DPG concentrations
for oxygen unloading in sick patients. Further studies should address function /
quality ofRBCs and investigate whether specific treatments could improve oxygen
transport by patients own blood.
The literature review showed several established animal models to study oxygen
delivery in relation to RBC 2,3-DPG. Further work should focus on exploring this
association. It is difficult to carry out such studies in critically ill patients, as there are
many abnormalities in factors controlling RBC 2,3-DPG level such as acid base
status, however, animal studies can be designed to explore this relation more before
starting a study that involves patients.
We have shown that there was a strong correlation between RBC 2,3-DPG level and
calculated in vivo P50. It was unclear if this relation due to mathematical linkage or
not. Further studies should be carried out to investigate this correlation. A laboratory
study where a special tonometer with a facility to control pH, PCO2, PO2, and
temperature during the plotting process should be used to plot the oxygen
haemoglobin dissociation curve in blood samples with known different
concentrations ofRBC 2,3-DPG. All other variables such as pH, PCO2, PO2, and
temperature should be standardised for all the samples through out the plotting
processes.
In chapter [4], our work has shown that a considerable number ofpatients are
anaemic before admission for elective orthopaedic surgery. The nature of this type of
anaemia is usually similar to the anaemia of chronic disease. We have shown that
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low pre-admission Hb values are associated with red cell transfusion. The findings
emphasise the need for more studies to define the nature of pre-operative anaemia,
the prevalence of iron deficiency and the potential benefits from pre-operative
haematinic treatment, which may decrease the need of red cell transfusion. My data,
based on a large population, should be used to design intervention studies in targeted
population in whom expensive therapies such as EPO are most likely to be coast
effective.
The studies that showed follow my work should include;
1) A cohort study to understand the pathophysiology ofpre-operative anaemia for
patients scheduled for major elective orthopaedic procedures. Anaemic patients at the
time of the pre-admission can be identified. This group ofpatients can be
investigated for their nutritional status by measuring Bi2, folate, and serum iron
levels. Measuring ferritin level should assess iron status.
2) Identifying patients for a randomised control trial ofpre-operative haematinics
administration. Patients should be divided in two groups at the time of pre-admission
clinic [treatment group, receive iron, folate, and Bj2, and placebo group]. Outcomes
from this study could be assessed by the rate of Hb rise from post-operative day 1 to
day 6, Hb rise from post-operative day 1 to day 30, percentage of patients receiving
red cell transfusion, units of red cells for 100 patients operated, and indicators of
rehabilitation e.g. return ofmobility.
Improved understanding in these areas could further decrease the need for blood
transfusion.
The present work was carried out in two settings of patients, critically ill and elective
orthopaedic surgery patients. Most of these patients are elderly, presenting with
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anaemia at admission or develop it during the course of their medical care and use
clinically important amount of allogeneic blood. The majority of these patients have
a similar type of anaemia, which is normocytic normochromic anaemia [similar to
the anaemia of chronic disease].
Data in this thesis illustrate some of the major outstanding questions in two key
blood user areas, namely, intensive care and elective orthopaedic surgery. Similar
questions are likely to apply to most other types of patients requiring red cell
transfusion. Increasing public awareness of the risks of blood transfusion and
political issues arising from variant CJD will require improved evidence based
transfusion practice. The data in my thesis raise many important questions to answer
the many outstanding questions in the area of anaemia and blood transfusion.
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THE METHODOLOGY OF THE LINKAGE PROCESSES
A number of data files were obtained from the hospital laboratory database, one file
for each month that contained the haematological records. For each blood sample
record, in addition to the specified results, there was a unique identifier (specimen
number) for the sample, the sample request date, and the patient's identifiers
[patient's forename, surname, gender, date ofbirth, hospital number, and location].
Patients' dataset included for each admission a unique identifier (index number),
patients' identifiers [patients' forename, surname, gender, date of birth, and hospital
number], and patients' demographic data.
The blood sample records in each time period were linked to the admission records
using a multi-stage process. This first involved looking for complete or partial
matches in forename, surname, gender, and date ofbirth between hospital laboratory
dataset and patients' dataset as follows:
1) All blood sample records were considered and those with identical forename,
surname, gender and date ofbirth to an admission record were identified, i.e. a
complete match on these four fields.
2) The blood sample records without complete matches were considered and those
with identical forename, surname and date of birth but different gender to an
admission record were identified, i.e. a partial match on these four fields.
396
3) The blood sample records without a complete or partial match were considered
and those with identical forename, surname and gender but different date of birth to
an admission record were identified, i.e. a partial match on these four fields.
4) The blood sample records without a complete or partial match were considered
and those with identical forename, gender and date ofbirth but different surname to
an admission record were identified, i.e. a partial match on these four fields.
5) The blood sample records without a complete or partial match were considered
and those with identical surname, gender and date ofbirth but different forename to
an admission record were identified, i.e. a partial match on these four fields.
6) The blood sample records without complete or partial matches were considered
and those with identical forename and surname but different gender and date ofbirth
to an admission record were identified, i.e. a partial match on these four fields.
7) The blood sample records without a complete or partial match were considered
and those with identical gender and date ofbirth but different forename and surname
to an admission record were identified, i.e. a partial match on these four fields.
Listings of all the partial matches identified in stages 2) to 7) above were then
checked manually. In particular the non-matching fields and hospital numbers from
the blood sample record and the admission record were reviewed.
Those blood sample records where this review identified the partial match as
producing an incorrect linkage between the blood sample and the admission were
removed from the linked blood samples dataset.
It was only possible to utilise the hospital number field when reviewing the partial
matches between blood sample records and the admissions rather than as part of the
identical fields matching process. This was due to inconsistent formats being used for
397
hospital numbers and the use ofmultiple hospital numbers for different blood
samples within a single hospital stay.
Finally the sample request date was used to exclude those blood samples taken
before or after the study period from the dataset of linked blood samples. Patients'
identifiers were deleted as a part of the data protection rules and were replaced by
unique identifiers (index number).
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